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EVALUATION OF PIEZOTOME CORTICOTOMIES ON CRANIAL BONE 
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Aim & Hypothesis: We hypothesized that the piezoelectric knife increases bone 
remodeling. The effect of a piezotome 2 prototype with different puissance and 
modulation settings on bone biology was compared under different bone resorption 
and/or bone formation conditions using an ex-vivo live bone organ culture 
Materials & Methods: We utilized an ex-vivo mouse calvarial bone culture system a n d  
piezocision surgical techniques with variable puissance and modulation settings under  
conditions of static versus dynamic, and formation versus resorption in order to decipher 
cellular, molecular, biological and genetic perturbations induced by piezocision surgery. 
In addition, we tested its impact on calvarial bone organ cultures in the presence of drugs 
such as bisphosphonate (zolendronic acid, ZOL) and insulin or its impact on bone healing 
with bone graft material such as Enamel matrix derivative (Emdogain).  
Results: The impact of the piezoelectric knife extends beyond the immediate site of 
mineralized bone defect/damage. The impact is ~6 times greater than the apparent initial 
mineralized bone injury, 1.6 mm2, and extends to immediate surrounding local periosteal 
and endosteal cell layers, 11 mm2, leaving the mineralized bone layer intact. There were 
also major differences between the static and dynamic model systems in bone defect 
	
	 ix
healing, resorption and new bone formation. There are also differences between the 
piezoelectric knife and bur in bone resorption and formation models and in both treated 
before or at the same time of the injury with bisphosphonate. In the calvarial defect repair 
model the defect closed much faster with the piezoelectric knife than with the bur. In a 
comparative study with controls versus piezotome or bur, and piezotome versus bur 
complete genomic analysis of changes revealed a large number of major differences in 
genomic expression levels. 
Conclusion: The extended effect of piezocision on the surrounding bone lining cells of 
the bone defect including de-vitalization of the proximal osteocytes within the intact 
mineralized bone matrix thet primes the bone to undergo rapid turnover. Piezocision 
incorporates high-frequency vibrational energy that can be transmitted a significant 
distance within the mineral phase and exploits the inherent bone cellular response 
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CHAPTER 1: INTRODUCTION 
1.1 Bone 
Bone is a dynamic organ which undergoes continuous remodeling. This 
remodeling consists of synchronized resorption and formation to maintain bone structure. 
The organic bone matrix consists of type I collagen and non-collagenous proteins. That 
makes up 30% of the bone composition while the remaining 70% is inorganic minerals. 
Multiple types of bone cells play major roles in the remodeling process.1  
Osteoclasts are multinucleated cells responsible for bone resorption. It is derived from 
hematopoietic cells of the mononuclear cell lineage.2  In addition to the osteoclast unique 
morphology, these cells can be identified by expression of tartrate-resistant acid 
phosphatase (TRAP) and the calcitonin receptor.3-5  Different cytokines such as receptor 
activator of nuclear factor kappa-Β ligand (RANKL), colony- stimulating factor 1 (CSf-
1) and osteoprotegerin (OPG)6-11 are crucial during osteoclast differentiation and 
maturation. Osteoclast receptors for hormones and cytokines such as PDGF,  calcitonin, 
interleukin (IL)-1, androgens, PTH, thyroid hormone, insulin, CSF-1 and IGF-1 have 
been identified. These hormones and cytokines play a major role in osteoclast activation 
and function.12-20  Bone resorption by osteoclast starts by alteration of osteoclast shape to 
form a ruffled and sealing border. Acids and lysosomal enzymes such as TRAP and 
cathepsin K are then secreted to dissolve bone.2,21,22 Fig 1&2. 
Osteoblasts originate from mesenchymal stem cells which also can differentiate to 




transcription factor 2 (Runx2) and osterix (Osx) play a crucial role in osteoblast 
differentiation.24,25 The main function of osteoblasts is production of collagen type I, 
control of bone maturation and mineralization.26 In addition osteoblasts produce 
paracrine and autocrine growth factors that promote differentiation and activation of 
other osteoblasts.27 Parathyroid hormone receptors have been identified in osteoblast 
which signals osteoclasts to initiate bone resorption. 28 Alkaline phosphatase (ALP) is 
one of the most useful biomarker for osteoblast Identification.29 Bone formation requires 
production of bone matrix and subsequent mineralization. Once osteoid is formed 
osteoblasts are entrapped in the bone matrix and to become osteocytes. Some remaining 
free cells become flat bone lining cells.1  
Osteocytes constitute the majority of bone cells (90-95%).30 They have long dendrite-like 
processes spreading through canaliculi tunnels. They communicate with other octeocytes 
and with bone lining cells through these processes.31,32 Osteocytes play a role in bone 











Figure 1: Schematic summary of bone cells interaction between each other. 
Bone matrix (B). Osteoclast (Oc). Ruffled border (RB). Clear zone (CZ). Howship lacuna 
(HL). Hydrogen ions (H+). Bicarbonate (HCO-). Carbonic anhydrase II (CAII). 
Cathepsin (Cp). Matrix Metalloproteinase-9 (MMP-9). Tartrate-Resistant Acid 
Phosphatase (TRAP). EphrinB2 (Eph2). EphrinB4 (Eph4). Osteoblasts (Ob). Receptor 
Activator of Nuclear Factor KB (RANKL). Osteoprotegerin (OPG). Collagenous (Col1). 
Osteocalcin (OCN). Osteopontin (OSP). Osteonectin (OSN). Bone Sialoprotein (BSP). 
Bone Morphogenetic Proteins (BMP). Osteocytes (Ot). Connexin 43 (Cx3). Bone lining 
cells (BLC). Prostaglandin E2 (PGE2). Nitric Oxide (NO). Insulin-like Growth Factor 






Figure 2. Schematic representation of bone remodeling.35 In this figure all phases of 












1.2 Peiezoelectric surgery 
The concept of “regional acceleratory phenomenon” (RAP), first described by 
Frost 36-38 , has been incorporated systematically into the new surgical procedures to 
facilitate orthodontic tooth movement. Although effective, corticotomy approach is very 
invasive and requires extensive flap elevations and bur generated osseous injury. 39-42  
Despite the fact that this procedure speeds orthodontic tooth movement and reduces the 
duration of treatment it has several undesirable effects. Few individuals are willing to 
undergo such aggressive surgical procedures that have the potential to generate post-
surgical discomfort and increase the risk of complications.43,44  To overcome these major 
disadvantages Park et al 45 and Kim et al 45,46 introduced a modified minimally invasive 
surgical approach known as “corticision”.  However, while the corticision procedure 
overcomes the extensive surgical flap reflection step of corticotomy the use of a 
reinforced scalpel and a mallet to pass through the gingival tissue and access the cortical 
bone exposes the patient to added surgical stress. To minimize these disadvantages a new 
minimally invasive surgical procedure utilizing a “piezoelectric surgical knife” has been 
used in sinus grafting, alveolar crest expansion and pre-prosthetic surgery.47,48 Compared 
to conventional bur and saw techniques Piezo-surgery not only provides precise and 
effortless cutting of bone but also allows selective cutting of the mineralized tissue with 
minimal impact on the surrounding soft tissue.49  These properties have generated major 
interest and increased use in both orthopedic and surgical approaches. A recent meta-
analysis study comparing conventional rotary osteotomy and Piezoelectric surgery in 




swelling and trismus) and the number of analgesics taken by the patients.50  Another 
systematic review showed that piezo-surgery caused significantly less swelling in third 
molar extraction in addition to less pain and trismus as compared to rotary osteotomy 
techniques.51 The Piezotome showed the smallest increase in intraosseous temperature 
compared to Piezo-surgery II and Surgysonic.52  This heat reduction in piezo-surgery can 
be attributed to the limited pressure required, modulated vibration frequency and the 
cavitation phenomenon required to achieve efficient bone cutting. Eriksson and 
Albrektsson (1983) showed that the threshold for heat induced bone necrosis is 47◦C 
(116.6◦F) for 1 min.53  
The impact and practical application of the piezotome technology is obvious and 
it is used clinically to provide accelerated orthodontic tooth movement. However, the 
intricate details of the observed clinical effects beyond the simple physical bone 
injury/cut remain uncharted territory. Furthermore, to optimize, discover and develop 
future clinical applications requires deciphering its fundamental impact at the cellular, 
molecular and mechanistic level in bone biology. Some investigations have attempted to 
provide details regarding cells vitality and osteoblast differentiation from bone chips 
harvested following Piezoelectric surgery or a conventional rotating drill.54  Von See et. 
al.,55 showed that the osteoblast-like cells was higher following piezoelectric surgery.  
Piezoelectric surgery produced higher levels of periosteal perfusion and better 
microcirculation in sub-periosteal preparations.56  Preti et al 57 studied osteogenesis and 




osteoblast cells and bone formation following piezosurgery compared to a conventional 
drill.  In addition, in the piezosurgery group the inflammatory factors, BMP-4, TGF-2, 
and IL-10 increased while pro-inflammatory cytokines were reduced in the early period. 
However in order to understand the biological impact of piezocision surgery beyond the 
simple physical bone injury we have utilized ex-vivo mouse calvarial bone organ culture 
models to provide details of the response of bone to different surgical techniques.58  In 
that study the piezotome settings were the fixed clinical instrument settings, i.e., 
puissance 255 and modulation 30 KHz. The present study evaluated and defined the 
impact of variable piozotome settings (puissance and modulation) using a piezotome 2 
prototype (Satelec, Acteongroup, Merignac France), Fig 3, on bone biology with 
reference to osteoclast differentiation/bone resorption and osteoblast differentiation/new 
bone formation. These two phenomena play central roles in the overall progression of 
orthodontic tooth movement. These studies of specific bone remodeling stages were also 
coupled with a “static” (elevated metal grid model) and “dynamic” (roller tube model) 





Figure 3: Piezotome 2 prototype device. In this prototype, puissance and modulation 












Bisphosphonates (BPs) were discovered in 1800s 59, but not used in medicine 
until the 1960s. It is a chemically stable analog of inorganic pyrophosphate (Ppi).60 It was 
first used as a calcification inhibitor 61 by binding to hydroxyapatite and preventing 
crystal growth.62 However, the most important discovery was that BPs inhibit bone 
resorption.63 They are used clinically as antiresorptive drugs for treatment of cancer bone 
metastasis, multiple myeloma, Paget disease and osteoporosis.64 There is a debate 
regarding the half-life of BP due to multiple factors affecting measurement but it is 
estimated to have a half-life of 10 years.65 Several side effects have been reported 
including gastrointestinal tract irritation, renal toxicity, hypocalcaemia and BP-related 























Effects of Bisphosphonate at a cellular level:  
a) Effect on Osteoclast:  
BPs have high affinity for hydroxyapatite crystals and it concentrates in areas of 
high bone turnover and osteoclastic activity. BPs can affect osteoclasts via different 
routes. It inhibits osteoclast differentiation and recruitment.67 It is also inhibits osteoclast 
activity on bone surface by altering their morphology,68,69 cytoskeleton68 and the ruffled 
border.68,70,71 Fig 5. 
b) Effect on Osteoblast:  
In addition to effects of BPs on osteoclasts they may also indirectly affect 
osteoblasts. Some studies have shown that neither osteoblast differentiation nor bone 
formation were affected.72-74 In contrast, Tobias et al.75 and Iwata et al.76 reported 
inhibitory effects on OB function and mineralization rate. BPs may impact osteoblasts by 
influencing RANKL signaling. They inhibit RANKL expression and increase OPG 
expression.77,78 In addition, BPs increase or decrease osteoblast differentiation and bone 
formation in a concentration dependent manner. Stimulation of osteoblastogenesis is seen 
with low concentrations of BPs ranging from 10−9 to 10−6 M while an inhibitory effect is 





















Insulin is a hormone produced and secreted by the beta cells of the pancreas.84  It 
is synthesized in the form of preproinsulin which undergoes a series of proteolytic 
cleavages to become insulin. Insulin is a protein consisting of 2 polypeptide chains. The 
first chain consists of 21 amino acid residues while the second chain contains 30 amino 
acid residues. Disulphide bridges link both chains and intra-chain disulphide bridge link 
residue 6 and 11 in the first chain.85 Insulin affect bone metabolism by altering the cells 
response to PTH and on collagen production. Osteoblast like cells incubated with insulin 
have decreased the ability of PTH to activate phospholipase C. Thus, it impairs the 
elevation of intracellular cAMP levels and PKC activity.86,87 In addition, Osteoblasts 
incubated with insulin have increased collagen production and bone mineralization.88-91 
Wei et al 92 reported that β cell replication in pancreas is stimulated by osteocalcin. The 
number of mitochondria increased in skeletal muscles of type 2 diabetic mice when 
osteocalcin was injected indicating that osteocalcin increases insulin sensitivity.93 These 
recent data suggest that under normal conditions osteocalcin will induce more insulin 
production and increase insulin sensitivity in skeletal muscle. Insulin would then 












1.5 Aim and hypothesis 
We hypothesized that use of the piezotome 2 prototype (Satelec, Acteongroup, Merignac 
France) would increase the bone remodeling process. The aim is to test the piezotome 2 
prototype effect on bone biology in ex-vivo bone organ culture. 
Specific Aims: Study the effect of Piezotome 2 prototype on: 
Specific Aim 1: 2D cell culture. 
Specific Aim 2: Calvarial bone resorption and formation cultured in BSA and FCS with 
dynamic movement.  
Specific Aim 3: Calvarial bone resorption and formation cultured in BSA with static 
model. 
Specific Aim 4: Calvarial bone resorption and formation cultured in BSA and FCS with 
ZOL 
Specific Aim 5: Calvarial bone formation cultured in BSA with and without insulin. 
Specific Aim 6: Calvarial bone regeneration in a critical defect model treated with 
resorbable collagen and emdogain cultured in BSA. 
Specific Aim 7: Bone remodeling in a non-critical defect model cultured in BSA with 
and without ZOL. 





CHAPTER 2: MATERIALS AND METHODS 
2.1 2D Cell Culture 
Cell cultures of Prostate cancer cells (PC3) and Breast cancer cells (MDA) lines were 
used to test the Piezotome 2 prototype effect on attached and suspended cells. Cells from 
each cell line were as either suspended or attached cells. Suspended cells are treated 
while floating in media. Attached cells were allowed to attach for 2 days to become 
confluent (>80% attached cells). Cells under both conditions were treated with different 
Piezotome settings (P:255, M:100), (P:255, M:30), (P:50, M:100) and (P:50, M:30). 
Treatment was done by inserting the piezotome blade to half the media depth for 5 
seconds. Cells were counted after 4 days of treatment. 
2.2 Organ Culture 
After receiving approval from the “Institutional Animal Care and Use Committee” 
calvarias from 5-7 day old neonatal CD-1 mice (Charles River Laboratories, MA) were 
dissected under sterile conditions and cut to produce a trapezoid structure (1cm x 0.6 cm) 
and washed briefly in culture medium. The bone organ culture medium consisted of 
Dulbecco’s modified Eagle medium (DMEM) supplemented with either bovine serum 
albumin (BSA) or Fetal Calf Serum (FCS), fraction V (5 mg/ml, Sigma Co.), 100 U/ml 
penicillin and 100 μg/ml streptomycin and 250 ng/ml amphotericin B (Gibco, Grand 
Island, NY). Supplementing the culture media with 1 mM (150 µg/ml) sodium ascorbate 
(Sigma, Co.) was used to induce bone formation (Bone apposition assay). These models 
were developed and used for other bone resorption/apposition studies and the detailed 




mentioned media in two different culture models. A rolling tube model which gives 
dynamic movement to the calvaria bone and a grid model which represents the static 
condition. 
2.3 Organ Culture Media 
DMEM is a unique medium containing higher concentration of amino acids and vitamins 
than other media. It was formulated with low glucose level (1 g/L) but it is usually used 
with higher glucose level (4.5 g/L). DMEM does not contain protiens, growth factors or 
lipids. Thus, it is often supplemented with Fetal Bovine Serum (FBS).  
2.3.1 Fetal Calf/Bovaine Serum (FCS/FBS) 
FCS/FBS with its high nutritional content is one of the most common supplements for 
cell culture media. It is effective in promoting and sustaining growth of insect and 
mammalian cells. It is extracted from bovine fetuses when pregnant female cattle are 
slaughtered. The concentration used ranged from 5% to 20% of the culture media. FCS 
composition is different from batch to batch; therefore, one of its drawbacks is lack of 
experiment reproducibility.99   
2.3.2 Bovine Serum Albumin (BSA) 
BSA contains 583 amino acids.100,101  The primary structure was reported in 1971102  and 
revised in 1990.103  It is the model protein used in many studies. It is structurally well 





2.4 Rolling tube model (Dynamic) 
A single calvarium was placed in each roller-tube (15 cm × 16 cm, Bellco, Inc. N.J.) 
containing 2 ml of bone culture media DMEM + (FCS or BSA). The roller tubes were 
sealed with a stopper and placed horizontally in a roller tube apparatus (Bellco 
Biotechnology, Inc. Vineland, N.J.) that makes 5 revolutions per minute in a 37°C 
incubator. Fig 7.96  
 
 




2.5 Grid model (static) 
The calvaria were placed on stainless grids in small tissue culture dishes (35 mm × 10 
mm, Corning Inc., NY) so that the bone was elevated and the media formed a thin film 
over the bone surface. Fig 8, Panel A&B. It was incubated at 37°C with 5% CO2 in a 
tissue culture incubator (NAPCO, Winchester, VA).107,108  
 
 






Figure 8, Panel B 
 
Figure 8: Grid Model.  
 
 
2.6 Neutral red (NR) staining to visualize osteoclast activity and silver nitrate 
staining for bone resorption- 
At the end of the experiment 70 mg/ml NR (Sigma, Co.) added to the media and 
incubated for 45 min at 37°C. NR provides a quantitative estimation of OC activity. OC 
cells are capable of rapid uptake of NR allowing clear contrast between osteoclasts and 
other bone cells.96,109,110  The calvaria were washed with PBS before fixation in 10% 
formalin overnight. The calvaria were washed once more with PBS and counter stained 
with 2% silver nitrate (Sigma-Aldrich) for 20 minutes. Under the microscope the silver 




2.7 Calcium analysis of the media 
Calcium release and uptake was measured in the media collected every two days. The 
calcium level was assessed by the reaction of calcium ions available in the media and the 
calcium chelating chromophoric O-Cresolphthalien complexone (Sigma-CO) reagent. 
This reaction forms a purple complex that can be measured by the absorbtion 
spectrophotometry. The assay was carried out in duplicate and the absorbance value were 
obtained using a Berthold TriStar LB 941 plate reader at wavelength of 560 ηm and 
normalized to the calvaria dry weight. A standard curve was established using calcium 
chloride standards with concentrations ranging from 0-100 ηmol/20 μl. Linearity of the 
assay and correlation coefficient greater than 0.99 were achieved with calcium reagent 
concentration of 1.8mg/10ml. The calcium reagent was prepared with Sodium 
Bicarbonate buffer at PH of 10.8. Each well contains 20 μl of the sample and 180 μl of 
the calcium reagent. Final calcium concentration normalized to the calvaria dry weight 
was used to obtain final units nmol/ml/mg calvaria dry weight.  
2.8 Tartrate resistant acid phosphatase TRAP activity 
TRAP enzyme activity was used as a marker for osteoclast activity and the final enzyme 
activity was expressed in units of (μmol/L-1min-1/mg protein). TRAP buffer stock was 
prepared based on the molecular weight of sodium acetate (MW= 82.03 g/mole) to a final 
concentration of 0.1 M and the PH adjusted to PH=5. Tartaric acid (MW=150.09 g/mole) 
is added to TRAP buffer stock to a final concentration of 50 mM. To prepare the reagent 
used in the analysis phosphate substrate (MW=371.14 g/mole) is added to the TRAP 




media sample and 200µl of TRAP reagent in each well and incubated at 37°C for 3 hours. 
To stop the enzymatic reaction 10 µl of 2M sodium hydroxide (NaOH) was added to all 
the wells. Absorbance was set to 405 in the plate reader. 
2.9 Alkaline Phosphatase (ALP) activity 
ALP activity was used as a marker for osteoblast activity. The final enzyme activity was 
expressed in units of (nmol/L-1min-1/mg protein). Phosphate substrate was added to 
ammonium bicarbonate to reach a final concentration of 10 µM. In a 96-well plate 100µl 
of media samples were added to 200µl of ALP reagent and incubated in 37°C for 3 hours. 
Absorbance was set to 405 in the plate reader. The same process of TRAP activity except 
that ammonium bicarbonate was used instead of TRAP buffer. In addition the plate was 
read after 2 hours without adding HCL. 
2.10 Histology Bone Thickness Measurements 
The histomorphometric analyses were carried out using Nikon Eclipse TE 2000-S 
inverted microscope interfaced with a computer equipped with AmScope 3.7 software for 
digital acquisition of pictures and quantitative measurements of mineralized bone 
thickness, areas of osteoclastic bone resorption and new osteoid formation using 
histology slides at 100x magnification. 
The percentage of bone resorption was calculated from measurements of total bone area 
before resorption and total bone area after resorption. Similarly, the percentage of bone 
formation was calculated from measurements of total bone area before formation and 





Chemical, biochemical, and quantitative histomorphometric data are presented as means 
±S.D. The original data sets were evaluated for group variance using Shapiro-Wilks test 
and found to have normal distribution and hence parametric statistical analysis was 
applied. The statistical significance of the differences between controls versus treatment 
groups and between different treatments groups were evaluated using one way ANOVA 
and Post-Hoc test. The differences between groups were considered statistically 



















2.12 Comparative effects of different piezoelectric settings and bur injury on bone 
Resorption and formation with BSA or FCS with and without sodium 
ascorbate in rolling tube model or Grid model 
The isolated calvaria were cultured in media for 48 hrs prior to injury procedures. The 
calvarial bone organs were primed to undergo osteoblastic bone formation by adding 
sodium ascorbate or osteoclastic bone resorption by omitting sodium ascorbate. The 
calvarial bones were cultured in DMEM media supplemented with either BSA in both 
rolling tube or grid models (N = 120) or FCS in rolling tube only (N = 60). Six groups in 
each one of the formation and resorption models in each culture media were set up as 
follows with 5 calvaria per group: (a) calvaria + media only (control); (b) piezotome 
(Puissance (P):255 and Modulation (M):100), (c) piezotome (P:255 and M:30), (d) 
piezotome (P:50 and M:100) (e) piezotome (P:50 and M:30); (f) Bur injury (0.25 mm 
diameter Komet carbide round bur mounted on high speed hand- piece). All 
corticotomies were standardized to reflect the same amount of injury. At the end of the 21 
days post injury culture period 2 calvaria from each group were processed for neutral red 
staining and silver nitrate counter staining. All calvaria were fixed in 10% formalin, 
decalcified with 0.1 HCl for 3 hrs, processed with 40 mM EDTA and stained with H & E 







Piezoelectric with bisphosphonate 
Zolondronic acid (2µM) was added either before the piezoelectric injury or at the same 
time of the injury. Two different groups were treated with bisphosphonate. The first one 
was treated with 6 days of bisphosphonate (3 doses) followed by 8 days combined with 
the Injury. The second group was treated for 8 days of both injury and bisphosphonate 
from the beginning of the study. All groups were cultured in the rolling tube model only. 
2.13 Comparative effects of different piezoelectric settings and bur injury on bone 
treated first with 6 days of Bisphosphonate and 8 days with injury and 
cultured with FCS or BSA- 
The isolated calvaria were cultured in the media for 48 hrs prior to injury procedures. The 
calvarial bones were primed to undergo bone formation by adding sodium ascorbate. The 
calvarial bone were cultured with DMEM media supplemented with either BSA or FCS 
(N=120). There were six groups in each resorption and formation systems as in previous 
experiments. All injuries were standardized to create the same amount of bone 
perforation-damage in size and depth. At the end of the 8 days post injury culture period 
2 calvaria from each group were processed for neutral red staining and silver nitrate 
counter staining. All 120 calvarias were fixed in 10% formalin, decalcified and stained 




2.14 Comparative effects of different piezoelectric settings and bur injury on bone 
treated 8 days of Bisphosphonate at the same time of the injury, cultured with 
FCS or BSA 
In this experiment the same procedures, sample size, and groups as in previous 
experiments were used except that the bisphosphonate treatment was used at the time of 
the injury. 
2.15 Comparative effects of clinical piezoelectric setting and bur injury on bone 
healing of non-critical bone defects treated with and without bisphosphonate 
The isolated calvaria were cultured in the media for 48 hrs prior to injury procedures. The 
calvarial bone organs were primed to undergo bone formation by adding sodium 
ascorbate. The calvarial bones were cultured with DMEM media supplemented with BSA 
(N=42). All calvaria subjected to non-critical defects size 0.7 mm. Half were treated with 
three doses of zolondronic acid 2µM. There were three groups in each bisphosphonate 
treated and non-treated models were set up as follows with 7 calvaria per group: (a) 
calvaria + media only (control); (b) piezotome (P:255 and M:30); (c) Bur injury (0.25 
mm diameter Komet carbide round bur mounted on high speed hand- piece). All injuries 
were standardized to create the same amount of bone perforation-damage in size and 
depth and were >2 mm away from the defect. At the end of the 30 days post injury 
culture period all calvaria were processed for neutral red staining. All 96 calvarias were 






Piezoelectric with Insulin 
2.16 Comparative effects of different piezoelectric settings and bur injury on bone 
formation treated with and without insulin 
The isolated calvaria were cultured in the media for 48 hrs prior to injury procedures. The 
calvarial bones were primed to undergo bone formation by adding sodium ascorbate 
alone or with the addition of insulin solution (10 nM) (Sigma Aldrich). The calvarial 
bones were cultured with DMEM media supplemented with BSA (N=60). Six groups in 
each vit C alone and vit C + insulin. All injuries were standardized to create the same 
amount of bone perforation-damage in size and depth. At the end of the 14 days post 
injury culture period 2 calvaria from each group were processed for neutral red staining. 















Piezoelectric with Bone Graft 
2.17 Comparative effects of different piezoelectric settings and bur injury on bone 
healing of critical bone defects treated resorbable collagen and emdogain 
The isolated calvaria were cultured in the media for 48 hrs prior to injury procedures. The 
calvarial bones were primed to undergo bone formation by adding sodium ascorbate and 
cultured with DMEM media supplemented with BSA (N=35). Critical defects size 2mm 
were performed to all calvarias. Piezotome and bur injuries were performed on the same 
parietal bone before the critical defects. All critical defects covered by resorbable 
collagen type I ( RCT resorbable collagen tape, ACE )  5 µl Enamel Matrix Derivative 
(Emdogaine), (30 mg/ml Straumann® Emdogain®) . Seven groups were set up as follows 
with 5 calvaria per group: (a) Resorbable collagen only (control); (b) Resorbable collagen 
and Emdogaine (control); (c) Resorbable collagen and Emdogaine beside the piezotome 
(P:255 and M:100) injury; (d) Resorbable collagen and Emdogaine beside the piezotome 
(P:255 and M:30) injury; (e) Resorbable collagen and Emdogaine beside the piezotome 
(P:50 and M:100) injury; (f) Resorbable collagen and Emdogaine beside the piezotome 
(P:50 and M:30) injury; (f) Resorbable collagen and Emdogaine beside the bur injury 
(0.25 mm diameter Komet carbide round bur mounted on high speed hand- piece). All 
injuries were standardized to create the same amount of bone perforation-damage in size 
and depth. At the end of the 14 days post injury culture period 2 calvaria from each group 
were processed for neutral red staining. All 35 calvarias were fixed in 10% formalin, 





2.18 Comparative effects of clinical piezoelectric setting and bur injury on gene 
expression on mice calvarial bone 
The isolated calvaria were cultured in media supplemented with ascorbic acid for 48 
hours prior to injury procedures to prime the calvarial bone to undergo formation. 
Calvaria were deprived of ascorbic acid to prevent bone formation and to allow the bone 
to undergo resorption only. After 48 hours surgical defects were produced by 
piezoelectric or bur in both parietal bones. The Control group represents calvarial bone 
with no defects. All six groups (3 groups in each culture model) were cultured again for 4 
hours in resorption or formation culture media models. After 4 hours culture period all 
calvarias (N=60) were processed for RNA purification. All calvarias were freeze-dried 
using liquid nitrogen and ground with mortar and pestle to fine powder. Rneasy mini kit 
(QIAGEN) protocol was used for purification of total RNA from animal tissues. The 
bone powder was then homogenized with buffer RLT and transferred to 2 ml 
microcentrifuge tubes. After the lysate was centrifuged for 3 minutes at full speed the 
supernatant was transferred to a new tube and 1 volume of 70% ethanol was added and 
mixed thoroughly. This sample mixture was transferred to RNeasy spin column placed in 
a 2 ml collection tube and centrifuged for 15 seconds at full speed (>10,000 rpm). The 
flow-through in collection tube was discarded. Buffer RW1 was added to spin column 
and centrifuged for 15 seconds at full speed. Flow-through in collection tube was 




speed. Spin column was the transferred in 1.5 ml tube and 50 µl of RNase-free water was 
added to spin column and centrifuged for 1 minute at full speed to elute RNA. 
RNA quantity and quality was determined by Nanodrop 2000 UV Visible 
Spectrophotometer (Thermo Scientific). Table 1 shows the absorbance of the RNA at 
different wavelengths. At the end, all samples were sent to do whole genome gene 
expression analysis using Mouse Gene Array 2.0ST at microarray and sequencing 
resource laboratory at Boston University medical campus. 
 





Mouse Gene 2.0 ST CEL files were normalized to produce gene-level expression values 
using the implementation of the Robust Multiarray Average (RMA)111  in the Affymetrix  
package (version 1.36.1)112  included in the Bioconductor software suite (version 2.11)113  














Formation 205.1 ng/µl 5.127 2.5 2.05 1.63 RNA 40
Piezo 
Formation 212.8 ng/µl 5.319 2.561 2.08 1.53 RNA 40
Bur 
Formation 225.4 ng/µl 5.635 2.719 2.07 1.57 RNA 40
Control 
Resorption 356.3 ng/µl 8.909 4.313 2.07 1.14 RNA 40
Piezo 
Resorption 327.8 ng/µl 8.196 3.948 2.08 0.9 RNA 40
Bur 




Behavioral Neuroscience Institute (Brainarray) at the University of Michigan114 . Array 
quality was assessed by computing Relative Log Expression (RLE) and Normalized 
Unscaled Standard Error (NUSE) using the affyPLM package (version 1.34.0).  
Principal Component Analysis (PCA) was performed using the prcomp R function with 
expression values that had been normalized across all samples to a mean of zero and a 
standard deviation of one.  
Human homologs of mouse genes were identified using HomoloGene (version 68). All 
microarray analyses were performed using the R environment for statistical computing 
(version 2.15.1).  
Gene Set Enrichment Analysis (GSEA)  
GSEA (version 2.2.1)115  was used to identify biological terms, pathways and processes 
that are coordinately up- or down-regulated within each pairwise comparison. The Entrez 
Gene identifiers of the human homologs of the genes interrogated by the array were 
ranked according to the log2-transformed fold change computed between each 
comparison. Mouse genes with multiple human homologs (or vice versa) were removed 
prior to ranking so that the ranked list represents only those human genes that match 
exactly one mouse gene. This ranked list was then used to perform pre-ranked GSEA 
analyses (default parameters with random seed 1234) using the Entrez Gene versions of 
the Hallmark, Biocarta, KEGG, Reactome, Gene Ontology (GO), and transcription factor 
and microRNA motif gene sets obtained from the Molecular Signatures Database 





CHAPTER 3: RESULTS 
3.1 Piezoelectric impact on cell culture 
We study the impact of Piezotome device on two different cell lines PC3 and MDA. 
3.1.1 PC3 
In figures 9&10, attached PC3 cells after 4 days of Piezoelectric injury were significantly 
reduced by the higher puissance setting (P:255). The low puissance setting also reduced 
the amount of viable cells but to a lesser degree compared to (P:255). Different modulation 
did not show any significant difference. In suspension PC3 cells (Figures 11&12) P:255 
with either 100 or 30 frequency settings reduced the live cells to almost zero. In contrast, 
(P:50) and other frequencies failed to reduce cell viability.  
 
 




















Figure 10: PC3 attached cells appearance after 4 days culture period. 
























Figure 12: PC3 suspension cells appearance after 4 days culture period.  








MDA cells are more aggressive than PC3 cells and become confluent much faster. Figure 
13&14 shows that piezotome treatment with high power intensity (255) reduced the 
attached MDA cells while low power intensity (50) failed to do so. These results were the 
same in suspension cells, Fig 15&16(Panel A&B). Vibration power of the piezotome had 
a wide range of impact on the cells. It not only affected the cells near the knife tip but it is 
also affected the cells in a wider range. Fig 6 shows a circular cellular defect from the 




























Figure 14: MDA attached cells appearance after 4 days culture period.  










Figure 15 (Panel A): MDA suspension cells count after 4 days culture period for 













Figure 15 (Panel B): MDA suspension cells appearance after 4 days culture period 
for high puissance settings. 




















Figure 16 (Panel B): MDA suspension cells appearance after 4 days culture period 






(A) Control, (B) 50:100, (C) 50:30. 
3.2 Piezotome cellular disruption compared to bur 
To study the impact of piezotome on bone biology defects made by piezotome and bur 
were processed immediately after the defect to visualize the instant impact of piezotome 
and bur on bone structure. Fig 17 shows the neutral red staining of the calvaria 
immediately after the defects were produced. The piezotome groups showed extended 
cellular disruption beyond the actual defects. This leaves the mineralized bone intact but 
without lining cells. This area will undergo a remodeling process in which the 
mineralized bone will act as a scaffold for the cells to migrate. In fig 18, histological 
examination showed complete absence of periosteal lining cells and disruption of the 
endosteum cellular layer which is not viable in NR staining in piezotome treated group. 
Bur failed to show such an effect. In fig 19, measurement of actual defects and cellular 
disruption showed that the impact is ~5x greater than the apparent mineralized bone 
defect and extends as substantial local cellular damage on the periosteal and endosteal cell 
layers leaving the mineralized layer intact. 
 
 




Neutral red staining immediately after piezotome defect (A) and Bur defect (B). White 





















Figure 18: H & E staining of calvaria immediately after defects. 









Figure 19: Area measurement of the actual and cellular defects. 
Solid blue bars show cellular disruption. Dotted bars represent actual damage. 
 
3.3 Piezoelectric impact on bone under BSA culture media 
3.3.1 Impact of injury on bone resorption 
(i) Dynamic roller tube model system: 
a) Histological evaluation- Figure 20 Panel 1 represents H & E histological 
observations at the end of 21 days of bone cultures post injury. Osteoclastic bone 
resorption in the parietal bone was minimal in the media alone controls (A), and bur 
group (F). The calvaria subjected to piezotome injury had increased osteoclastic bone 
resorption at the site of injury (B-E). The degree of bone resorption in some cases 
proximal to the defect site was extensive with complete dissolution of the mineralized 
bone matrix. In addition, the impact of piezotome injury and the response of the bone 




section (ii) below. In the dynamic bone resorption model the final overall effect appeared 
substantial in which the initial physical full defect to the mineralized bone was 
accompanied with an extended damage to the periosteal and endosteal cellular layers 
surrounding the site of injury that did not have cellular recovery, see section (c) below. 
This impact beyond the bone defect itself clearly plays an important role in the overall 
bone response to piezocision. It has the effect of stimulating the bone turnover via 
osteoclast differentiation and bone resorption to a much greater range of area. This 
phenomenon can be attributed to the synergistic effects of mineralized bone injury and 
the vibrational frequency/ultrasonic oscillations. However, in the bone formation model 
the mineralized bone defects and the impact on the surrounding bone lining cells showed 
cellular recovery including the cellular bridging of the defect site in piezocision, Figure 
20 Panel 2.  This indicates that the extended cellular damage is reversible and depends on 
whether the bone is exposed to additional stimuli favoring resorption or formation post 
injury. These events are indeed the precise simulations in orthodontic tooth movement 
where bone injury coupled with increased physical pressure on one side would induce 
rapid bone resorption while the opposite side with injury undergoes bone formation. 
b) Quantitative analysis of the changes in media calcium, and TRAP activity- 
Figure 21, Panel (a) shows total cumulative calcium release in media for the groups over 
a 21 day culture period. Unstimulated controls showed some calcium release whereas 
those subjected to different treatment regimens showed increased calcium release with 
piezotome (M= 30 kHz) induced injury showing the highest levels. These data are 




quantitative TRAP enzyme activity was consistent with the degree of calcium release and 
histological observations, Figure 21, Panel (b). Piezotome groups showed elevated TRAP 
activity compared to both control and Bur groups. The results for calcium release and 
TRAP activity were all analyzed by two tailed paired t-test with unequal variance to show 
statistical significance (Figure 21). 
c) Global visualization of osteoclast formation by neutral red-  
We globally visualized the osteoclasts by NR, Figure 22 Panels 1-3. The control group 
(untreated calvaria) showed no distinct  resorptive multinucleated osteoclasts, Figure 22, 
Panel 1. In contrast, injury sites showed variable levels of numerous and distinct NR 
stained multinucleated osteoclasts, Figure 22 Panels 1-3, with maximum osteoclast 
formation and bone resorption observed in the piezotome groups. The impact of 
piezotome beyond the actual full bone defects on the surrounding periosteal/endosteal 
cell layers was clearly visible with lack of NR stained areas demonstrating absence of 
vital cells when piezotome with settings P-255 & M-100, P-255 & M-30, and P-50 & M-
100 which do not recover over 21 days. However, the piezotome with settings P-50 & M-
30 showed cellular recovery of both the bone defects and the surrounding cell layers. In 
comparison bur induced defects showed no indication of extended cellular damage 
beyond the actual site of full bone defect and this appears to undergo cellular recovery. 
The bur group had significantly lower level of such occurrence comparable to the control 
group. The piezotome induced injury on one parietal bone hemisphere induced significant 
osteoclast formation and bone resorption at a distance (the contralateral non-injured 




this phenomenon. These data were consistent with the observations from histological 
observations, calcium change in the media measurements and TRAP activity. 
Quantitative histomorphometric analysis- To validate the results further, we performed 
area measurements of bone thickness before and after injury for all the groups. Figure 23 
show the amount of bone resorbed in control and injury groups. In control and bur groups 
the amount of bone resorbed was minimal. In contrast the Piezotme groups decreased the 
bone thickness of the calvaria by 25% to 48%. These data were consistent with the above 







Figure 20 Panel 1: H & E histological evaluation of cross-sections of calvarial bones 
subjected to different surgical injuries in the bone resorption model under dynamic 
culture conditions.  
(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur 







Figure 20 Panel 2: H & E histological evaluation of cross-sections of calvarial bones 
subjected to different surgical injuries in the bone resorption and formation 
conditions. 
Bone formation model; A) control; (B) piezotome defects; (C) bur defects, show cellular 
bridging of the bone damage sites.  Bone resorption model; (D) Control; (E) piezocision; 







Figure 21, Panel a 
 
 
Figure 21, Panel b 
 
Figure 21: Quantitative calcium release and TRAP enzyme activity analysis for 
calvarial bone resorption model under dynamic culture conditions. 











Figure 22 Panel 2 
 
Figure 22 Panel 3 
Figure 22: Neutral red staining of calvarial bones subjected to bone injury in 
resorption model under dynamic culture conditions: 
Panel 1 NR stained calvaria, (a) & (b), media alone no treatment control at low and high 
magnifications 40x and 200x), respectively. (c) – (d), calvaria treated with piezotome 
setting puissance-255 and modulation-100 at low and high magnifications 40x and 200x, 
respectively. Panel 2 NR stained calvaria, (a) & (b) Piezotome setting puissance-255 
modulation-30 at low and high magnifications 40x and 200x. (c) & (d), Piezotome setting 
puissance-50 and modulation-100 at low and high magnifications 40x and 200x, 
respectively. Panel 3 NR stained calvaria, (a) & (b) Piezotome setting puissance-50 
modulation-30 at low and high magnifications 40x and 100x, respectively. (c) NR stained 
calvaria low 40x magnification of defect side of calvarial parietal hemisphere subjected 
to bur injury directly. Arrows indicate full physical bone defects.  Circled areas highlight 
the extended initial cellular damage on the periosteal and endosteal cell layers which do 
not recover over 21 days and showing the intact mineralized bone matrix visible as grey 





Figure 23: Global % bone resorption determined by histomorphometric analysis of 















(ii)  Static grid model system:  
a) Histological evaluation - Figure 24 represents H & E histological observations at 
the end of 21 days of bone cultures post injury. There was no significant osteoclastic 
bone resorption in controls, piezotome with settings (P:50, M:30) and bur groups (A, E 
and F). The calvaria subjected to piezotome injury with low puissance and high 
modulation (P:50, M:100) showed increased level of osteoclastic resorption areas in the 
parietal bone at the site of injury alongside the high puissance settings (B-D). 
b) Quantitative analysis of the changes in media calcium, and TRAP activity- 
Figure 25, Panel (a) shows total cumulative changes in media calcium for the groups over 
a 21 day culture period. Unstimulated controls showed the lowest calcium release 
whereas those subjected to different treatment regiments showed variable levels of 
calcium release with piezotome induced injury showing the highest levels of calcium 
release (reflective of major bone resorption) especially piezotome groups (P-255 & M-
100, -30 and P-50 & M-100). Bur and P-50 & M-30 groups showed significantly lower 
levels of calcium release and hence low level of bone resorption compared to the other 
injury groups. These data are consistent with the histological observations in Figure 24. 
The quantitative TRAP enzyme activity was consistent in which higher power groups 
showed high TRAP activities indicating increased levels of osteoclast differentiation, 
Figure 25, Panel (b). 
c) Global visualization of osteoclast formation by neutral red- Figure 26, Panels 
1-3, represents NR and silver nitrate staining. Due to low calcium release, see Figure 25, 





silver nitrate counter stained samples showing no significant bone resorption areas.  In 
our resorption model system under static conditions the cells proliferate and heal the 
defect area which was not the case for the dynamic conditions, see section (i) (c) above.   
d) Quantitative histomorphometric analysis-  Measurements of bone thickness 
before and after injury for all the groups presented in Figure 27. Piezotome groups (P-255 
& M-100, -30) with higher puissance have the highest amount of resorption 36% and 
33% respectively. Piezotome with lower puissance and high modulation showed 
reduction in bone thickness by 21%. Other injury groups showed lower resorption effect 
(7-10%) on bone thickness compared to the control group (15%). 
 
Figure 24: H & E histological evaluation of cross-sections of calvarial bones 
subjected to different surgical injuries in the bone resorption model in static state. 
(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur 






Figure 25, Panel a 
 
 
Figure 25, Panel b 
 
Figure 25: Quantitative calcium release and TRAP enzyme activity analysis for 
calvarial bone resorption model under dynamic culture conditions.  




for osteoclast quantitation. 
 
 























Figure 26: Neutral red and silver nitrate staining for calvarial bone in static state 
resorption model: 
Panel 1, (a) – (c), media alone no treatment control, (a) & (b) NR stained calvaria,. (c) 
NR stained calvaria counterstained with silver nitrate. (d) – (f), calvaria treated with 
piezotome setting puissance (255) modulation (100), (d) & (e) NR stained calvaria. (f) 
NR stained calvaria counterstained with silver nitrate. Magnifications 40x. Panel 2, (a) & 
(b), Piezotome setting puissance (255) modulation (30). (a) NR stained calvaria, 
magnification 40x; (b) NR stained calvaria counterstained with silver nitrate, 
magnification 40x. (c) – (e), Piezotome setting puissance (50) modulation (100), (c) NR 
stained calvaria magnification 40x. (d) & (e) NR stained calvaria counterstained with 
silver nitrate, magnifications 40x and 100x, respectively. Panel 3, (a) – (c), Piezotome 
setting puissance (50) modulation (30). (a) NR stained calvaria, magnification 40x. (b) 
and (c) NR stained calvaria counterstained with silver nitrate, magnifications 40x and 
100x, respectively. (d) NR stained calvaria of defect side of calvarial parietal hemisphere 
subjected to bur injury directly, magnification 40x. (e) NR stained calvaria counterstained 
with silver magnification nitrate 40x. 
 
 
Figure 27. Global % bone resorption determined by histomorphometric analysis of 





3.3.2 Injury impact on bone formation 
(i) Dynamic roller tube model system: 
a) Histological evaluation– Figure 28 shows new osteoid formation. Control and 
Bur groups showed scant osteoblast differentiation and little osteoid formation. 
Piezotome groups with low power setting (50 mA) had higher osteoblast differentiation 
and similar osteoid formation.The higher power setting (255 mA) groups showed more 
osteoblast differentiation and approximately twice as much osteoid formation.  
b) Quantitative analysis of the changes in media calcium, and ALP activity- 
Calcium analysis was consistent with histological findings, Figure 29, Panel (a). High 
power setting (255 mA) groups had much more calcium uptake than control and other 
injury regimens. ALP activity was measured to assess the degree of osteoblast activity, 
Figure 29, Panel (b).  ALP analysis showed a high level of ALP activity in Piezotome 
groups with high puissance (255 mA) setting compared to control and other injury 
groups. 
c) Quantitative histomorphometric analysis: The measurement of bone thickness 
before and after injury revealed that piezotome setting (P:255, M:30) had 2.3 fold 
increased bone formation. Piezotome setting (P:255, M:100) showed the second highest 
bone formation (1.7 fold, Figure 30). Controls showed some bone formation 1.1 and 
Piezotome setting (P-50 & M-100) showed less bone formation 0.7. Piezotome (P-50 & 





Figure 28: H & E histological evaluation of cross-sections of calvarial bones 
subjected to different surgical injuries in the bone formation model in dynamic 
state. 
(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur 







Figure 29 Panel a 
 
Figure 29 Panel b 
Figure 29: Quantitative calcium uptake analysis and ALP enzyme activity for bone 




(a) calcium uptake, and (b), ALP enzyme activity for osteoblast quantitation. 
 
Figure 30: Percentage of osteoblastic bone formation determined by 
histomorphometric analysis of the histological sections in bone formation model 













(ii) Static grid model system: 
a) Histological evaluation– In this model all groups had different degrees of 
osteoblast differentiation and bone formation, Figure 31. Piezotome with higher 
puissance (255 mA) setting and (P-50 & M-100) group showed extensive osteoblast 
differentiation and bone formation while control and other injury groups exhibited 
diminished levels. 
b) Quantitative analysis of the changes in media calcium and ALP activity- The 
calcium analysis within the injury groups showed highest level of uptake with piezotome 
settings (P- 255 & M-100) and (P-50 & M-30) with lesser calcium uptake for the other 
two setting of piezotome while the bur injury group showed the least calcium uptake, 
Figure 32, Panel (a). ALP activity with higher puissance settings have more ALP activity 
compared to other groups, Figure 32, Panel (b).  
c) Quantitative histomorphometric analysis- The area measurements of 
bone thickness before and after injury also revealed that (250 mA) setting induced almost 






Figure 31: H & E histological evaluation of cross-sections of calvarial bones 
subjected to different surgical injuries in the bone formation model in static state. 
(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur 








Figure 32 Panel a 
 
 
Figure 32 Panel b 
Figure 32: Quantitative calcium uptake analysis and ALP enzyme activity in the 
bone formation model under static culture conditions. 






Figure 33: Global % osteoblastic bone formation determined by histomorphometric 


















3.4  Piezoelectric impact on bone in rolling tube model under FCS culture media. 
a) Histological evaluation - Figure 34 Panel (a & b) represents H & E histological 
observations 21 days post injury. As described previously, FCS media is different 
from batch to batch which gives rise to difficulty in experimental reproducibility. 
Figure 34 panel (a) shows some osteoblast differentiation and bone formation. On 
the other hand, the ascorbic acid supplemented group, fig 34 panel (b), showed 
higher bone formation and geater defect closure. Even when we deprived the 
calvarial bone of ascorbic acid it was able to close some of the defects without any 
new osteoid formation. The FCS experiments do not show resorption when we 
exclude the ascorbic acid due to remnants of ascorbic acid in the FCS. 
b) Quantitative analysis of the changes in media calcium, and TRAP activity- Fig 
37, Panel (a)  and fig 38, Panel (a), Calcium analysis in both groups showed calcium 
uptake from the media. Ascorbic acid supplemented group showed higher calcium 
uptake. Figure 37, panel (c) Fig 38, panel (c) showed that the ascorbic acid 
supplemented groups have higher amount of TRAP enzyme activity compared to 
non-supplemented group except for control and P:255,M:100 groups. These results 
showed the discrepancy in results when the media was supplemented with FCS. 
c) Global visualization of osteoclast formation by neutral red and silver nitrate- 
Neutral red and silver nitrate staining showed cellular migration and defects closure 






























































Figure 34, Panel b 
 
Figure 34: H & E histological evaluation of cross-sections of calvarial bones 
subjected to different surgical injuries in the bone cultured in FCS media. 
Panel (a) without Ascorbic acid. Panel (b) with ascorbic acid. (A) Control, (B) 




















































































Figure 35: Neutral red staining for calvarial bone subjected to different injuries 
cultured in FCS culture medium: 
Panel (a) without Ascorbic acid. Panel (b) with ascorbic acid ((A) Control, (B) 











































































Figure 36, Panel b 
 
Figure 36: Silver nitrate staining for calvarial bone subjected to different surgical 
injuries cultured in FCS culture medium: 
Panel (a) without Ascorbic acid. Panel (b) with ascorbic acid. (A) Control, (B) 
P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur groups. 
magnification 40x. 
 





Figure 37, Panel b 
 




Figure 37: Quantitative calcium uptake/release analysis, ALP, TRAP enzyme 
activity in the bone cultured under FCS media. 



















Figure 38, Panel b 
 






Figure 38: Quantitative calcium uptake/release analysis, ALP, TRAP enzyme 
activity in the bone cultured under FCS media and VitC. 

















3.5 Piezoelectric effect on bones treated with bisphosphonate 
3.5.1 Piezoelectric effect on bones treated with bisphosphonate 6 days prior to the 
injury with and without ascorbic acid 
3.5.1.1 BSA 
I. Resorption: 
a) Histological evaluation – Fig 39 showed that bisphosphonate treatment prior to 
injury prevented the resorption phenomenon we presented earlier. There is little or 
no osteoclast differentiation and bone resorption. Three doses of bisphosphonate 
prevented osteoclast differentiation and bone resorption. 








Calcium release showed in Fig 41, panel (a) that Piezotome groups have low 
calcium release compared to control and bur groups. TRAP activity showed the 
opposite in which high puissance setting have higher TRAP activity, Fig 41 panel 
(b). 
c) Global visualization of osteoclast formation by neutral red:- NR and silver 
nitrate staining showed the effect of the piezotome on the cellular layer around the 



















Figure 39 : H & E histological evaluation of cross-sections of calvarial bones in 
resorption model treated with bisphosphonate prior injury under BSA culture 
media. 







































Figure 40: Neutral red and silver nitrate staining for calvarial bone in resorption 
model treated with bisphosphonate prior injury under BSA culture media: 






Figure 41, Panel a 
 
 
Figure 41, Panel b 
 
Figure 41: Quantitative calcium uptake/release analysis, TRAP enzyme activity in 




(a) Calcium uptake, and (b) TRAP activity. 
II. Formation: 
a) Histological evaluation :- Fig 42 showed that the control group had some bone 
formation and osteoblast differentiation. The high puissance setting showed greater 
osteoblast differentiation and bone formation. The P:50, M:30 and bur groups did 
not show such bone formation. 
b) Quantitative analysis of the changes in media calcium, and ALP activity:- 
Calcium analysis in Fig 44, panel (a) are consistent with the histology. 255 
puissance and P:50 M:100  have elevated levels of calcium uptake compared to 
other groups. ALP activity is also consistent with histology and calcium analysis. 
Fig 44, panel (b). 
c) Global visualization of osteoclast formation by neutral red:- NR and SV 
staining showed high number of cells staining which indicate increased cell activity. 




































Figure 42 : H & E histological evaluation of cross-sections of calvarial bones in 
resorption model treated with bisphosphonate and VitC prior injury under BSA 





















































Figure 43: Neutral red and silver nitrate staining for calvarial bone in formation 
model treated with bisphosphonate and VitC prior injury under BSA culture 
media: 








Figure 44, Panel a 
 
 
Figure 44, Panel b 
 
Figure 44: Quantitative calcium uptake/release analysis, ALP enzyme activity in the 
bone cultured under BSA with Bisphosphonate and VitC. 






I. Without Ascorbic Acid: 
a) Histological evaluation – Fig 45 illustrates the histology. There is minimum 
osteoclast differentiation and bone resorption in all groups. 
b) Quantitative analysis of the changes in media calcium, and TRAP activity:- In fig 
47, panel (a) calcium levels of high puissance settings showed negative value 
which indicates calcium uptake and bone formation. It was not eviedent in 
histology pictures due to low calcium levels and the bisphosphonate treatment 
prior injury. TRAP activity was higher in the high puissance groups and control 
group. Fig 47, panel (b) 
c) Global visualization of osteoclast formation by neutral red:- NR and SV stainings 

































Figure 45 : H & E histological evaluation of cross-sections of calvarial treated with 
bisphosphonate prior injury under FCS culture media. 


























































Figure 46: Neutral red and silver nitrate staining for calvarial bone treated with 
bisphosphonate prior injury under FCS culture media: 









Figure 47, Panel a 
 
Figure 47, Panel b 
Figure 47: Quantitative calcium uptake/release analysis, TRAP enzyme activity in 








(a) Calcium uptake, and (b) TRAP activity. 
II. With Ascorbic Acid: 
a) Histological evaluation – In Fig 48, no group showed any bone formation and all 
groups had very limited osteoblast differentiation. 
b) Quantitative analysis of the changes in media calcium, and ALP activity:- all groups 
in Fig 50, panel (a) showed some degree of calcium uptake. In Fig 50, panel (b) all 
groups also had some ALP activity. The high puissance have the least activity. 
c) Global visualization of osteoclast formation by neutral red:- both stainings failed to 
show any osteoclast differentiation and bone resorption. The cellular defect around 





















Figure 48 : H & E histological evaluation of cross-sections of calvarial bones treated 
with bisphosphonate and VitC prior injury under FCS culture media. 













































Figure 49: Neutral red and silver nitrate staining for calvarial bone in formation 
model treated with bisphosphonate and VitC prior injury under FCS culture media. 








Figure 50, Panel a 
 
Figure 50, Panel b 
Figure 50: Quantitative calcium uptake/release analysis, ALP enzyme activity in the 
bone cultured under FCS with Bisphosphonate and VitC. 




3.5.2 Piezoelectric impact on bone treated with bisphosphonate at the time of the injury 
3.5.2.1 BSA 
I. Resorption 
a) Histological evaluation – In Fig 51, The control group showed little osteoclast 
differentiation and bone resorption. Puissance 255 with Modulation 30 showed 
extensive amount of bone resorption. The P:50,M:30 and Bur groups does not 
show any osteoclast differentiation and bone resorption.  
b) Quantitative analysis of the changes in media calcium, and TRAP activity:- Fig 
53, Panel (a) Calcium level of piezotome groups is elevated compared to control 
and bur groups. Low puissance groups were the highest calcium release. TRAP 
activity was consistent with the calcium release. Fig 53, panel (b). 
c) Global visualization of osteoclast formation by neutral red:-  NR and SN staining 
revealed some osteoclast activity in piezotome groups while control and bur 
groups did not show this activity, Fig 52. 
These findings suggest potential bone cells response to the injury before complete 
accumulation of bisphosphonate. Cells were able to differentiate and initiate bone 
resorption unlike the previous experiment n which calvaria were treated with 























Figure 51 : H & E histological evaluation of cross-sections of calvarial bones treated 
with bisphosphonate at the same time of injury under BSA culture media. 





























































Figure 52: Neutral red and silver nitrate staining for calvarial bone in resorption 








(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P:50,M:100, (E) P:50,M:30, (F) Bur 
groups. 
 
Figure 53, Panel a 
 




Figure 53: Quantitative calcium uptake/release analysis, TRAP enzyme activity in 
the bone cultured under BSA with Bisphosphonate treatment at the same time of 
injury.  
(a) Calcium uptake, and (b) TRAP activity. 
II. Formation 
a) Histological evaluation -  In this formation model the control group had 
extensive osteoblast differentiation and bone formation. Piezotome groups 
also had extensive osteoblast differentiation but with less new osteoid 
formation. The bur group had limited osteoblast differentiation and bone 
formation. Fig 54. 
b) Quantitative analysis of the changes in media calcium, and ALP activity:- 
Calcium and ALP activity were consistent with the histological findings, Fig 
56. 
c) Global visualization of osteoclast formation by neutral red:- NR staining does 
not show any osteoclast differentiation while SN staining showed some bone  
deposition in the defect area in some piezo groups. Fig 55. Cells were able to 
migrate and close some of the exposed bone in piezotome groups. This was 





































Figure 54: H & E histological evaluation of cross-sections of calvarial bones treated 
with bisphosphonate at the same time of injury under BSA culture media and 
Vitamin C. 


















































































Figure 55: Neutral red and silver nitrate staining for calvarial bone in formation 
model treated with bisphosphonate at the same time of injury under BSA culture 
media with Vitamin C: 





















Figure 56, Panel a 
 




Figure 56: Quantitative calcium uptake/release analysis, ALP enzyme activity in the 
bone cultured under BSA with Bisphosphonate treatment at the same time of injury 
with Vitamin C. 
(a) Calcium uptake, and (b) ALP activity. 
3.5.2.2 FCS 
I. Without Ascorbic Acid: 
a) Histological evaluation – In this model histological examination showed that 
control, P:50 and bur groups showed no bone resorption nor osteoclast 
differentiation. In contrast the 250 puissance group showed both bone resorption 
and formation, Fig 57. 
b) Quantitative analysis of the changes in media calcium, and TRAP activity:- The 
piezotome group with modulation 30 Hz have higher calcium release compared to 
other groups, Fig 59, panel (a). All groups showed some TRAP activity, Fig 59, 
panel (b). 
c) Global visualization of osteoclast formation by neutral red:-  NR staining showed 
that Puissance 255 groups have limited cell staining compare to other groups. SN 


































Figure 57 : H & E histological evaluation of cross-sections of calvarial bones treated 
with bisphosphonate at the same time of injury under FCS culture media.  





































































Figure 58: Neutral red and silver nitrate staining for calvarial bone treated with 
bisphosphonate at the same time of injury under FCS culture media:. 
(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur 
groups. 
 
Figure 59, Panel a 
 
 




Figure 59: Quantitative calcium uptake/release analysis, TRAP enzyme activity in 
the bone cultured under FCS with Bisphosphonate treatment at the same time of 
injury.  
(a) Calcium uptake, and (b) TRAP activity. 
 
II. With Ascorbic Acid: 
a) Histological evaluation – In this model, all groups showed varying degrees of 
new osteoblast differentiation and new osteoid deposition. The control group 
showed extensive bone formation and some osteoblast differentiation while 
puissance 255 showed extensive osteoblast differentiation with less new osteoid 
formation. Puissance 50 group showed fewer osteoblast differentiation and bone 
formation. Bur group showed limited bone formation, Fig 60 
b) Quantitative analysis of the changes in media calcium, and TRAP activity:- 
Calcium analysis was consistent with histological pictures. Fig 62, pane (a). In 
ALP activity, all groups showed elevated ALP activity. Bur and Control groups 
have higher ALP activity compare to piezotome groups, Fig 62, panel (b). 
c) Global visualization of osteoclast formation by neutral red:-  Fig 61 presents NR 
and SN stainings. In NR staining there was no osteoclast differentiation in all 
groups. In SN staining piezotome groups showed some staining in the defect area 


































Figure 60 : H & E histological evaluation of cross-sections of calvarial bones treated 
with bisphosphonate at the same time of injury under FCS culture media with 
Vitamin C. 








































































Figure 61: Neutral red and silver nitrate staining for calvarial bone treated with 
bisphosphonate at the same time of injury under FCS culture media and Vit C:. 
 (A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) 
Bur groups. 
 





Figure 62, Panel b 
Figure 62: Quantitative calcium uptake/release analysis, ALP enzyme activity in the 
bone cultured under FCS with Bisphosphonate treatment at the same time of injury 
with Vitamin C.  
(a) Calcium uptake, and (b) ALP activity. 
 
3.6 Piezoelectric impact on bone healing of non-critical bone defects treated with 
and without bisphosphonate 
3.6.1 Defects treated with Ascorbic acid 
Figure 63, Panels (a-c) showed the calvaria treated with ascorbic acid without 
bisphosphonate treatment. The control group (Panel a) showed initial defect healing in 
the 2nd week of treatment and complete cellular closure at the end of the 4th week. In 
contrast, Piezotome injured (Panel b) calvarias showed cellular migration from the first 
few days of the injury and complete cellular defect closure in the beginning of 3rd week. 
In fact, cells migrated and closed 75% of the defect by day 12 of the treatment  Bur group 
(Panel c) failed to show complete cellular closure. These results confirmed the 
stimulation effect of piezotome when the injury applied in close proximity to the defects. 








Figure 63, Panel a 
 






Figure 63, Panel c 
 
Figure 63: Non-critical Defect cellular healing treated with ascorbic acid only. 
Panels (a) Control, (b) Piezotome, (c) Bur groups. Defect pictures taken at 5 different 
time points (A) 5 days, (B) 12 days, (C) 19 days, (D) 23 days, (E) 30 days, and (F) 



















3.6.2 Defects treated with bisphosphonate 
Figure 64, Panels (a-c) showed defect regeneration after treatment with three doses of 
bisphosphonate. All groups showed delayed healing and impaired cellular migration due 
to bisphosphonate treatment. Control group (Panel a) showed very limited cellular 
migration at the end of third week and beginning of the fourth week. After 30 days, cells 
migrated farther and were able to close 40-50% of the defect. Contrarily piezotome group 
(Panel b) showed a similar delay in the first two weeks but cells migrated rapidly to close 
the defect in the last week. Bur group (Panel c) was similar to the control group but with 
more initial cellular migration. As discussed in chapter 1, bisphosphonate has some 
impact on osteoblast cells. Hence the cellular proliferation and migration to close the 









Figure 64, Panel a 
 
 





Figure 64, Panel c 
 
Figure 64: Non-critical Defect cellular healing treated with bisphosphonate. 
Panels (a) Control, (b) Piezotome, (c) Bur groups. Defect pictures taken at 5 different 
time points (A) 5 days, (B) 12 days, (C) 19 days, (D) 23 days, (E) 30 days, and (F) 












3.7 Piezoelectric impact on bone biology treated with and without Insulin 
a) Histological evaluation – Fig 65 showed histological slides of calvaria treated 
with ascorbic acid. New osteoid formation was present in all groups but it was 
less evident in bur group. On the other hand, calvaria treated with insulin showed 
an increase in osteoblast differentiation compared to calvaria treated with ascorbic 
acid. fig 66 
b) Quantitative analysis of the changes in media calcium, and ALP activity:- 
Calcium analysis in Fig 69 panel (a), showed calvaria treated with ascorbic acid 
only have higher calcium uptake than insulin treated calvaria. The only groups 
showed statistical difference between insulin treated and not treated are control 
and bur groups. In insulin treated group calvaria treated with high puissance 
settings and (P:30, M:100) show elevated calcium uptake. ALP activity showed 
the opposite. It showed elevated ALP activity in insulin treated groups compared 
to ascorbic acid groups. Fig 69, Panel (b). All groups treated with insulin except 
Bur showed statistically significant higher ALP compared to ascorbic acid groups. 
c) Global visualization of osteoclast formation by neutral red and silver 
nitrate:- NR and SV staining showed high cells staining which indicate cells 







   
   
   
Figure 65: H & E histological evaluation of cross-sections of calvarial bones 
subjected to different surgical injuries in the bone cultured in BSA media with 
ascorbic acid. 
(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur 













   
   
   
Figure 66: H & E histological evaluation of cross-sections of calvarial bones 
subjected to different surgical injuries in the bone cultured in FCS media. 
Panel (a) without Ascorbic acid. Panel (b) with ascorbic acid. (A) Control, (B) 







































































Figure 67: Neutral red and silver nitrate staining for calvarial bone treated with 
ascorbic acid for 14 days under BSA culture media:. 
(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur 
































































































Figure 68: Neutral red and silver nitrate staining for calvarial bone treated with 
Insulin for 14 days under BSA culture media: 
(A) Control, (B) P:255,M:100, (C) P:255,M:30, (D) P: 50,M:100, (E) P:50,M:30, (F) Bur 





















Figure 69, Panel a 
 
 
Figure 69, Panel b 
 
Figure 69: Quantitative calcium uptake analysis, ALP enzyme activity in the bone 




(a) Calcium uptake, and (b) ALP activity. 
3.8 Piezoelectric impact on bone healing of critical bone defects treated with 
resorbable collagen and emdogain 
 Histological evaluation – Fig 70 shows that all groups have some degree of cellular 
migration to the defect. Group treated with collagen only (A) showed limited cellular 
migration to the defect side and minimal cellular proliferation in the defect borders. In 
the group treated with collagen and emdogain (B), there was more cellular migration 
to the defect side. Piezotome treated groups (C-F) showed much more cellular 
migration to the defect site and defect peripheries. P:50, M:100 was the highest 
among the piezo groups. The most noticed feature was the formed bone in the defect 
border area with piezotome groups.  
 Quantitative analysis of the changes in media calcium, and ALP activity:- 
Calcium analysis in Fig 72 panel (a), showed no statistical difference between all 
groups. On the other hand, ALP activity in Fig 72 panel (b) showed calvaria treated 
with resorbable collagen and emdogain except bur group have higher levels of 
calcium uptake from calvaria treated with collagen only 
 Global visualization of osteoclast formation by neutral red:- NR staining Fig 71 
shows high cellular staining in the groups treated with emdogain specially in the 
defect borders. 
 Piezotome treated groups enhance bone formation in the defect side. More cellular 
migration and bone formation could be more evident if the calvaria were cultured for 






















































Figure 70 : H & E histological evaluation of cross-sections of calvarial bones with 
critical defects treated with resorbable collagen and emdogain under BSA culture 
media with Vitamin C.  
(A) Collagen only, (B) Collagen and Emdogain, (C) P:255,M:100, (D) P:255,M:30, (E) 




















































































































Figure 71: Neutral red staining for calvarial bone with Critical defects treated with 
resorbable collagen and emdogain under BSA culture media:.  
(A) Collagen only, (B) Collagen and Emdogain, (C) P:255,M:100, (D) P:255,M:30, (E) 











Figure 72, Panel a 
 
 
Figure 72, Panel b 
 
Figure 72: Quantitative calcium uptake analysis, ALP enzyme activity in the 
calvarial bone with critical defects treated with resorbable collagen and emdogain 




(a) Calcium uptake, and (b) ALP activity. 
3.9 Piezoelectric impact on mice gene expression compared to bur 
I. Formation 
Calvarias processed for RNA extraction and genetic expression using microarrays after 4 
hours culture period. Total gene counts (25206 gene) were expressed and comparison of 
fold change between groups were presented. Figure 73 presents scatter plot graph of the 
total gene regulation. When the piezotome group were compared to control, 777 gene 
were up-regulated more than two fold. It also shows 325 genes down-regulated more than 
two fold (Panel a). This massive gene expression was also evident when the piezotome 
group was compared to the bur group. Piezotome upregulated 741 genes and down-
regulated 349 genes compared to bur. In contrast bur upregulated only 277 genes and 
down-regulated 296 genes when compared to control. These genes level support the 
results presented earlier in which the piezotome impact enhanced the bone formation and 
osteoblast differentiation. 
In order to look in depth genes were filtered to include genes related to bone only. 301 
genes were identified using gene odontology (GO). Figure 74 presents the gene 
expression level comparison between the groups. Due to low gene number associated 
with bone comparison was set as 1.5 fold change difference. Panel (a) presents the gene 
expression level comparison between Piezotome and control. Out of 301 genes, 49 gene 
were up-regulated and 43 genes were down-regulated. Piezotome compared to bur also 
showed upregulation of 37 genes and downregulation of 44 genes. Bur also showed up-




Genes that up-regulated or down-regulated by at least 1.5 fold after piezotome defect 
compared to bur defect are listed in table 2. The majority of the up-regulated genes have 
an impact on either osteoblast recruitment, differentiation and proliferation such as 
(Ptprc, Transferrin, Osr1) or inhibit osteoclast differentiation such as (Innp5d, Lilrp3 and 
Sfrp1). The majority of the down-regulated genes favor osteoclastogenesis like Areg, 
Epha2, Ssp1, Bglap, Ptgs2 and Acp5 or they inhibit osteoblast differentiation like 
Germelin, Areg, Epha2, Cited1 and Bglap. 
GSEA provides a broader view into the differential gene expression. It looks into gene 
sets that already established through well studied pathways. Table 3 shows the pathways 
that are associated directly to bone and bone cells. Normalized enrichment scores were 
elevated in GO negative regulation of osteoclast differentiation ( p value <0.01 and FDR 
q value < 0.05). There was no statistical significance of any osteoblast differentiation sets 
between piezo and bur groups. However, GSEA gene sets report showed 3472 / 6077 
gene sets that are upregulated in Piezo vs Bur in formation log2 fold change. 906 / 3472 
gene sets are significant at FDR < 25%. 509 / 3472 gene sets are significantly enriched at 
nominal pvalue < 1% and 906 / 3472 gene sets are significant at FDR < 25%. On the 
other hand, 2605 / 6077 gene sets are downregulated in Piezo vs Bur in formation log2 
fold change. 202 / 2605 gene sets are significantly enriched at FDR < 25%. 323 / 2605 
gene sets are significantly enriched at nominal pvalue < 1% and 624 / 2605 gene sets are 













































































Figure 73, Panel b 
 
Figure 73: Total genes differential expression level in calvarial bone cultured in 
formation model for 4 hours. 
Panel (a) genes differential expression in piezotome compared to control. Panel (b) genes 
differential expression in piezotome compared to bur. Panel (c) genes differential 








































































Control gene expression (Log 2)
Piezotome vs Control bone related gene expression under 
formation model 
Up-regulated genes ≥ 1.5 (n=49)
Down-regulated genes ≤ -1.5 (n=43)











































Figure 74, Panel c 
 
Figure 74: Bone related genes differential expression level in calvarial bone cultured 
in formation model for 4 hours. 
Panel (a) bone related genes differential expression in piezotome compared to control. 
Panel (b) bone related genes differential expression in piezotome compared to bur. Panel 




























































































































































Table 2: Bone related genes Up-regulated or Down-regulated by Piezotome 



































































































Table 3: Bone related genes Up-regulated or Down-regulated by Bur compared to 














































































































Table 4: Bone related genes Up-regulated or Down-regulated by Piezotome 
compared to Bur in formation model. 
 
 
















20 0.64 1.71 0.0083 0.0362
GO_REGULATION_OF_OSTEOCLAST_DIFFEREN
TIATION
56 0.47 1.52 0.0224 0.1261
GO_REGULATION_OF_BONE_RESORPTION 31 0.51 1.46 0.0554 0.1733
GO_REGULATION_OF_BONE_REMODELING 40 0.41 1.25 0.1738 0.3932
GO_BONE_CELL_DEVELOPMENT 20 0.42 1.09 0.3691 0.6208
GO_BONE_RESORPTION 19 0.42 1.09 0.3586 0.6302
GO_OSTEOCLAST_DIFFERENTIATION 28 0.37 1.06 0.3754 0.6574
GO_BONE_REMODELING 33 0.35 1.04 0.4281 0.6862
GO_REGULATION_OF_OSTEOBLAST_PROLIFER
ATION
23 0.37 1.01 0.4495 0.7206
GO_POSITIVE_REGULATION_OF_OSTEOCLAST
_DIFFERENTIATION
24 0.35 0.97 0.5104 0.7762
GO_OSTEOBLAST_DIFFERENTIATION 119 0.24 0.88 0.7132 0.8814
GO_OSTEOBLAST_DEVELOPMENT 17 0.30 0.77 0.7729 0.9609
GO_POSITIVE_REGULATION_OF_OSTEOBLAST
_DIFFERENTIATION
59 ‐0.18 ‐0.68 0.9801 0.9781
GO_REGULATION_OF_OSTEOBLAST_DIFFEREN
TIATION
110 ‐0.21 ‐0.90 0.7574 0.8051
GO_BONE_GROWTH 20 ‐0.32 ‐0.93 0.5678 0.7519
GO_BONE_MINERALIZATION 37 ‐0.28 ‐0.96 0.5152 0.7243
GO_BONE_DEVELOPMENT 150 ‐0.23 ‐1.03 0.3779 0.6164
GO_NEGATIVE_REGULATION_OF_OSTEOBLAST
_DIFFERENTIATION
40 ‐0.31 ‐1.08 0.3414 0.5594
GO_REGULATION_OF_BONE_DEVELOPMENT 16 ‐0.40 ‐1.09 0.3670 0.5443
GO_BONE_MORPHOGENESIS 77 ‐0.27 ‐1.10 0.2788 0.5380
GO_ENDOCHONDRAL_BONE_MORPHOGENESI
S
45 ‐0.31 ‐1.11 0.2727 0.5267
GO_CARTILAGE_DEVELOPMENT_INVOLVED_IN
_ENDOCHONDRAL_BONE_MORPHOGENESIS







In this culture model we deprived the calvaria of ascorbic acid to direct the bone to 
undergo resorption only without the ability to form any new bone. After 4 hours culture 
the microarray analysis revealed the differential genetic expression levels. Piezotome 
defects when compared to control showed 177 up-regulated genes more than 2 fold and 
59 down-regulated genes below -2 fold (fig 75, panel a). Bur defects also showed similar 
gene regulation when compared to control with 201 genes up-regulated and 84 down-
regulated (fig 75, panel b). However, when we compare piezotome to bur defects, 34 
genes were up-regulated and 67 down-regulated (fig 75, panel c). This difference in gene 
expression levels were very low when compared to the genes up-regulated or down-
regulated in the formation model. 
All genes were filtered to include only bone and bone cell related genes (n=301). 
Among those genes piezotome showed up-regulation of 21 genes and down-regulation of 
14 genes compared to control group (fig 76, panel a). On the other hand, Bur also showed 
the same gene expression 23,13 up/down regulated respectively (fig 76, panel c). 
However, piezotome up-regulated 9 genes and down-regulated 8 genes when compared 
to bur defect (fig 76, panel b). Among these 9 genes up-regulated by piezotome is Twist2 
gene with 1.9 fold increase compare to bur. Twist2 expression inhibit osteoblast 
maturation and hold the cell lineage into preosteoblast stage. Wnt3 was also increased by 




osteoblastogenesis. Plexin b1 also was upregulated. It is important in the communication 
between osteoclast and osteoblast cells. Last but not least, fibrillin 2 was upregulated by 
1.7 fold. It acts on extracellular microfibril production and in osteoblast formation. When 
we look to the 8 downregulated genes we found genes related to osteoblast differentiation 
such as Mir23a and genes related to inhibition of osteoclast differentiation and formation 
such as IL6, Clec2i and Clec2g (Table 4). 
Finally, GSEA does not show any statistical difference in bone gene sets between 
piezotome and bur groups (Table 5). However, In the GSEA gene sets report, 3054 / 6077 
gene sets are upregulated in Piezo vs Bur in resorption log2 fold change. 163 / 3054 gene 
sets are significant at FDR < 25%, 196 / 3054 gene sets are significantly enriched at 
nominal pvalue < 1% and 365 / 3054 gene sets are significantly enriched at nominal 
pvalue < 5%. On the other hand, 3023 / 6077 gene sets are downregulated in Piezo vs Bur 
in resorption log2 fold change. 103 / 3023 gene sets are significantly enriched at FDR < 
25%, 194 / 3023 gene sets are significantly enriched at nominal pvalue < 1% and 481 / 




















































Figure 75, Panel b 
 
 



































































Figure 75: Total genes differential expression level in calvarial bone cultured in 
resorption model for 4 hours. 
Panel (a) genes differential expression in piezotome compared to control. Panel (b) genes 
differential expression in piezotome compared to bur. Panel (c) genes differential 





















































































































Figure 76, Panel c 
 
Figure 76: Bone related genes differential expression level in calvarial bone cultured 
in resorption model for 4 hours. 
Panel (a) bone related genes differential expression in piezotome compared to control. 
Panel (b) bone related genes differential expression in piezotome compared to bur. Panel 















Areg amphiregulin 5.7 
Ryr1 ryanodine receptor 1, skeletal muscle 3.2 
Ptgs2 prostaglandin-endoperoxide synthase 2 3.1 
Nppc natriuretic peptide type C 3.0 
Twist2 twist homolog 2 (Drosophila) 2.5 
Cited1 
Cbp/p300-interacting transactivator with Glu/Asp-rich 
carboxy-terminal domain 1 
2.3 
Cdk6 cyclin-dependent kinase 6 1.9 
Wnt3 wingless-related MMTV integration site 3 1.8 
Mir23a microRNA 23a 1.8 
Bmp2 bone morphogenetic protein 2 1.8 
Tnfsf11 tumor necrosis factor (ligand) superfamily, member 11 1.7 









tumor necrosis factor receptor superfamily, member 11b 
(osteoprotegerin) 
1.6 
Fgf2 fibroblast growth factor 2 1.6 
Notch1 notch 1 1.6 
Junb Jun-B oncogene 1.6 
Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 1.5 
Epha2 Eph receptor A2 1.5 
Hspg2 perlecan (heparan sulfate proteoglycan 2) 1.5 
Bmpr1b bone morphogenetic protein receptor, type 1B 1.5 
Hpse heparanase -1.5 
Msx1 homeobox, msh-like 1 -1.5 
Sp7 Sp7 transcription factor 7 -1.5 
Phospho1 phosphatase, orphan 1 -1.5 
Csf1r colony stimulating factor 1 receptor -1.5 
Clec5a C-type lectin domain family 5, member a -1.5 
Rarg retinoic acid receptor, gamma -1.5 
Msx2 homeobox, msh-like 2 -1.5 
Hey1 hairy/enhancer-of-split related with YRPW motif 1 -1.6 
Dlx5 distal-less homeobox 5 -1.6 
Ccl5 chemokine (C-C motif) ligand 5 -1.6 
Rspo2 R-spondin 2 homolog (Xenopus laevis) -1.7 
Id4 inhibitor of DNA binding 4 -1.7 
Snai2 snail homolog 2 (Drosophila) -2.0 
 
Table 6: Bone related genes Up-regulated or Down-regulated by Piezotome 















Piezo vs Bur 
Areg amphiregulin 8.4 
Ptgs2 prostaglandin-endoperoxide synthase 2 4.3 
Nppc natriuretic peptide type C 4.2 
Cited1 
Cbp/p300-interacting transactivator with Glu/Asp-
rich carboxy-terminal domain 1 
4.1 
Mir23a microRNA 23a 3.4 
Tnfsf11 
tumor necrosis factor (ligand) superfamily, 
member 11 
2.1 
Ryr1 ryanodine receptor 1, skeletal muscle 2.1 
Fgf2 fibroblast growth factor 2 2.1 
Clec2i C-type lectin domain family 2, member i 1.9 
Ank progressive ankylosis 1.9 
Vegfa vascular endothelial growth factor A 1.8 
Tnfrsf11b 
tumor necrosis factor receptor superfamily, 
member 11b (osteoprotegerin) 
1.8 
Pthlh parathyroid hormone-like peptide 1.7 
Bmp2 bone morphogenetic protein 2 1.7 
Cdk6 cyclin-dependent kinase 6 1.7 
Junb Jun-B oncogene 1.7 
Ucma 
upper zone of growth plate and cartilage matrix 
associated 
1.6 
Wwtr1 WW domain containing transcription regulator 1 1.5 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.5 
Hand2 
heart and neural crest derivatives expressed 
transcript 2 
1.5 
Wnt11 wingless-related MMTV integration site 11 1.5 
2410016O06Rik RIKEN cDNA 2410016O06 gene 1.5 




Ccl5 chemokine (C-C motif) ligand 5 -1.5 
Ptprc protein tyrosine phosphatase, receptor type, C -1.5 
Plxnb1 plexin B1 -1.5 
Hey1 hairy/enhancer-of-split related with YRPW motif 1 -1.6 
Rarg retinoic acid receptor, gamma -1.6 
Eif2ak2 
eukaryotic translation initiation factor 2-alpha 
kinase 2 
-1.7 
Id4 inhibitor of DNA binding 4 -1.7 
Xdh xanthine dehydrogenase -1.7 
Dlx5 distal-less homeobox 5 -1.8 
Phospho1 phosphatase, orphan 1 -1.8 
Rspo2 R-spondin 2 homolog (Xenopus laevis) -2.4 
Snai2 snail homolog 2 (Drosophila) -2.5 
 
 
Table 7: Bone related genes Up-regulated or Down-regulated by Bur compared to 







Table 8: Bone related genes Up-regulated or Down-regulated by Piezotome 



















































GO_REGULATION_OF_OSTEOBLAST_PROLIFERATION 23 0.42 1.30 0.1458 0.5615
GO_OSTEOBLAST_DIFFERENTIATION 119 0.30 1.26 0.0870 0.6082
GO_ENDOCHONDRAL_BONE_MORPHOGENESIS 45 0.31 1.15 0.2363 0.7440
GO_BONE_DEVELOPMENT 150 0.25 1.14 0.1993 0.7486
GO_BONE_MINERALIZATION 37 0.31 1.07 0.3474 0.8294
GO_REGULATION_OF_BONE_REMODELING 40 0.25 0.90 0.6455 0.9571
GO_NEGATIVE_REGULATION_OF_OSTEOCLAST_DIFF
ERENTIATION
20 0.29 0.87 0.6592 0.9765
GO_POSITIVE_REGULATION_OF_OSTEOBLAST_DIFFE
RENTIATION
59 0.18 0.67 0.9743 1.0000
GO_BONE_CELL_DEVELOPMENT 20 0.22 0.66 0.9112 1.0000
GO_OSTEOBLAST_DEVELOPMENT 17 ‐0.23 ‐0.67 0.9099 0.9993
GO_CARTILAGE_DEVELOPMENT_INVOLVED_IN_END
OCHONDRAL_BONE_MORPHOGENESIS
19 ‐0.23 ‐0.67 0.8966 0.9997
GO_REGULATION_OF_OSTEOBLAST_DIFFERENTIATIO
N
110 ‐0.19 ‐0.82 0.8866 0.9516
GO_BONE_MORPHOGENESIS 77 ‐0.21 ‐0.88 0.7115 0.9129
GO_REGULATION_OF_OSTEOCLAST_DIFFERENTIATIO
N
56 ‐0.24 ‐0.92 0.5757 0.8773
GO_BONE_REMODELING 33 ‐0.29 ‐1.00 0.4295 0.7742
GO_BONE_GROWTH 20 ‐0.33 ‐1.01 0.4437 0.7646
GO_NEGATIVE_REGULATION_OF_OSTEOBLAST_DIFF
ERENTIATION
40 ‐0.28 ‐1.02 0.4269 0.7583
GO_BONE_RESORPTION 19 ‐0.36 ‐1.08 0.3528 0.6817
GO_POSITIVE_REGULATION_OF_OSTEOCLAST_DIFFE
RENTIATION
24 ‐0.36 ‐1.13 0.2847 0.6155
GO_OSTEOCLAST_DIFFERENTIATION 28 ‐0.42 ‐1.38 0.0764 0.3831
GO_REGULATION_OF_BONE_RESORPTION 31 ‐0.41 ‐1.39 0.0747 0.3684








CHAPTER 4: DISCUSSION 
One of the major limitations of orthodontic tooth movement is the time required achieve 
the desired end result which could be as long as 2 years. There is increasing need for 
orthodontic treatment by patients with a wide range of ages. The desire for improved 
esthetic look in older individuals, has also increased the need for improved orthodontic 
tooth movement and has prompted the introduction of a variety of new surgical 
techniques as detailed in the introduction. One of those surgical techniques is the 
piezoelectric knife which has a number of advantages. The precise and selective cutting 
capacity of the piezoelectric knife and the physico-chemical changes induced in the bone 
microenvironment by its ultrasonic properties are likely characteristics that provide better 
results in certain procedures and in other cases enable procedures to be possible as 
compared to conventional bur approaches. For example, it is possible to combine hard 
tissue and soft tissue grafting using piezocision in cases of gingival recession correction 
and bone augmentation which is not possible with corticision approach. In 2009 Dibart 
introduced a new minimally invasive procedure that he called “Piezocision™”.117 
This technique combines micro-incisions with selective tunneling that allows hard or soft 
tissue grafting and piezoelectric bone decortication. We have successfully applied this 
Piezocision technique in rapid treatment of Class II 118  and Class III 119  patients, and in 
combination with lingual orthodontics 120  and the Invisalign system 121,122  to establish 
improved esthetics and speedy treatment. In a randomized controlled trial the use of 
piezocision in orthodontic tooth movement of adult patients reduced the overall treatment 




corticotomy and piezocision were shown to reduce the treatment time.124 Despite the 
increased clinical applications and clinically improved outcomes there is limited 
knowledge of the impact on bone cells and biology beyond the physical damage of bone 
at the site of surgery. In order to address some of the potential hidden effects we have 
utilized an ex-vivo live calvarial bone culture under conditions to dissociate the specific 
bone remodeling stages and permit the bone to undergo either osteoblast 
differentiation/bone formation or osteoclast differentiation/bone resorption in response 
to external stimuli. The model systems have been well established and used in number of 
biological fields effectively to provide important and unique insights.58,96-98,125  In the 
present study our results using piezocision with different settings and bone culture under 
conditions of static versus dynamic, and formation versus resorption have highlighted 
several important datasets. Firstly, on close analysis the impact of the piezoelectric knife 
extends beyond the actual damage site of mineralized bone. The results showed that the 
impact is ~5x greater than the apparent mineralized bone defect and extends itself as 
substantial local cellular damage on the periosteal and endosteal cell layers leaving the 
mineralized layer intact. This effect is significant in terms of loss of bone lining cells 
including osteocytes within the intact mineralized bone matrix that primes the bone to 
undergo rapid resorption. Importantly, the present study provides the first set of cryptic 
effects of piezoelectric knife surgery that has been not understood previously and explains 
why its use in clinical orthodontic tooth movement generates ~2x faster tooth 
movement.123  Secondly, comparison of the static and dynamic model systems showed 




provided overall enhanced impact. Thirdly, in the bone formation model there is increased 
capacity of the bone to heal and the extent of osteoblast differentiation and the degree of 
new osteoid formation extend beyond the site of injury and immediate local area close to 
injury site. This suggests that the observed impact is beyond the simple damage to the 
mineralized bone area and reflects transmittance of puissance and vibrational energy to a 
significant distance and somewhat taps into the inherent bone cellular response 
mechanism(s). The results also defined that puissance (P) & modulation (M) settings play 
a major role in the degree of cellular damage to the bone lining cells and osteocytes of the 
intact mineralized bone matrix surrounding the full bone defect.  In the dynamic 
resorption model system the settings P-255 & M-30, P-255 & M-100 and P-50 & M-100 
provided the maximum and the same degree of bone resorption while P-50 & M-30 and 
bur showed significantly lower bone resorption.  In the static resorption model system the 
settings P-255 & M-30 and P-255 & M-100 were the most effective.  These data suggest 
that the clinically used setting of P-255 & M-30 is sufficient for observing maximal 
induction of bone resorption and increased orthodontic tooth movement. Despite several 
major advantages of piezocision surgery in orthodontic tooth movement, there has been 
some controversy regarding the use of piezocision and its potential side effect regarding 
tooth root resorption.126  However, that study unfortunately does not reflect the biological 
events/response over the full length of typical orthodontic movement irrespective of 
using piezocision. Focal surface root resorption over 28 days is the initial reaction that 
commonly occurs with or without piezocision. Interestingly, the micro-osteoperforation 




documented that focal surface root resorptions in the apical region are common and 
normally occur in 85% of individuals undergoing “no clinical orthodontic treatment” and 
they recover/repair naturally.128,129 In the case of orthodontic force induced root 
resorption upon cessation of an orthodontic force active root resorption stops and an 
anatomic repair takes place. The functional repair requires 4-6 weeks of rest while 
anatomic repair needs at least 8 weeks.130,131 
Firstly, the piezocision approach is technique sensitive and the outcome is dependent on 
the expertise of the operator. That is (i) if the surgery is performed too close to the root 
without the consideration to the piezoelectric settings then increased potential for root 
resorption is anticipated, and (ii) piezoelectric knife angulation needs to be controlled 
which can increase the potential to induce root damage/resorption. Secondly, tooth 
crowding should be evaluated as this will define potential for cellular damage in bone 
lining cells juxtaposed to the tooth root including impact on the periodontal 
ligament/cells. Importantly, our current study showed that the distance of impact on bone 
cells including the mineralized bone defect sites is ~5.5 mm along the piezo-knife length 
(longitudinal) and ~2 mm in width reflecting a global area of ~ 11 mm2 that would 
undergo rapid remodeling. This suggests that piezoelectric knife cut should be equal to or 
greater than ~2 mm removed from the tooth root to minimize potential direct 
root/periodontal ligament cell damage. Interestingly, this can be compared with the actual 
mineralized bone matrix full defect which is only 2.5 mm (length) by 0.6 mm (width) 




piezoelectric settings gave the order of bone defect cellular healing is P-50 & M-30 > 
P>255 & M-30 ≥ P-50 & M-100 > P-255 & M-100. The clinical setting of P-255 & M-30 
which produces overall enhanced bone formation may not be the optimal setting for 
regeneration/cellular healing of the bone at the edge of the cut due to damaged cell layer 
immediately adjacent to surgical cut. Hence, for general orthopedics and dental surgery 
procedures (not related to orthodontic tooth movement) where bone fusion, healing and 
bone regeneration from the edge of the cut is needed, use of lower P-100 to -150 with M-
30 may be more beneficial. This is because with such settings the mineralized bone tissue 
surgical cutting capacity of piezoelectric knife will still be sufficient but with reduced 
cellular damage to endosteal/periosteal bone cells and osteocytes within the mineralized 
bone matrix surrounding the surgical site. 
In our bisphosphonate experiments, the piezoelectric knife had the potential to 
stimulate bone resorption and formation when the treatment was given at the same time 
of the injury. This is due to the ability of bone lining cells to react to the injury for a 
couple of days before the accumulation of bisphosphonate in bone. The amount of new 
osteoid formed was substantial. This was not evident when the calvarial bone was treated 
before the injury. Although the bone does not form as much in ZOL treated group prior to 
injury, its reparative response after the defect stopped for ~ 3 weeks. Cells afterwards 
were able to migrate and close the defect. These findings suggest that bisphosphonate 
affects not only the osteoclasts, it also affect osteoblasts. 
Tobias et al.75and Iwata et al.76 reported inhibitory effects on OB function and 




osteoblastogenesis other studies showed that low dose of the drug stimulates bone 
formation while higher doses inhibit bone formation.79,80,82  In our study, calvarial bones 
with bisphosphonate treatment in the formation model before the injury showed limited 
cellular migration and proliferation compared to the group treated at the time of injury. 
In insulin treated calvaria, calcium uptake was higher in piezotome groups compared to 
bur. Ascorbic acid only showed higher calcium uptake compared to insulin treated. 
However, ALP activity was higher in the insulin treated calvaria. These findings suggest 
that insulin stimulated osteoblast differentiation. Our findings were similar to a study that 
showed that insulin stimulates osteoblast differentiation and increase osteocalcin 
production.94  
  Piezoelectric treatment stimulated osteoblast differentiation and bone formation 
by increased expression of genes related to osteoblast differentiation. In the formation 
model genes that were up-regulated have an impact on either osteoblast recruitment, 
differentiation and proliferation such as (Ptprc, Transferrin, Osr1) or inhibits osteoclast 
differentiation such as (Inpp5d, Lilrp3 and Sfrp1). Transferrin gene expression was up-
regulated by 4 fold compared to bur treatment. Transferrin increases collagen synthesis 
and ALP activity.132 Osr1 was also upregulated by 3.7 fold compared to bur. The Osr1 
knockout mice reduced osteoblast gene markers.133 Ptprc gene expression was also 4.1 
fold higher in piezotome group. PTPs are regulators of cellular differentiation and 
development. Wheeler et al,134 showed that one of the PTP family, Osteotesticular (OST), 
influences osteoblast development. Other members of PTP family should thoroughly 




Lilrp3 is expressed in osteoclast cells and it alters osteoclast development and possible 
inhibitory effect on osteoclast cells.135 Other highly regulated gene in the piezotome 
group was Sfrp1. Sfrp1 was 4 fold up-regulated compared to bur. Sfrp1 gene is expressed 
by osteoblast and constrain osteoclast differentiation.136  
The majority of the down-regulated genes like Areg, Epha2, Ssp1, Bglap, Ptgs2 and 
Acp5 favor osteoclastogenesis or Germelin, Areg, Epha2, Cited1 and Bglap inhibit 
osteoblast differentiation. Amphiregulin (Areg) is down-regulated by piezoelectric knife 
injury -.2 fold compared to bur. Areg gene not only stimulates osteoclast formation but 
also impacts OPG production.137  Furthermore, some in vitro experiments showed an 
inhibitory effect of Amphiregulin on osteoblast differentiation.138,139 The Epha2 gene has 
dual effects on both osteoblast and osteoclast cells. In our experiment Epha2 was down-
regulated 2.9 fold in piezotome group compared to bur. Epha2 stimulates 
osteoclastogenesis and inhibits osteoblastogenesis.140 Osteopontin (Ssp1) was also down-
regulated by piezotome injury (2.9 fold). Osteopontin mediates osteoclast attachment to 
bone minerals and bone resorption.141 Osteocalcin (Bglap) is also down-regulated 2.6 
fold by piezotome compared to bur. Osteocalcin is a well-studied protein that stimulates 
osteoclast differentiation and function.142 It is secreted by osteoblasts and is considered to 
be a marker for bone turnover. It is highly associated with bone mineralization more than 
new bone matrix formation.143 Acid Phosphatase 5, Tartrate Resistant (ACP5) is also one 
of the major markers for osteoclast activity. Mice deprived of TRAP showed decreased 




Gremlin is the gene most down-regulated by piezoelectric injury. Gremlin acts as BMP 
antagonist and therefore impairs osteoblast differentiation and function.145 Last but not 
least, Ptgs2 gene expression is down-regulated by 2.9 fold. Ptgs2 is also referred to as 
Cox2 enzyme. This gene is associated with osteoclastogenesis in which its activation is 
induced by RANKL and is therefore involved in osteoclast differentiation.146   
It is important to note that the gene expression studies are cover only 4 hours post injury 
by piezotome in the formation model. There were enormous differences in bone related 
gene expression between piezotome and bur groups injury approaches when calvarial 
bone cultured in the bone formation model. In contrast calvarial bones cultured after 
injury in the bone resorption model do not show as many gene expression differences as 
the formation model. This might be due to the time required for osteoclast to differentiate 
and function. Osteoclast recruitment and differentiation is to some extent controlled by 
osteoblast signals. RANKL induced genes were increased from the first day to day 3 and 
increased on day 5.147 Nevertheless, piezotome up-regulated 9 genes and down-regulated 
8 genes when compared to bur defect. Among these 9 genes up-regulated by piezotome is 
Twist2 gene with 1.9 fold increase compare to bur. Twist2 expression inhibits osteoblast 
maturation and holds cells in preosteoblast stage. Wnt3 was also increased by 1.7 fold. It 
is one of the genes included in the Wnt-pathway which stimulate osteoblastogenesis. 
Plexin b1 also was upregulated. It is important in the communication between osteoclasts 
and osteoblasts. In addition, fibrillin 2 was upregulated by 1.7 fold. It increases 
extracellular microfibril production and is involved in osteoblast formation. The 8 down-




related to inhibition of osteoclast differentiation and formation such as IL6, Clec2i and 
Clec2g. 
 A large number of relevant genes related to bone formation and bone resorption have 
major differences between the piezotome versus bur injury. The impact on bone biology 
demonstrates that the piezotome has a unique capacity to generate biological responses 
beyond the simple bone injury. Nevertheless although many advantages can be attributed 
to such studies they do have some limitations that include: 1- They are ex-vivo models 
that can provide knowledge about specific areas of bone biology but ultimately there is a 
need to confirm and expand such investigations to in-vivo experimental animal 
approaches. 2- In our studies, we removed all the confounding factors such as growth 
factors and hormones which is not the case in vivo clinical practice. 3- Some of the 
studies need to be carried out at different time points i.e., as a function of time to provide 
broader and clearer understanding of the general biological events and support the 












The piezoelectric procedure generates bone damage specifically to mineralized tissue and 
simultaneously stimulates bone cells at a distance through high-frequency vibrations. 
This is similar to the absence or presence of a mechanical load/fluid sheer. The increased 
rate of bone remodeling when coupled with piezoelectric takes advantage of, (a) initial 
small actual physical mineralized bone loss/defect, and (b) priming the larger surrounding 
intact mineralized bone that is devoid of bone lining cell layers and vital osteocytes to 
undergo remodeling. It is clearly apparent that the piezoelectric knife technology has 
been one of the major advancements in the field of both orthopedic and dental surgery of 







APPENDIX 1: ALL GENES UP-REGULATED OR DOWN-REGULATED BY 













16365  730249  Irg1  immunoresponsive gene 1  14.0 
72258  54207  Kcnk10  potassium channel, subfamily K, member 10  11.1 





80891    Fcrls  Fc receptor‐like S, scavenger receptor  10.1 
414084  79931  Tnip3  TNFAIP3 interacting protein 3  9.3 
381651  152816  Gm1045  predicted gene 1045  9.2 





18124  8013  Nr4a3  nuclear receptor subfamily 4, group A, member 3  8.2 
14282  2354  Fosb  FBJ osteosarcoma oncogene B  8.1 






20603  6611  Sms  spermine synthase  7.8 





17167  8685  Marco  macrophage receptor with collagenous structure  7.3 





16197  3575  Il7r  interleukin 7 receptor  7.1 
15200  1839  Hbegf  heparin‐binding EGF‐like growth factor  7.0 
14289  2358  Fpr2  formyl peptide receptor 2  6.9 
100034
251 
  Wfdc17  WAP four‐disulfide core domain 17  6.9 









269799  440077  Clec4a1  C‐type lectin domain family 4, member a1  6.0 





545205  81696  Olfr111  olfactory receptor 111  5.7 
56792  26228  Stap1  signal transducing adaptor family member 1  5.7 
15109  3034  Hal  histidine ammonia lyase  5.7 
17533  4360  Mrc1  mannose receptor, C type 1  5.7 
23833    Cd52  CD52 antigen  5.7 
667373  3434  Gm14446  predicted gene 14446  5.6 
100038
909 
11025  Gm14548  predicted gene 14548  5.5 














19293  5816  Pvalb  parvalbumin  5.4 
80719  10261  Igsf6  immunoglobulin superfamily, member 6  5.3 
12813  1300  Col10a1  collagen, type X, alpha 1  5.3 









15117  3037  Has2  hyaluronan synthase 2  5.3 
320832  10326  Sirpb1a  signal‐regulatory protein beta 1A  5.2 









16411  3687  Itgax  integrin alpha X  5.1 
56644  64581  Clec7a  C‐type lectin domain family 7, member a  5.1 
17857    Mx1  myxovirus (influenza virus) resistance 1  5.1 
17084  9450  Ly86  lymphocyte antigen 86  5.1 
100217
427 
  Snord52  small nucleolar RNA, C/D box 52  5.0 













12362  834  Casp1  caspase 1  4.8 
71733  56241  Susd2  sushi domain containing 2  4.7 





13058  1536  Cybb  cytochrome b‐245, beta polypeptide  4.6 
241431  129446  Xirp2  xin actin‐binding repeat containing 2  4.6 
12045  597  Bcl2a1b  B cell leukemia/lymphoma 2 related protein A1b  4.6 
12845  1311  Comp  cartilage oligomeric matrix protein  4.6 
83433  54209  Trem2  triggering receptor expressed on myeloid cells 2  4.6 
57329  56914  Otor  otoraplin  4.5 
13025    Ctla2b  cytotoxic T lymphocyte‐associated protein 2 beta  4.5 
667597    BC023105  cDNA sequence BC023105  4.5 









54199  9034  Ccrl2  chemokine (C‐C motif) receptor‐like 2  4.4 
14621  127534  Gjb4  gap junction protein, beta 4  4.4 
12350  761  Car3  carbonic anhydrase 3  4.4 
20345  6404  Selplg  selectin, platelet (p‐selectin) ligand  4.4 
27052  313  Aoah  acyloxyacyl hydrolase  4.4 
19692  5967  Reg1  regenerating islet‐derived 1  4.4 






12522  9308  Cd83  CD83 antigen  4.4 
12506  962  Cd48  CD48 antigen  4.3 
227929  9595  Cytip  cytohesin 1 interacting protein  4.3 
211228  126364  Lrrc25  leucine rich repeat containing 25  4.3 
13654  1959  Egr2  early growth response 2  4.2 





20753  6698  Sprr1a  small proline‐rich protein 1A  4.1 
14281  2353  Fos  FBJ osteosarcoma oncogene  4.1 






  Mir3096  microRNA 3096  4.0 
71436  23767  Flrt3  fibronectin leucine rich transmembrane protein 3  4.0 
12504  920  Cd4  CD4 antigen  4.0 
16840  11061  Lect1  leukocyte cell derived chemotaxin 1  4.0 









15511    Hspa1b  heat shock protein 1B  4.0 





73690  11010  Glipr1  GLI pathogenesis‐related 1 (glioma)  3.9 







  Mir1983  microRNA 1983  3.9 
23880  2533  Fyb  FYN binding protein  3.9 
12950  1404  Hapln1  hyaluronan and proteoglycan link protein 1  3.9 
107321  9404  Lpxn  leupaxin  3.9 
73149    Clec4a3  C‐type lectin domain family 4, member a3  3.9 





403395  10143  Clec3a  C‐type lectin domain family 3, member a  3.8 
19264  5788  Ptprc  protein tyrosine phosphatase, receptor type, C  3.8 
100504
034 
  Gm20024  predicted gene, 20024  3.8 
17884  4622  Myh4  myosin, heavy polypeptide 4, skeletal muscle  3.8 






17474  338339  Clec4d  C‐type lectin domain family 4, member d  3.8 
71310  23158  Tbc1d9  TBC1 domain family, member 9  3.8 
109272  4604  Mybpc1  myosin binding protein C, slow‐type  3.7 
56847  220  Aldh1a3  aldehyde dehydrogenase family 1, subfamily A3  3.7 
63953  11221  Dusp10  dual specificity phosphatase 10  3.7 
18619  5179  Penk  preproenkephalin  3.7 




22337  7421  Vdr  vitamin D receptor  3.7 






104759  122618  Pld4  phospholipase D family, member 4  3.7 
235086  22997  Igsf9b  immunoglobulin superfamily, member 9B  3.7 





11690  241  Alox5ap  arachidonate 5‐lipoxygenase activating protein  3.7 
67281  6167  Rpl37  ribosomal protein L37  3.7 





12044  597  Bcl2a1a  B cell leukemia/lymphoma 2 related protein A1a  3.7 
245945  54502  Rbm47  RNA binding motif protein 47  3.7 
19735  5997  Rgs2  regulator of G‐protein signaling 2  3.6 
12308  794  Calb2  calbindin 2  3.6 
240672  1847  Dusp5  dual specificity phosphatase 5  3.6 
19850    Rnu3a  U3A small nuclear RNA  3.6 
237313  53832  Il20ra  interleukin 20 receptor, alpha  3.6 
12475  929  Cd14  CD14 antigen  3.5 
381484    Gm5150  predicted gene 5150  3.5 


















66889  79589  Rnf128  ring finger protein 128  3.5 
109648  4852  Npy  neuropeptide Y  3.5 
16414  3689  Itgb2  integrin beta 2  3.4 
100316
700 
  Mir1949  microRNA 1949  3.4 
14276  2350  Folr2  folate receptor 2 (fetal)  3.4 
98711  157506  Rdh10  retinol dehydrogenase 10 (all‐trans)  3.4 





















230587  148979  Glis1  GLIS family zinc finger 1  3.4 
20556    Slfn2  schlafen 2  3.4 
244418  157285  D8Ertd82e DNA segment, Chr 8, ERATO Doi 82, expressed  3.3 
16190  3566  Il4ra  interleukin 4 receptor, alpha  3.3 





192187  23166  Stab1  stabilin 1  3.3 
12524  942  Cd86  CD86 antigen  3.3 





20393  6446  Sgk1  serum/glucocorticoid regulated kinase 1  3.3 
18442  5029  P2ry2  purinergic receptor P2Y, G‐protein coupled 2  3.2 
74413  123036  Tc2n  tandem C2 domains, nuclear  3.2 
320253  115123  March3  membrane‐associated ring finger (C3HC4) 3  3.2 
100526
475 
  Mir3076  microRNA 3076  3.2 
17182  4148  Matn3  matrilin 3  3.2 
15945  3627  Cxcl10  chemokine (C‐X‐C motif) ligand 10  3.2 
11630  202  Aim1  absent in melanoma 1  3.2 
80910  53831  Gpr84  G protein‐coupled receptor 84  3.2 





13040  1520  Ctss  cathepsin S  3.2 
12491  948  Cd36  CD36 antigen  3.2 
381290  493  Atp2b4  ATPase, Ca++ transporting, plasma membrane 4  3.2 
21926  7124  Tnf  tumor necrosis factor  3.2 
11501  101  Adam8  a disintegrin and metallopeptidase domain 8  3.2 


























20017  84172  Polr1b  polymerase (RNA) I polypeptide B  3.2 
12267  719  C3ar1  complement component 3a receptor 1  3.2 







  Snora15  small nucleolar RNA, H/ACA box 15  3.1 










23921  10603  Sh2b2  SH2B adaptor protein 2  3.1 
18600  11240  Padi2  peptidyl arginine deiminase, type II  3.1 
55985  10563  Cxcl13  chemokine (C‐X‐C motif) ligand 13  3.1 
14744  8477  Gpr65  G‐protein coupled receptor 65  3.1 
243574  84541  Kbtbd8  kelch repeat and BTB (POZ) domain containing 8  3.1 







  Snord43  small nucleolar RNA, C/D box 43  3.1 
231327  5471  Ppat  phosphoribosyl pyrophosphate amidotransferase  3.1 
22177  7305  Tyrobp  TYRO protein tyrosine kinase binding protein  3.1 
67664    Rnf125  ring finger protein 125  3.1 
66341  493861  Eid3  EP300 interacting inhibitor of differentiation 3  3.1 
14580  2670  Gfap  glial fibrillary acidic protein  3.1 
623505    Gm6436  predicted gene 6436  3.1 
22041  7018  Trf  transferrin  3.1 
233001    Nlrp9a  NLR family, pyrin domain containing 9A  3.1 











  Snora7a  small nucleolar RNA, H/ACA box 7A  3.1 
244668  57568  Sipa1l2  signal‐induced proliferation‐associated 1 like 2  3.0 





22151  7280  Tubb2a  tubulin, beta 2A class IIA  3.0 
211948  201626  Pde12  phosphodiesterase 12  3.0 
319446  64174  Dpep2  dipeptidase 2  3.0 
279572    Tlr13  toll‐like receptor 13  3.0 
12774  1234  Ccr5  chemokine (C‐C motif) receptor 5  3.0 
74091  80896  Npl  N‐acetylneuraminate pyruvate lyase  3.0 
22778  10320  Ikzf1  IKAROS family zinc finger 1  3.0 





12978  1436  Csf1r  colony stimulating factor 1 receptor  3.0 
547253  54625  Parp14  poly (ADP‐ribose) polymerase family, member 14  3.0 
14283  8061  Fosl1  fos‐like antigen 1  3.0 
16792  7805  Laptm5  lysosomal‐associated protein transmembrane 5  3.0 





105855  3071  Nckap1l  NCK associated protein 1 like  3.0 
54353  8935  Skap2  src family associated phosphoprotein 2  3.0 
16409  3684  Itgam  integrin alpha M  2.9 














17972  4689  Ncf4  neutrophil cytosolic factor 4  2.9 
118452  79870  Baalc  brain and acute leukemia, cytoplasmic  2.9 
387247    Mirlet7d  microRNA let7d  2.9 






108101  83706  Fermt3  fermitin family homolog 3 (Drosophila)  2.9 




94179  25984  Krt23  keratin 23  2.9 
14064  2151  F2rl2  coagulation factor II (thrombin) receptor‐like 2  2.9 
66943  80148  Pqlc1  PQ loop repeat containing 1  2.9 
21345  6876  Tagln  transgelin  2.9 









622976    Gm6377  predicted gene 6377  2.9 
16331  3635  Inpp5d  inositol polyphosphate‐5‐phosphatase D  2.9 
104369    Snora69  small nucleolar RNA, H/ACA box 69  2.9 
22324  7409  Vav1  vav 1 oncogene  2.9 
83490  118788  Pik3ap1  phosphoinositide‐3‐kinase adaptor protein 1  2.9 
219144  115761  Arl11  ADP‐ribosylation factor‐like 11  2.9 
66102  58191  Cxcl16  chemokine (C‐X‐C motif) ligand 16  2.9 














57875  51129  Angptl4  angiopoietin‐like 4  2.8 
14990    H2‐M2  histocompatibility 2, M region locus 2  2.8 
66106  23676  Smpx  small muscle protein, X‐linked  2.8 
12493  951  Cd37  CD37 antigen  2.8 
12839  1297  Col9a1  collagen, type IX, alpha 1  2.8 





231805  29992  Pilra  paired immunoglobin‐like type 2 receptor alpha  2.8 
100217
423 
  Snord19  small nucleolar RNA, C/D box 19  2.8 
16168  3600  Il15  interleukin 15  2.8 





15559  3357  Htr2b  5‐hydroxytryptamine (serotonin) receptor 2B  2.8 












224454  79683  Zdhhc14  zinc finger, DHHC domain containing 14  2.8 









110109  4839  Nop2  NOP2 nucleolar protein homolog (yeast)  2.8 
104662  55720  Tsr1  TSR1, 20S rRNA accumulation, homolog (yeast)  2.8 
217304  124599  Cd300lb  CD300 antigen like family member B  2.8 
65221  51296  Slc15a3  solute carrier family 15, member 3  2.8 
12571  1021  Cdk6  cyclin‐dependent kinase 6  2.8 
17079  4064  Cd180  CD180 antigen  2.8 





17476  219972  Mpeg1  macrophage expressed gene 1  2.8 
214854  93082  Neurl3  neuralized homolog 3 homolog (Drosophila)  2.8 
73884  57683  Zdbf2  zinc finger, DBF‐type containing 2  2.8 
384864    Gm1943  WD repeat domain 70 pseudogene  2.7 
56193  5341  Plek  pleckstrin  2.7 
14619  2706  Gjb2  gap junction protein, beta 2  2.7 
433864  64434  Nom1  nucleolar protein with MIF4G domain 1  2.7 
24088  7097  Tlr2  toll‐like receptor 2  2.7 









71916  11062  Dus4l  dihydrouridine synthase 4‐like (S. cerevisiae)  2.7 
13618  1910  Ednrb  endothelin receptor type B  2.7 
52040  5514  Ppp1r10  protein phosphatase 1, regulatory subunit 10  2.7 
11629  199  Aif1  allograft inflammatory factor 1  2.7 





21955  7138  Tnnt1  troponin T1, skeletal, slow  2.7 





387252    Mirlet7f‐1  microRNA let7f‐1  2.7 









12505  960  Cd44  CD44 antigen  2.7 
66491  5441  Polr2l  polymerase (RNA) II (DNA directed) polypeptide L  2.7 
74155  54206  Errfi1  ERBB receptor feedback inhibitor 1  2.7 
100040
972 
56849  Tceal7  transcription elongation factor A (SII)‐like 7  2.7 







  Snora73a  small nucleolar RNA, H/ACA box 73a  2.7 









21956  7139  Tnnt2  troponin T2, cardiac  2.6 
100316
707 
  Mir1957  microRNA 1957  2.6 
100316
932 
  Snora28  small nucleolar RNA, H/ACA box 28  2.6 
55989  51602  Nop58  NOP58 ribonucleoprotein homolog (yeast)  2.6 
77630  56978  Prdm8  PR domain containing 8  2.6 
59053  51236  Fam203a  family with sequence similarity 203, member A  2.6 
387163    Mir145  microRNA 145  2.6 





225594    Gm4841  predicted gene 4841  2.6 
241633  79895  Atp8b4  ATPase, class I, type 8B, member 4  2.6 
240690  9705  St18  suppression of tumorigenicity 18  2.6 
16181  3557  Il1rn  interleukin 1 receptor antagonist  2.6 
116847  5549  Prelp  proline arginine‐rich end leucine‐rich repeat  2.6 
20305    Ccl6  chemokine (C‐C motif) ligand 6  2.6 
100041
787 


















  Mir5121  microRNA 5121  2.6 






21817  7052  Tgm2  transglutaminase 2, C polypeptide  2.6 
66922  22800  Rras2  related RAS viral (r‐ras) oncogene homolog 2  2.6 












  Gm19767  predicted gene, 19767  2.6 
215632  23550  Psd4  pleckstrin and Sec7 domain containing 4  2.6 
19271  5795  Ptprj  protein tyrosine phosphatase, receptor type, J  2.6 
100217
461 
  Snord89  small nucleolar RNA, C/D box 89  2.6 















381650    Thap6  THAP domain containing 6  2.5 
72544  118460  Exosc6  exosome component 6  2.5 










20375  6688  Sfpi1  SFFV proviral integration 1  2.5 
17929  8736  Myom1  myomesin 1  2.5 
75678  64768  Ippk  inositol 1,3,4,5,6‐pentakisphosphate 2‐kinase  2.5 
100216
532 
  Snord2  small nucleolar RNA, C/D box 2  2.5 
226691  3428  AI607873  expressed sequence AI607873  2.5 
67045  55781  Riok2  RIO kinase 2 (yeast)  2.5 








70769    Nolc1  nucleolar and coiled‐body phosphoprotein 1  2.5 
13684  1977  Eif4e  eukaryotic translation initiation factor 4E  2.5 
100529
074 
  Snora33  small nucleolar RNA, H/ACA box 33  2.5 
94092  10626  Trim16  tripartite motif‐containing 16  2.5 
12587  8190  Mia1  melanoma inhibitory activity 1  2.5 






12824  1280  Col2a1  collagen, type II, alpha 1  2.5 
74732  8676  Stx11  syntaxin 11  2.5 
20963  6850  Syk  spleen tyrosine kinase  2.5 
21393  8557  Tcap  titin‐cap  2.5 
20363  6414  Sepp1  selenoprotein P, plasma, 1  2.5 
69740  51611  Dph5  DPH5 homolog (S. cerevisiae)  2.5 
69072  10969  Ebna1bp2  EBNA1 binding protein 2  2.5 









69668  84317  Ccdc115  coiled‐coil domain containing 115  2.5 
11450  9370  Adipoq  adiponectin, C1Q and collagen domain containing  2.5 










107765  27063  Ankrd1  ankyrin repeat domain 1 (cardiac muscle)  2.5 
723902    Mir7‐1  microRNA 7‐1  2.5 





94176  1794  Dock2  dedicator of cyto‐kinesis 2  2.5 
14129  2209  Fcgr1  Fc receptor, IgG, high affinity I  2.5 
17970  4688  Ncf2  neutrophil cytosolic factor 2  2.5 
17916  4542  Myo1f  myosin IF  2.5 
234549  55027  Heatr3  HEAT repeat containing 3  2.4 
100217
433 




11475  59  Acta2  actin, alpha 2, smooth muscle, aorta  2.4 
21929  7128  Tnfaip3  tumor necrosis factor, alpha‐induced protein 3  2.4 
12373  845  Casq2  calsequestrin 2  2.4 
100217
456 
  Snord53  small nucleolar RNA, C/D box 53  2.4 
77286  55922  Nkrf  NF‐kappaB repressing factor  2.4 







  Gm3591  predicted gene 3591  2.4 
55987  119587  Cpxm2  carboxypeptidase X 2 (M14 family)  2.4 
751527    Mir19b‐1  microRNA 19b‐1  2.4 









11936    Fxyd2  FXYD domain‐containing ion transport regulator 2  2.4 
67291  339230  Ccdc137  coiled‐coil domain containing 137  2.4 
667277  715  C1rb  complement component 1, r subcomponent B  2.4 
27984  79180  Efhd2  EF hand domain containing 2  2.4 
212032  3101  Hk3  hexokinase 3  2.4 
54720  1827  Rcan1  regulator of calcineurin 1  2.4 













11472  88  Actn2  actinin alpha 2  2.4 
56696  29933  Gpr132  G protein‐coupled receptor 132  2.4 
74145  2162  F13a1  coagulation factor XIII, A1 subunit  2.4 
16145    Igtp  interferon gamma induced GTPase  2.4 





214763  115004  Mb21d1  Mab‐21 domain containing 1  2.4 












217431  79954  Nol10  nucleolar protein 10  2.4 





70839  64805  P2ry12  purinergic receptor P2Y, G‐protein coupled 12  2.4 
320982  10123  Arl4c  ADP‐ribosylation factor‐like 4C  2.4 
237436  283431  Gas2l3  growth arrest‐specific 2 like 3  2.4 
17180  4146  Matn1  matrilin 1, cartilage matrix protein  2.4 
72515  23160  Wdr43  WD repeat domain 43  2.4 
13063  54205  Cycs  cytochrome c, somatic  2.4 
20606  6752  Sstr2  somatostatin receptor 2  2.4 
14219  1490  Ctgf  connective tissue growth factor  2.4 





19219  5734  Ptger4  prostaglandin E receptor 4 (subtype EP4)  2.4 
100217
462 
  Snord92  small nucleolar RNA, C/D box 92  2.4 
228491  54989  Zfp770  zinc finger protein 770  2.4 





18175  4892  Nrap  nebulin‐related anchoring protein  2.4 





12229  695  Btk  Bruton agammaglobulinemia tyrosine kinase  2.4 
17227    Mcpt4  mast cell protease 4  2.4 
66793  79645  Efcab1  EF hand calcium binding domain 1  2.4 
338365  84102  Slc41a2  solute carrier family 41, member 2  2.4 
19378  8854  Aldh1a2  aldehyde dehydrogenase family 1, subfamily A2  2.4 
67728  1802  Dph2  DPH2 homolog (S. cerevisiae)  2.4 
100310
813 
  Snora16a  small nucleolar RNA, H/ACA box 16A  2.4 
100302
499 
  Snora3  small nucleolar RNA, H/ACA box 3  2.4 
76294  140458  Asb5  ankyrin repeat and SOCs box‐containing 5  2.4 
15277  3099  Hk2  hexokinase 2  2.4 
27056  3663  Irf5  interferon regulatory factor 5  2.4 
449630    Snord15a  small nucleolar RNA, C/D box 15A  2.4 









19220  5737  Ptgfr  prostaglandin F receptor  2.3 























  Snord22  small nucleolar RNA, C/D box 22  2.3 
100217
444 













104366    Snora64  small nucleolar RNA, H/ACA box 64  2.3 
100306
945 
  Snora73b  small nucleolar RNA, H/ACA box 73b  2.3 
15162  3055  Hck  hemopoietic cell kinase  2.3 













170741  29990  Pilrb1  paired immunoglobin‐like type 2 receptor beta 1  2.3 
50785  9394  Hs6st1  heparan sulfate 6‐O‐sulfotransferase 1  2.3 
18826  3936  Lcp1  lymphocyte cytosolic protein 1  2.3 
100043
636 
  AI662270  expressed sequence AI662270  2.3 








433520    Gm14403  predicted gene 14403  2.3 
109019  64859  Nabp1  nucleic acid binding protein 1  2.3 














235036  56342  Ppan  peter pan homolog (Drosophila)  2.3 
56095  117246  Ftsj3  FtsJ homolog 3 (E. coli)  2.3 
234214  8470  Sorbs2  sorbin and SH3 domain containing 2  2.3 
217303  11314  Cd300a  CD300A antigen  2.3 






















102623    AI414108  expressed sequence AI414108  2.3 
70465  79084  Wdr77  WD repeat domain 77  2.3 
54711  5326  Plagl2  pleiomorphic adenoma gene‐like 2  2.3 
12363  837  Casp4  caspase 4, apoptosis‐related cysteine peptidase  2.3 
631323    Gm12250  predicted gene 12250  2.3 
404711    Ighg2c  immunoglobulin heavy constant gamma 2C  2.3 
93695  10457  Gpnmb  glycoprotein (transmembrane) nmb  2.3 
16822  3937  Lcp2  lymphocyte cytosolic protein 2  2.3 









17189  4151  Mb  myoglobin  2.3 
105675  10105  Ppif  peptidylprolyl isomerase F (cyclophilin F)  2.3 




217944  9771  Rapgef5  Rap guanine nucleotide exchange factor (GEF) 5  2.3 
19695  130120  Reg3g  regenerating islet‐derived 3 gamma  2.3 
227522  10557  Rpp38  ribonuclease P/MRP 38 subunit (human)  2.3 
100740    AI839979  expressed sequence AI839979  2.3 
68048  64782  Aen  apoptosis enhancing nuclease  2.3 
20288  4481  Msr1  macrophage scavenger receptor 1  2.3 
68051  10204  Nutf2  nuclear transport factor 2  2.3 
11702  262  Amd1  S‐adenosylmethionine decarboxylase 1  2.3 
71607  124460  Snx20  sorting nexin 20  2.3 
97112  51068  Nmd3  NMD3 homolog (S. cerevisiae)  2.3 
381110  151393  Fam82a1  family with sequence similarity 82, member A1  2.3 
14747  1240  Cmklr1  chemokine‐like receptor 1  2.3 
17896  4635  Myl4  myosin, light polypeptide 4  2.3 
11474    Actn3  actinin alpha 3  2.3 
100503
548 






67134  10528  Nop56  NOP56 ribonucleoprotein homolog (yeast)  2.2 















319430  27202  Gpr77  G protein‐coupled receptor 77  2.2 
276905  79637  Armc7  armadillo repeat containing 7  2.2 
239759  200879  Liph  lipase, member H  2.2 
68794  2318  Flnc  filamin C, gamma  2.2 





12508  963  Cd53  CD53 antigen  2.2 
70930  55035  Nol8  nucleolar protein 8  2.2 
21333  6863  Tac1  tachykinin 1  2.2 













434246  493829  Trim72  tripartite motif‐containing 72  2.2 















26888  50856  Clec4a2  C‐type lectin domain family 4, member a2  2.2 
20284  11341  Scrg1  scrapie responsive gene 1  2.2 









67895  5464  Ppa1  pyrophosphatase (inorganic) 1  2.2 
545909    Vmn2r39  vomeronasal 2, receptor 39  2.2 










22294  8409  Uxt  ubiquitously expressed transcript  2.2 
50493  7296  Txnrd1  thioredoxin reductase 1  2.2 
100504
223 
  Gm20120  predicted gene, 20120  2.2 
12767  7852  Cxcr4  chemokine (C‐X‐C motif) receptor 4  2.2 
56707  7769  Zfp111  zinc finger protein 111  2.2 
102058  149371  Exoc8  exocyst complex component 8  2.2 












  Gm19941  predicted gene, 19941  2.2 








13610  1903  S1pr3  sphingosine‐1‐phosphate receptor 3  2.2 
12778  57007  Cxcr7  chemokine (C‐X‐C motif) receptor 7  2.2 
17869  4609  Myc  myelocytomatosis oncogene  2.2 





216161  22904  Sbno2  strawberry notch homolog 2 (Drosophila)  2.2 
244666  83932  Sprtn  SprT‐like N‐terminal domain  2.2 
13178  1633  Dck  deoxycytidine kinase  2.2 
77569  22998  Limch1  LIM and calponin homology domains 1  2.2 
16177  3554  Il1r1  interleukin 1 receptor, type I  2.2 
100043
497 
  Gm4477  predicted gene 4477  2.2 
100217
420 
  Snora81  small nucleolar RNA, H/ACA box 81  2.2 





57319  10924  Smpdl3a  sphingomyelin phosphodiesterase, acid‐like 3A  2.1 
233781  64131  Xylt1  xylosyltransferase 1  2.1 
68626  60528  Elac2  elaC homolog 2 (E. coli)  2.1 





319181  8347  Hist1h2bg  histone cluster 1, H2bg  2.1 
52855  3903  Lair1  leukocyte‐associated Ig‐like receptor 1  2.1 









235380  23312  Dmxl2  Dmx‐like 2  2.1 
381801  9797  Tatdn2  TatD DNase domain containing 2  2.1 
633640  64417  Gm7120  predicted gene 7120  2.1 
20612  6614  Siglec1  sialic acid binding Ig‐like lectin 1, sialoadhesin  2.1 
77591  1662  Ddx10  DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 10  2.1 













69121  25884  Chrdl2  chordin‐like 2  2.1 
232413  160364  Clec12a  C‐type lectin domain family 12, member a  2.1 
12837  1295  Col8a1  collagen, type VIII, alpha 1  2.1 







  Snora2b  small nucleolar RNA, H/ACA box 2B  2.1 
78286  89797  Nav2  neuron navigator 2  2.1 
100303
740 










21825  7057  Thbs1  thrombospondin 1  2.1 
14629  2729  Gclc  glutamate‐cysteine ligase, catalytic subunit  2.1 







  Snord16a  small nucleolar RNA, C/D box 16A  2.1 
57742    Abhd1  abhydrolase domain containing 1  2.1 
208426  654502  Iqcj  IQ motif containing J  2.1 









67876  80219  Coq10b  coenzyme Q10 homolog B (S. cerevisiae)  2.1 
53414  705  Bysl  bystin‐like  2.1 




























18987  5452  Pou2f2  POU domain, class 2, transcription factor 2  2.1 
100503
094 





574428  84225  Zmynd15  zinc finger, MYND‐type containing 15  2.1 
232370  9746  Clstn3  calsyntenin 3  2.1 






627049  168850  Zfp800  zinc finger protein 800  2.1 
19204  5724  Ptafr  platelet‐activating factor receptor  2.1 
12156  650  Bmp2  bone morphogenetic protein 2  2.1 
66448  55052  Mrpl20  mitochondrial ribosomal protein L20  2.1 
74178  83931  Stk40  serine/threonine kinase 40  2.1 
54375  51582  Azin1  antizyme inhibitor 1  2.1 


















14455    Gas5  growth arrest specific 5  2.1 





68279  255231  Mcoln2  mucolipin 2  2.1 
433406    Gm13363  predicted gene 13363  2.1 











  Snord69  small nucleolar RNA, C/D box 69  2.1 
14620  2707  Gjb3  gap junction protein, beta 3  2.1 
234779  5336  Plcg2  phospholipase C, gamma 2  2.1 
217119  64132  Xylt2  xylosyltransferase II  2.1 
83453  91851  Chrdl1  chordin‐like 1  2.1 
30878  8862  Apln  apelin  2.1 
67115  9045  Rpl14  ribosomal protein L14  2.1 
387216    Mir23a  microRNA 23a  2.1 
93700  56103  Pcdhgb2  protocadherin gamma subfamily B, 2  2.1 
100217
468 
  Snord45b  small nucleolar RNA, C/D box 45B  2.1 
56318  55  Acpp  acid phosphatase, prostate  2.1 
56503  54851  Ankrd49  ankyrin repeat domain 49  2.1 





67179  55246  Ccdc25  coiled‐coil domain containing 25  2.0 
26549  26548  Itgb1bp2  integrin beta 1 binding protein 2  2.0 
103737  5193  Pex12  peroxisomal biogenesis factor 12  2.0 
17874  4615  Myd88  myeloid differentiation primary response gene 88  2.0 










71839  29948  Osgin1  oxidative stress induced growth inhibitor 1  2.0 
19870    Snord73a  small nucleolar RNA, C/D box U73A  2.0 
77652    Zfp955a  zinc finger protein 955A  2.0 





20312  6376  Cx3cl1  chemokine (C‐X3‐C motif) ligand 1  2.0 
240665  54619  Ccnj  cyclin J  2.0 
384783  8660  Irs2  insulin receptor substrate 2  2.0 
594843    Has2as  HAS2 antisense RNA (non‐protein coding)  2.0 
19944    Rpl29  ribosomal protein L29  2.0 
105203  54906  BC016423  cDNA sequence BC016423  2.0 
22042  7037  Tfrc  transferrin receptor  2.0 
216869  409  Arrb2  arrestin, beta 2  2.0 








171166  55283  Mcoln3  mucolipin 3  2.0 





14190  10875  Fgl2  fibrinogen‐like protein 2  2.0 
225998  6096  Rorb  RAR‐related orphan receptor beta  2.0 
20190  6261  Ryr1  ryanodine receptor 1, skeletal muscle  2.0 
83924  7107  Gpr137b  G protein‐coupled receptor 137B  2.0 










56349  10276  Net1  neuroepithelial cell transforming gene 1  2.0 
545645    Gm13283  predicted gene 13283  2.0 





67245  57162  Peli1  pellino 1  2.0 
387142    Mir24‐1  microRNA 24‐1  2.0 
16178  7850  Il1r2  interleukin 1 receptor, type II  2.0 
11838  23237  Arc  activity regulated cytoskeletal‐associated protein  2.0 
245474  1736  Dkc1  dyskeratosis congenita 1, dyskerin  2.0 
246177  64005  Myo1g  myosin IG  2.0 





98496  55022  Pid1  phosphotyrosine interaction domain containing 1  2.0 
226610  149297  Fam78b  family with sequence similarity 78, member B  2.0 
59006  51778  Myoz2  myozenin 2  2.0 
19218  5733  Ptger3  prostaglandin E receptor 3 (subtype EP3)  2.0 
330050  222234  Fam185a  family with sequence similarity 185, member A  2.0 
723843    Mir337  microRNA 337  2.0 
22376  7454  Was  Wiskott‐Aldrich syndrome homolog (human)  2.0 





13051  1524  Cx3cr1  chemokine (C‐X3‐C) receptor 1  2.0 
15900  3394  Irf8  interferon regulatory factor 8  2.0 
11541  136  Adora2b  adenosine A2b receptor  2.0 






  Gm19845  predicted gene, 19845  2.0 
13609  1901  S1pr1  sphingosine‐1‐phosphate receptor 1  2.0 
227937  8502  Pkp4  plakophilin 4  2.0 
18008    Nes  nestin  2.0 
58223  4327  Mmp19  matrix metallopeptidase 19  2.0 





20005  6133  Rpl9  ribosomal protein L9  2.0 































21426  22797  Tfec  transcription factor EC  2.0 
13009  8048  Csrp3  cysteine and glycine‐rich protein 3  2.0 
20592  8284  Kdm5d  lysine (K)‐specific demethylase 5D  2.0 









78251  730087  Zfp712  zinc finger protein 712  2.0 
28071  221830  Twistnb  TWIST neighbor  2.0 
633057    Gm7102  predicted gene 7102  2.0 
54140  552  Avpr1a  arginine vasopressin receptor 1A  2.0 











  Gm19852  predicted gene, 19852  2.0 
18538  5111  Pcna  proliferating cell nuclear antigen  2.0 
387135    Mir18  microRNA 18  2.0 
13449  9046  Dok2  docking protein 2  2.0 
15442  10855  Hpse  heparanase  2.0 
100316
777 
  Mir1969  microRNA 1969  2.0 
14961  3119  H2‐Ab1  histocompatibility 2, class II antigen A, beta 1  2.0 
12014  60468  Bach2  BTB and CNC homology 2  2.0 
57750  55759  Wdr12  WD repeat domain 12  2.0 
433667  81573  Ankrd13c  ankyrin repeat domain 13c  2.0 
382062  255809  AB124611  cDNA sequence AB124611  2.0 





108673  79080  Ccdc86  coiled‐coil domain containing 86  2.0 
109270  55615  Prr5  proline rich 5 (renal)  2.0 







  Gm19592  predicted gene, 19592  2.0 
319876  22837  Cobll1  Cobl‐like 1  2.0 
18761  5588  Prkcq  protein kinase C, theta  2.0 
216984  2124  Evi2b  ecotropic viral integration site 2b  2.0 





53311  4608  Mybph  myosin binding protein H  2.0 
100306
952 
  Snora78  small nucleolar RNA, H/ACA box 7  2.0 
69956  55037  Ptcd3  pentatricopeptide repeat domain 3  2.0 
236312  3428  Pyhin1  pyrin and HIN domain family, member 1  2.0 
108897  83543  Aif1l  allograft inflammatory factor 1‐like  2.0 
100628
630 
  Mir5124  microRNA 5124  2.0 
211255  84078  Kbtbd7  kelch repeat and BTB (POZ) domain containing 7  2.0 
16476  3725  Jun  Jun oncogene  2.0 
66953  83879  Cdca7  cell division cycle associated 7  2.0 
11829  361  Aqp4  aquaporin 4  2.0 
67242  79833  Gemin6  gem (nuclear organelle) associated protein 6  ‐2.0 














19339  5864  Rab3a  RAB3A, member RAS oncogene family  ‐2.0 
110075  651  Bmp3  bone morphogenetic protein 3  ‐2.0 













621156    Apoo‐ps  apolipoprotein O, pseudogene  ‐2.0 
97423    R74862  expressed sequence R74862  ‐2.0 
545848    Igkv4‐80  immunoglobulin kappa variable 4‐80  ‐2.0 
52830  55629  Pnrc2  proline‐rich nuclear receptor coactivator 2  ‐2.0 
22678  80108  Zfp2  zinc finger protein 2  ‐2.0 










224796  53405  Clic5  chloride intracellular channel 5  ‐2.0 





192976  388341  BC046404  cDNA sequence BC046404  ‐2.0 
13809  2028  Enpep  glutamyl aminopeptidase  ‐2.0 
110033  3835  Kif22  kinesin family member 22  ‐2.0 
93674    Cml3  camello‐like 3  ‐2.0 
50767  10908  Pnpla6  patatin‐like phospholipase domain containing 6  ‐2.0 
20198  6275  S100a4  S100 calcium binding protein A4  ‐2.0 
20750  6696  Spp1  secreted phosphoprotein 1  ‐2.0 
22774  84107  Zic4  zinc finger protein of the cerebellum 4  ‐2.0 
217887  122616  BC022687  cDNA sequence BC022687  ‐2.0 









17534  9902  Mrc2  mannose receptor, C type 2  ‐2.0 
19228  5745  Pth1r  parathyroid hormone 1 receptor  ‐2.0 
100126
434 
  Trgj4  T cell receptor gamma joining 4  ‐2.0 
16160  3593  Il12b  interleukin 12b  ‐2.0 
















432985    Gm5476  type II keratin Kb17P pseudogene  ‐2.0 
20249  6319  Scd1  stearoyl‐Coenzyme A desaturase 1  ‐2.0 
243385  285513  Gprin3  GPRIN family member 3  ‐2.0 
14009  2115  Etv1  ets variant gene 1  ‐2.0 
246196  11179  Zfp277  zinc finger protein 277  ‐2.0 
77827  84626  Krba1  KRAB‐A domain containing 1  ‐2.0 














74754  1718  Dhcr24  24‐dehydrocholesterol reductase  ‐2.0 
68394    Ccdc163  coiled‐coil domain containing 163  ‐2.0 











67554  253512  Slc25a30  solute carrier family 25, member 30  ‐2.0 





216795  7483  Wnt9a  wingless‐type MMTV integration site 9A  ‐2.0 
18194  50814  Nsdhl  NAD(P) dependent steroid dehydrogenase‐like  ‐2.0 
74030  54453  Rin2  Ras and Rab interactor 2  ‐2.0 




667503    Gm8672  predicted gene 8672  ‐2.0 







56032  10641  Nprl2  nitrogen permease regulator‐like 2  ‐2.0 
68964  80169  Ctc1  CTS telomere maintenance complex component 1  ‐2.0 
100526
515 
  Mir1247  microRNA 1247  ‐2.0 
93717  56107  Pcdhga9  protocadherin gamma subfamily A, 9  ‐2.0 
12842  1277  Col1a1  collagen, type I, alpha 1  ‐2.0 
238257  161291  Tmem30b  transmembrane protein 30B  ‐2.0 
13437  23549  Dnpep  aspartyl aminopeptidase  ‐2.0 
14089  2191  Fap  fibroblast activation protein  ‐2.0 
97761  9905  Sgsm2  small G protein signaling modulator 2  ‐2.0 
217138  79170  Prr15l  proline rich 15‐like  ‐2.0 
16797  27040  Lat  linker for activation of T cells  ‐2.0 
14958  3005  H1f0  H1 histone family, member 0  ‐2.0 






52666  115557  Arhgef25  Rho guanine nucleotide exchange factor (GEF) 25  ‐2.0 
99899  10561  Ifi44  interferon‐induced protein 44  ‐2.0 
15229  2297  Foxd1  forkhead box D1  ‐2.0 
545655    Gm13287  predicted gene 13287  ‐2.0 
217716  27030  Mlh3  mutL homolog 3 (E coli)  ‐2.0 
258447    Olfr1241  olfactory receptor 1241  ‐2.1 






14748  2827  Gpr3  G‐protein coupled receptor 3  ‐2.1 
68743  54443  Anln  anillin, actin binding protein  ‐2.1 
67760  54407  Slc38a2  solute carrier family 38, member 2  ‐2.1 





227693  10444  Zer1  zer‐1 homolog (C. elegans)  ‐2.1 
68852  221091  Lrrn4cl  LRRN4 C‐terminal like  ‐2.1 
668923    Zfp442  zinc finger protein 442  ‐2.1 





16601  687  Klf9  Kruppel‐like factor 9  ‐2.1 




68877  84232  Maf1  MAF1 homolog (S. cerevisiae)  ‐2.1 





233651  8642  Dchs1  dachsous 1 (Drosophila)  ‐2.1 
114714  5889  Rad51c  RAD51 homolog c (S. cerevisiae)  ‐2.1 





21827  7059  Thbs3  thrombospondin 3  ‐2.1 
18104  1728  Nqo1  NAD(P)H dehydrogenase, quinone 1  ‐2.1 
70737  57530  Cgn  cingulin  ‐2.1 





54194  26993  Akap8l  A kinase (PRKA) anchor protein 8‐like  ‐2.1 





244238  116534  Mrgpre  MAS‐related GPR, member E  ‐2.1 
13607    Eda  ectodysplasin‐A  ‐2.1 
100316
709 





66488  84908  Fam136a  family with sequence similarity 136, member A  ‐2.1 





20922  6827  Supt4h1  suppressor of Ty 4 homolog 1 (S. cerevisiae)  ‐2.1 
268697  891  Ccnb1  cyclin B1  ‐2.1 
385643  3827  Kng2  kininogen 2  ‐2.1 
22715  346171  Zfp57  zinc finger protein 57  ‐2.1 





241066  79800  Carf  calcium response factor  ‐2.1 
100502
774 
  Gm19363  predicted gene, 19363  ‐2.1 




















66970  23635  Ssbp2  single‐stranded DNA binding protein 2  ‐2.1 
18582  5147  Pde6d  phosphodiesterase 6D, cGMP‐specific, rod, delta  ‐2.1 





14245  23175  Lpin1  lipin 1  ‐2.1 
105841  22898  Dennd3  DENN/MADD domain containing 3  ‐2.1 
360213  80128  Trim46  tripartite motif‐containing 46  ‐2.1 
213649  128272  Arhgef19  Rho guanine nucleotide exchange factor (GEF) 19  ‐2.1 
216505  113791  Pik3ip1  phosphoinositide‐3‐kinase interacting protein 1  ‐2.1 
26970  30814  Pla2g2e  phospholipase A2, group IIE  ‐2.1 





18628  8863  Per3  period homolog 3 (Drosophila)  ‐2.2 












  Mir3081  microRNA 3081  ‐2.2 
14137  2222  Fdft1  farnesyl diphosphate farnesyl transferase 1  ‐2.2 









101113  90203  Snx21  sorting nexin family member 21  ‐2.2 
624049    Gm6468  predicted gene 6468  ‐2.2 
69837  84759  Pcgf1  polycomb group ring finger 1  ‐2.2 
238412    Ighv2‐3  immunoglobulin heavy variable 2‐3  ‐2.2 
12583  1036  Cdo1  cysteine dioxygenase 1, cytosolic  ‐2.2 
50788  55336  Fbxl8  F‐box and leucine‐rich repeat protein 8  ‐2.2 
51793  23564  Ddah2  dimethylarginine dimethylaminohydrolase 2  ‐2.2 
15040  3133  H2‐T23  histocompatibility 2, T region locus 23  ‐2.2 














67009  64927  Ttc23  tetratricopeptide repeat domain 23  ‐2.2 
11567  10677  Avil  advillin  ‐2.2 
11670  218  Aldh3a1  aldehyde dehydrogenase family 3, subfamily A1  ‐2.2 





223672    Apol9a  apolipoprotein L 9a  ‐2.2 
19883  6095  Rora  RAR‐related orphan receptor alpha  ‐2.2 
20648  6640  Snta1  syntrophin, acidic 1  ‐2.2 
20250    Scd2  stearoyl‐Coenzyme A desaturase 2  ‐2.2 
65086  23566  Lpar3  lysophosphatidic acid receptor 3  ‐2.2 





58203  81030  Zbp1  Z‐DNA binding protein 1  ‐2.2 
80892  79776  Zfhx4  zinc finger homeodomain 4  ‐2.2 
16545  11081  Kera  keratocan  ‐2.2 
170799  219790  Rtkn2  rhotekin 2  ‐2.2 
213742    Xist  inactive X specific transcripts  ‐2.2 
380912  55893  Zfp395  zinc finger protein 395  ‐2.2 










12903  1381  Crabp1  cellular retinoic acid binding protein I  ‐2.2 





240034    Zfp760  zinc finger protein 760  ‐2.3 
73680  653121  Zbtb8a  zinc finger and BTB domain containing 8a  ‐2.3 
109323  114905  C1qtnf7  C1q and tumor necrosis factor related protein 7  ‐2.3 
16880  3977  Lifr  leukemia inhibitory factor receptor  ‐2.3 
110751  80332  Adam33  a disintegrin and metallopeptidase domain 33  ‐2.3 













13482  1803  Dpp4  dipeptidylpeptidase 4  ‐2.3 
19222  5739  Ptgir  prostaglandin I receptor (IP)  ‐2.3 
622728    Ighv1‐75  immunoglobulin heavy variable 1‐75  ‐2.3 
55994  4093  Smad9  SMAD family member 9  ‐2.3 
67177  81620  Cdt1  chromatin licensing and DNA replication factor 1  ‐2.3 
















212539    Gm266  predicted gene 266  ‐2.3 
110196  2224  Fdps  farnesyl diphosphate synthetase  ‐2.3 
20744  55342  Strbp  spermatid perinuclear RNA binding protein  ‐2.3 

















12263  717  C2  complement component 2 (within H‐2S)  ‐2.3 
17309  4248  Mgat3  mannoside acetylglucosaminyltransferase 3  ‐2.3 
232232  79885  Hdac11  histone deacetylase 11  ‐2.4 
73804  11004  Kif2c  kinesin family member 2C  ‐2.4 
56742  84722  Psrc1  proline/serine‐rich coiled‐coil 1  ‐2.4 





72017  51706  Cyb5r1  cytochrome b5 reductase 1  ‐2.4 
224829  55809  Trerf1  transcriptional regulating factor 1  ‐2.4 









258861    Olfr763  olfactory receptor 763  ‐2.4 
243277  283383  Gpr133  G protein‐coupled receptor 133  ‐2.4 
22724  51043  Zbtb7b  zinc finger and BTB domain containing 7B  ‐2.4 
100217
447 
  Scarna3b  small Cajal body‐specific RNA 3B  ‐2.4 
22032  9618  Traf4  TNF receptor associated factor 4  ‐2.4 
20299  6367  Ccl22  chemokine (C‐C motif) ligand 22  ‐2.4 
212503  196743  Paox  polyamine oxidase (exo‐N4‐amino)  ‐2.4 
20614  6616  Snap25  synaptosomal‐associated protein 25  ‐2.4 
68385  116238  Tlcd1  TLC domain containing 1  ‐2.4 
74614  128506  Ocstamp  osteoclast stimulatory transmembrane protein  ‐2.4 
93710  56113  Pcdhga2  protocadherin gamma subfamily A, 2  ‐2.4 
20897  64220  Stra6  stimulated by retinoic acid gene 6  ‐2.4 





278097  54470  Armcx6  armadillo repeat containing, X‐linked 6  ‐2.4 
12062  624  Bdkrb2  bradykinin receptor, beta 2  ‐2.4 
67608  26502  Narf  nuclear prelamin A recognition factor  ‐2.4 





320924  147372  Ccbe1  collagen and calcium binding EGF domains 1  ‐2.5 
333193    BC053749  cDNA sequence BC053749  ‐2.5 
54636  11152  Wdr45  WD repeat domain 45  ‐2.5 
210544  93594  Wdr67  WD repeat domain 67  ‐2.5 
71898    Apol9b  apolipoprotein L 9b  ‐2.5 





78751  376940  Zc3h6  zinc finger CCCH type containing 6  ‐2.5 





71973  348093  Rbpms2  RNA binding protein with multiple splicing 2  ‐2.5 
13393  1747  Dlx3  distal‐less homeobox 3  ‐2.5 
210719  283078  Mkx  mohawk homeobox  ‐2.5 












17394  4317  Mmp8  matrix metallopeptidase 8  ‐2.5 
223920  8435  Soat2  sterol O‐acyltransferase 2  ‐2.5 
77045  605  Bcl7a  B cell CLL/lymphoma 7A  ‐2.5 
381269  55686  Mreg  melanoregulin  ‐2.6 
56554    Raet1d  retinoic acid early transcript delta  ‐2.6 
72194  84961  Fbxl20  F‐box and leucine‐rich repeat protein 20  ‐2.6 
15042    H2‐T24  histocompatibility 2, T region locus 24  ‐2.6 
12452  901  Ccng2  cyclin G2  ‐2.6 
17286  4223  Meox2  mesenchyme homeobox 2  ‐2.6 
22436  7498  Xdh  xanthine dehydrogenase  ‐2.6 
100316
865 
  Gm10931  predicted gene 10931  ‐2.6 
213081  57728  Wdr19  WD repeat domain 19  ‐2.6 
494448  23466  Cbx6  chromobox 6  ‐2.6 





19661  5949  Rbp3  retinol binding protein 3, interstitial  ‐2.6 
19411  5916  Rarg  retinoic acid receptor, gamma  ‐2.6 
12159  652  Bmp4  bone morphogenetic protein 4  ‐2.6 
140742  27244  Sesn1  sestrin 1  ‐2.7 
12096  632  Bglap  bone gamma carboxyglutamate protein  ‐2.7 
71373  51334  Prr16  proline rich 16  ‐2.7 
235493  56204  BC031353  cDNA sequence BC031353  ‐2.7 
100041
677 











  Mir2137  microRNA 2137  ‐2.7 





75785  54800  Klhl24  kelch‐like 24 (Drosophila)  ‐2.7 
14302  2444  Frk  fyn‐related kinase  ‐2.7 









17329    Cxcl9  chemokine (C‐X‐C motif) ligand 9  ‐2.8 
54123  3665  Irf7  interferon regulatory factor 7  ‐2.8 
100628
593 
  Mir5125  microRNA 5125  ‐2.8 
20215  6295  Sag  retinal S‐antigen  ‐2.8 
77864  388403  Ypel2  yippee‐like 2 (Drosophila)  ‐2.8 
21677  8463  Tead2  TEA domain family member 2  ‐2.8 





223332  202151  Ranbp3l  RAN binding protein 3‐like  ‐2.8 
66264  79140  Ccdc28b  coiled coil domain containing 28B  ‐2.8 
100504
196 
  Gm10023  predicted gene 10023  ‐2.8 
69938  9805  Scrn1  secernin 1  ‐2.8 
69065  79094  Chac1  ChaC, cation transport regulator 1  ‐2.9 
258534    Olfr1361  olfactory receptor 1361  ‐2.9 
23892  26585  Grem1  gremlin 1  ‐2.9 









237928  162466  Phospho1  phosphatase, orphan 1  ‐3.0 
20379  6424  Sfrp4  secreted frizzled‐related protein 4  ‐3.0 
235406  257364  Snx33  sorting nexin 33  ‐3.0 
22142  7846  Tuba1a  tubulin, alpha 1A  ‐3.0 
16987  4047  Lss  lanosterol synthase  ‐3.0 
13052  1525  Cxadr  coxsackie virus and adenovirus receptor  ‐3.0 
13396  1750  Dlx6  distal‐less homeobox 6  ‐3.0 
71130  284948  Sh2d6  SH2 domain containing 6  ‐3.0 
218772  5915  Rarb  retinoic acid receptor, beta  ‐3.0 





110454    Ly6a  lymphocyte antigen 6 complex, locus A  ‐3.1 














11609  186  Agtr2  angiotensin II receptor, type 2  ‐3.2 
12424  885  Cck  cholecystokinin  ‐3.2 
13198  1649  Ddit3  DNA‐damage inducible transcript 3  ‐3.3 
18424  5015  Otx2  orthodenticle homolog 2 (Drosophila)  ‐3.3 
14860    Gsta4  glutathione S‐transferase, alpha 4  ‐3.4 
11433    Acp5  acid phosphatase 5, tartrate resistant  ‐3.4 
13627  1915  Eef1a1  eukaryotic translation elongation factor 1 alpha 1  ‐3.4 
















232790  126014  Oscar  osteoclast associated receptor  ‐3.6 
78248  51309  Armcx1  armadillo repeat containing, X‐linked 1  ‐3.6 





277154  57523  Nynrin  NYN domain and retroviral integrase containing  ‐3.8 
15039    H2‐T22  histocompatibility 2, T region locus 22  ‐4.0 
17395  4318  Mmp9  matrix metallopeptidase 9  ‐4.0 
26399  5608  Map2k6  mitogen‐activated protein kinase kinase 6  ‐4.0 
97086  133308  Nhedc2  Na+/H+ exchanger domain containing 2  ‐4.2 





16421  3695  Itgb7  integrin beta 7  ‐4.8 











13380  22943  Dkk1  dickkopf homolog 1 (Xenopus laevis)  ‐5.3 
100041
546 





12353  765  Car6  carbonic anhydrase 6  ‐8.5 









APPENDIX 2: ALL GENES UP-REGULATED OR DOWN-REGULATED BY 











14282  2354  Fosb  FBJ osteosarcoma oncogene B  8.7 
15200  1839  Hbegf  heparin‐binding EGF‐like growth factor  8.1 
18124  8013  Nr4a3  nuclear receptor subfamily 4, group A, member 3  7.0 
381651  152816  Gm1045  predicted gene 1045  6.5 
100303
740 
  Snora75  small nucleolar RNA, H/ACA box 75  6.5 
15116  3036  Has1  hyaluronan synthase1  6.5 
240672  1847  Dusp5  dual specificity phosphatase 5  6.2 


















13406  1758  Dmp1  dentin matrix protein 1  4.8 
18049  4803  Ngf  nerve growth factor  4.7 






215418  64651  Csrnp1  cysteine‐serine‐rich nuclear protein 1  4.6 
16878  3976  Lif  leukemia inhibitory factor  4.5 
21930  7130  Tnfaip6  tumor necrosis factor alpha induced protein 6  4.4 
13681  1973  Eif4a1  eukaryotic translation initiation factor 4A1  4.2 
72258  54207  Kcnk10  potassium channel, subfamily K, member 10  4.1 
15370  3164  Nr4a1  nuclear receptor subfamily 4, group A, member 1  4.1 




































15117  3037  Has2  hyaluronan synthase 2  3.5 










20393  6446  Sgk1  serum/glucocorticoid regulated kinase 1  3.4 
100306
945 
  Snora73b  small nucleolar RNA, H/ACA box 73b  3.4 
71847    Gmcl1l  germ cell‐less homolog 1 (Drosophila)‐like  3.4 
14283  8061  Fosl1  fos‐like antigen 1  3.4 
14239  2307  Foxs1  forkhead box S1  3.3 
16323  3624  Inhba  inhibin beta‐A  3.3 
19735  5997  Rgs2  regulator of G‐protein signaling 2  3.3 





20753  6698  Sprr1a  small proline‐rich protein 1A  3.2 
17131  4092  Smad7  SMAD family member 7  3.2 
54720  1827  Rcan1  regulator of calcineurin 1  3.2 





235086  22997  Igsf9b  immunoglobulin superfamily, member 9B  3.1 




57742    Abhd1  abhydrolase domain containing 1  3.1 
14281  2353  Fos  FBJ osteosarcoma oncogene  3.0 
14584  9945  Gfpt2  glutamine fructose‐6‐phosphate transaminase 2  3.0 
18793  5329  Plaur  plasminogen activator, urokinase receptor  3.0 
11839  374  Areg  amphiregulin  3.0 
76650  140809  Srxn1  sulfiredoxin 1 homolog (S. cerevisiae)  3.0 
50778  5996  Rgs1  regulator of G‐protein signaling 1  3.0 
100306
944 








71920  255324  Epgn  epithelial mitogen  2.9 
17082  9173  Il1rl1  interleukin 1 receptor‐like 1  2.9 
100039
794 
  Gm2427  predicted gene 2427  2.9 







  Snora30  small nucleolar RNA, H/ACA box 30  2.9 
100526
502 
  Mir3095  microRNA 3095  2.8 
12014  60468  Bach2  BTB and CNC homology 2  2.8 
19652  5935  Rbm3  RNA binding motif protein 3  2.8 
24064  10253  Spry2  sprouty homolog 2 (Drosophila)  2.8 
100217
460 
  Snord85  small nucleolar RNA, C/D box 85  2.8 
100217
456 
  Snord53  small nucleolar RNA, C/D box 53  2.8 
94179  25984  Krt23  keratin 23  2.8 
231327  5471  Ppat  phosphoribosyl pyrophosphate amidotransferase  2.8 












  Gm4477  predicted gene 4477  2.7 
75590  1852  Dusp9  dual specificity phosphatase 9  2.7 
















244668  57568  Sipa1l2  signal‐induced proliferation‐associated 1 like 2  2.7 





15937  8870  Ier3  immediate early response 3  2.7 
100041
651 





217304  124599  Cd300lb  CD300 antigen like family member B  2.6 
18648  5223  Pgam1  phosphoglycerate mutase 1  2.6 
22413  7472  Wnt2  wingless‐related MMTV integration site 2  2.6 
16193  3569  Il6  interleukin 6  2.6 
57425    U90926  cDNA sequence U90926  2.6 









26556  9456  Homer1  homer homolog 1 (Drosophila)  2.6 










21824  7056  Thbd  thrombomodulin  2.5 
66192    Lage3  L antigen family, member 3  2.5 
100217
451 
  Snora7a  small nucleolar RNA, H/ACA box 7A  2.5 





320913    Trdv2‐2  T cell receptor delta variable 2‐2  2.5 






  Tcp10c  t‐complex protein 10c  2.5 
381823  81575  Apold1  apolipoprotein L domain containing 1  2.5 
100217
433 
  Snord88a  small nucleolar RNA, C/D box 88A  2.5 
19124  10544  Procr  protein C receptor, endothelial  2.5 





70574  1368  Cpm  carboxypeptidase M  2.5 
100628
579 
    2.5 
13874  2069  Ereg  epiregulin  2.5 
14299  23413  Ncs1  neuronal calcium sensor 1  2.5 
338365  84102  Slc41a2  solute carrier family 41, member 2  2.4 
14621  127534  Gjb4  gap junction protein, beta 4  2.4 
56318  55  Acpp  acid phosphatase, prostate  2.4 
233315  54893  Mtmr10  myotubularin related protein 10  2.4 
100217
417 









22339  7422  Vegfa  vascular endothelial growth factor A  2.4 



















12167  658  Bmpr1b  bone morphogenetic protein receptor, type 1B  2.4 
11732  56172  Ank  progressive ankylosis  2.4 









594844  158931  Tceal3  transcription elongation factor A (SII)‐like 3  2.3 





14620  2707  Gjb3  gap junction protein, beta 3  2.3 
330192  79720  Vps37b  vacuolar protein sorting 37B (yeast)  2.3 










17384  4319  Mmp10  matrix metallopeptidase 10  2.3 





13836  1969  Epha2  Eph receptor A2  2.3 
100217
424 










74747  54541  Ddit4  DNA‐damage‐inducible transcript 4  2.3 




















  Snord17  small nucleolar RNA, C/D box 17  2.2 
56715  27342  Rabgef1  RAB guanine nucleotide exchange factor (GEF) 1  2.2 
100316
700 
  Mir1949  microRNA 1949  2.2 




17691    Sik1  salt inducible kinase 1  2.2 
622733    Olfr764  olfactory receptor 764  2.2 
319876  22837  Cobll1  Cobl‐like 1  2.2 
22761  161882  Zfpm1  zinc finger protein, multitype 1  2.2 










20698  8877  Sphk1  sphingosine kinase 1  2.2 
12156  650  Bmp2  bone morphogenetic protein 2  2.2 
100217
418 
  Snora44  small nucleolar RNA, H/ACA box 44  2.2 
13655  1960  Egr3  early growth response 3  2.2 
109648  4852  Npy  neuropeptide Y  2.2 
100302
499 











627987    Gm6820  predicted gene 6820  2.2 
14573  2668  Gdnf  glial cell line derived neurotrophic factor  2.2 





67895  5464  Ppa1  pyrophosphatase (inorganic) 1  2.2 
104366    Snora64  small nucleolar RNA, H/ACA box 64  2.2 
22151  7280  Tubb2a  tubulin, beta 2A class IIA  2.2 
94092  10626  Trim16  tripartite motif‐containing 16  2.2 








  Gm3591  predicted gene 3591  2.1 
13653  1958  Egr1  early growth response 1  2.1 
73679    Tex19.1  testis expressed gene 19.1  2.1 
108673  79080  Ccdc86  coiled‐coil domain containing 86  2.1 
100217
440 









18159  4880  Nppc  natriuretic peptide type C  2.1 





12061  623  Bdkrb1  bradykinin receptor, beta 1  2.1 












18619  5179  Penk  preproenkephalin  2.1 
81489  3337  Dnajb1  DnaJ (Hsp40) homolog, subfamily B, member 1  2.1 





64898  9663  Lpin2  lipin 2  2.1 
12062  624  Bdkrb2  bradykinin receptor, beta 2  2.1 
85029    Rpph1  ribonuclease P RNA component H1  2.1 
381650    Thap6  THAP domain containing 6  2.1 
320982  10123  Arl4c  ADP‐ribosylation factor‐like 4C  2.1 
73884  57683  Zdbf2  zinc finger, DBF‐type containing 2  2.1 
76080  79183  Ttpal  tocopherol (alpha) transfer protein‐like  2.1 
14825  2920  Cxcl1  chemokine (C‐X‐C motif) ligand 1  2.1 
11702  262  Amd1  S‐adenosylmethionine decarboxylase 1  2.1 
329679  57600  Fnip2  folliculin interacting protein 2  2.1 
107652  6675  Uap1  UDP‐N‐acetylglucosamine pyrophosphorylase 1  2.1 
100216
537 
  Snord104 small nucleolar RNA, C/D box 104  2.1 
56847  220  Aldh1a3  aldehyde dehydrogenase family 1, subfamily A3  2.1 







628746  23429  Gm6910  predicted gene 6910  2.1 









20613  6615  Snai1  snail homolog 1 (Drosophila)  2.1 
382277    Gm5169  predicted gene 5169  2.1 
24066  81848  Spry4  sprouty homolog 4 (Drosophila)  2.1 
18030  4783  Nfil3  nuclear factor, interleukin 3, regulated  2.1 
217149  284106  Cisd3  CDGSH iron sulfur domain 3  2.1 
387239    Mir199b  microRNA 199b  2.1 
19252  1843  Dusp1  dual specificity phosphatase 1  2.1 
100217
432 
  Snord71  small nucleolar RNA, C/D box 71  2.1 
381801  9797  Tatdn2  TatD DNase domain containing 2  2.1 
104662  55720  Tsr1  TSR1, 20S rRNA accumulation, homolog (yeast)  2.1 
623505    Gm6436  predicted gene 6436  2.1 
21378    Tbrg3  transforming growth factor beta regulated gene 3  2.1 
68048  64782  Aen  apoptosis enhancing nuclease  2.1 
100302
498 
  Snora21  small nucleolar RNA, H/ACA box 21  2.1 
66175  389125  Mustn1  musculoskeletal, embryonic nuclear protein 1  2.1 




















57815  166378  Spata5  spermatogenesis associated 5  2.1 





57875  51129  Angptl4  angiopoietin‐like 4  2.0 
100039
913 





18712  5292  Pim1  proviral integration site 1  2.0 









20893  8553  Bhlhe40  basic helix‐loop‐helix family, member e40  2.0 
19225  5743  Ptgs2  prostaglandin‐endoperoxide synthase 2  2.0 





74732  8676  Stx11  syntaxin 11  2.0 
72323  140459  Asb6  ankyrin repeat and SOCS box‐containing 6  2.0 
16402  3678  Itga5  integrin alpha 5 (fibronectin receptor alpha)  2.0 
242083  151742  Ppm1l  protein phosphatase 1 (formerly 2C)‐like  2.0 
449630    Snord15a  small nucleolar RNA, C/D box 15A  2.0 
16172  23765  Il17ra  interleukin 17 receptor A  2.0 
118445    Klf16  Kruppel‐like factor 16  2.0 
14915  2980  Guca2a  guanylate cyclase activator 2a (guanylin)  2.0 
100216
530 
  Snord118 small nucleolar RNA, C/D box 118  2.0 
404315  284383  Olfr372  olfactory receptor 372  2.0 





19332  55647  Rab20  RAB20, member RAS oncogene family  2.0 
22350  7430  Ezr  ezrin  2.0 
100216
535 
  Scarna9  small Cajal body‐specific RNA 9  2.0 
56552    Vmn2r26  vomeronasal 2, receptor 26  2.0 
232855  374928  Zfp772  zinc finger protein 772  2.0 
11910  467  Atf3  activating transcription factor 3  2.0 
69573  29923  Hilpda  hypoxia inducible lipid droplet associated  2.0 






19870    Snord73a  small nucleolar RNA, C/D box U73A  2.0 
100019  23195  Mdn1  midasin homolog (yeast)  2.0 
114716  200734  Spred2  sprouty‐related, EVH1 domain containing 2  2.0 
217995  55127  Heatr1  HEAT repeat containing 1  2.0 
12571  1021  Cdk6  cyclin‐dependent kinase 6  2.0 
258536  81697  Olfr1360  olfactory receptor 1360  2.0 
103466  51559  Nt5dc3  5'‐nucleotidase domain containing 3  2.0 
380785  57596  Begain  brain‐enriched guanylate kinase‐associated  2.0 




67177  81620  Cdt1  chromatin licensing and DNA replication factor 1  2.0 
624681    Btnl6  butyrophilin‐like 6  2.0 
259056    Olfr584  olfactory receptor 584  2.0 





















16477  3726  Junb  Jun‐B oncogene  2.0 
100526
503 










208164  389558  Fam180a  family with sequence similarity 180, member A  2.0 
16728  3897  L1cam  L1 cell adhesion molecule  2.0 







  Mir1900  microRNA 1900  2.0 
56330  9141  Pdcd5  programmed cell death 5  2.0 
70769    Nolc1  nucleolar and coiled‐body phosphoprotein 1  2.0 
66857  79887  Plbd1  phospholipase B domain containing 1  ‐2.0 





215819  57224  Nhsl1  NHS‐like 1  ‐2.0 
12428  890  Ccna2  cyclin A2  ‐2.0 





56744  5196  Pf4  platelet factor 4  ‐2.0 
94332  57863  Cadm3  cell adhesion molecule 3  ‐2.0 



















108755  57226  Lyrm2  LYR motif containing 2  ‐2.0 






18417  5010  Cldn11  claudin 11  ‐2.0 
23961    Oas1b  2'‐5' oligoadenylate synthetase 1B  ‐2.0 
20128    Trim30a  tripartite motif‐containing 30A  ‐2.0 
277154  57523  Nynrin  NYN domain and retroviral integrase containing  ‐2.0 










216961  84940  Coro6  coronin 6  ‐2.0 
13143  23604  Dapk2  death‐associated protein kinase 2  ‐2.0 
15464    Hrc  histidine rich calcium binding protein  ‐2.0 
13395  1749  Dlx5  distal‐less homeobox 5  ‐2.0 
243864  4277  Mill2  MHC I like leukocyte 2  ‐2.0 
71564  113177  Izumo4  IZUMO family member 4  ‐2.0 
54396  345611  Irgm2  immunity‐related GTPase family M member 2  ‐2.0 
234309  84869  Cbr4  carbonyl reductase 4  ‐2.0 
106821  221443  AI314976  expressed sequence AI314976  ‐2.0 
102791  6988  Tcta  T cell leukemia translocation altered gene  ‐2.0 























170799  219790  Rtkn2  rhotekin 2  ‐2.0 
68082  142679  Dusp19  dual specificity phosphatase 19  ‐2.0 
50915  2888  Grb14  growth factor receptor bound protein 14  ‐2.0 
114301  54873  Palmd  palmdelphin  ‐2.0 
668517    Ighv1‐37  immunoglobulin heavy variable 1‐37  ‐2.0 





406220  374454  Krt77  keratin 77  ‐2.0 
270906  55771  Prr11  proline rich 11  ‐2.0 
16859  284194  Lgals9  lectin, galactose binding, soluble 9  ‐2.0 
13393  1747  Dlx3  distal‐less homeobox 3  ‐2.0 
170677  92211  Cdhr1  cadherin‐related family member 1  ‐2.0 
13607    Eda  ectodysplasin‐A  ‐2.0 
13237    Defa3  defensin, alpha, 3  ‐2.0 
20315  6387  Cxcl12  chemokine (C‐X‐C motif) ligand 12  ‐2.0 
225845  11145  Pla2g16  phospholipase A2, group XVI  ‐2.0 





268807  340359  Klhl38  kelch‐like 38 (Drosophila)  ‐2.0 
15366  3161  Hmmr  hyaluronan mediated motility receptor (RHAMM)  ‐2.0 
56045  25939  Samhd1  SAM domain and HD domain, 1  ‐2.0 









74760  5866  Rab3il1  RAB3A interacting protein (rabin3)‐like 1  ‐2.0 
26434  23627  Prnd  prion protein dublet  ‐2.0 
227960  25801  Gca  grancalcin  ‐2.0 
110751  80332  Adam33  a disintegrin and metallopeptidase domain 33  ‐2.0 








381148  389333  Gm1614  predicted gene 1614  ‐2.0 
11475  59  Acta2  actin, alpha 2, smooth muscle, aorta  ‐2.0 
240038    Gm4944  predicted gene 4944  ‐2.0 
26909  9156  Exo1  exonuclease 1  ‐2.0 
12159  652  Bmp4  bone morphogenetic protein 4  ‐2.0 





12869    Cox8b  cytochrome c oxidase, subunit VIIIb  ‐2.1 





114886  114757  Cygb  cytoglobin  ‐2.1 
72154  79898  Zfp157  zinc finger protein 157  ‐2.1 
15042    H2‐T24  histocompatibility 2, T region locus 24  ‐2.1 
100041
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76933    Ifi27l2a  interferon, alpha‐inducible protein 27 like 2A  ‐2.1 






243912  126393  Hspb6  heat shock protein, alpha‐crystallin‐related, B6  ‐2.1 
60411  64105  Cenpk  centromere protein K  ‐2.1 
140703  129080  Emid1  EMI domain containing 1  ‐2.1 
14962  629  Cfb  complement factor B  ‐2.1 
244198  283298  Olfml1  olfactomedin‐like 1  ‐2.1 
13423  1777  Dnase2a  deoxyribonuclease II alpha  ‐2.1 





14431  2593  Gamt  guanidinoacetate methyltransferase  ‐2.1 
20377  6422  Sfrp1  secreted frizzled‐related protein 1  ‐2.1 
20167  6253  Rtn2  reticulon 2 (Z‐band associated protein)  ‐2.1 
53311  4608  Mybph  myosin binding protein H  ‐2.1 
15945  3627  Cxcl10  chemokine (C‐X‐C motif) ligand 10  ‐2.1 








20272  6332  Scn7a  sodium channel, voltage‐gated, type VII, alpha  ‐2.1 
320678  25900  Iffo1  intermediate filament family orphan 1  ‐2.1 






24110  11274  Usp18  ubiquitin specific peptidase 18  ‐2.1 
69743  54897  Casz1  castor zinc finger 1  ‐2.1 
217082  3131  Hlf  hepatic leukemia factor  ‐2.1 
57896  51315  Krcc1  lysine‐rich coiled‐coil 1  ‐2.1 
20846  6772  Stat1  signal transducer and activator of transcription 1  ‐2.1 
73173  54510  Pcdh18  protocadherin 18  ‐2.1 





236312  3428  Pyhin1  pyrin and HIN domain family, member 1  ‐2.1 
19339  5864  Rab3a  RAB3A, member RAS oncogene family  ‐2.2 
666794  221662  Rbm24  RNA binding motif protein 24  ‐2.2 
243385  285513  Gprin3  GPRIN family member 3  ‐2.2 





54123  3665  Irf7  interferon regulatory factor 7  ‐2.2 











  Snord70  small nucleolar RNA, C/D box 70  ‐2.2 





12180  150572  Smyd1  SET and MYND domain containing 1  ‐2.2 
17855  4598  Mvk  mevalonate kinase  ‐2.2 
56615  4257  Mgst1  microsomal glutathione S‐transferase 1  ‐2.2 
12373  845  Casq2  calsequestrin 2  ‐2.2 
20307    Ccl8  chemokine (C‐C motif) ligand 8  ‐2.2 









19348  10112  Kif20a  kinesin family member 20A  ‐2.2 






























20583  6591  Snai2  snail homolog 2 (Drosophila)  ‐2.2 






17172  429  Ascl1  achaete‐scute complex homolog 1 (Drosophila)  ‐2.2 














17079  4064  Cd180  CD180 antigen  ‐2.2 
208098  116337  Panx3  pannexin 3  ‐2.2 





77938  9679  Fam53b  family with sequence similarity 53, member B  ‐2.3 









74616  79634  Scrn3  secernin 3  ‐2.3 
208890  115111  Slc26a7  solute carrier family 26, member 7  ‐2.3 
99899  10561  Ifi44  interferon‐induced protein 44  ‐2.3 
20378  2487  Frzb  frizzled‐related protein  ‐2.3 
20210    Saa3  serum amyloid A 3  ‐2.3 
17263    Meg3  maternally expressed 3  ‐2.3 
21426  22797  Tfec  transcription factor EC  ‐2.3 
14184  2261  Fgfr3  fibroblast growth factor receptor 3  ‐2.3 
240034    Zfp760  zinc finger protein 760  ‐2.3 
56525  9310  Zfp235  zinc finger protein 235  ‐2.3 
78751  376940  Zc3h6  zinc finger CCCH type containing 6  ‐2.3 
21809  7043  Tgfb3  transforming growth factor, beta 3  ‐2.3 
12805  1272  Cntn1  contactin 1  ‐2.3 
11923  58158  Neurod4  neurogenic differentiation 4  ‐2.3 




















68828  81493  Sync  syncoilin  ‐2.3 
13527  1837  Dtna  dystrobrevin alpha  ‐2.3 
58994  55512  Smpd3  sphingomyelin phosphodiesterase 3, neutral  ‐2.3 
13605  1894  Ect2  ect2 oncogene  ‐2.3 





66568  25950  Rwdd3  RWD domain containing 3  ‐2.4 





















81799  114899  C1qtnf3  C1q and tumor necrosis factor related protein 3  ‐2.4 
67242  79833  Gemin6  gem (nuclear organelle) associated protein 6  ‐2.4 
21956  7139  Tnnt2  troponin T2, cardiac  ‐2.4 
434246  493829  Trim72  tripartite motif‐containing 72  ‐2.4 
225861  254122  Snx32  sorting nexin 32  ‐2.4 
243371  65999  Lrrc61  leucine rich repeat containing 61  ‐2.4 
279572    Tlr13  toll‐like receptor 13  ‐2.4 
55932  115361  Gbp3  guanylate binding protein 3  ‐2.4 
12140  2173  Fabp7  fatty acid binding protein 7, brain  ‐2.4 





212518  503542  Sprn  shadow of prion protein  ‐2.5 
20684    Sp100  nuclear antigen Sp100  ‐2.5 
213436  203430  Zcchc5  zinc finger, CCHC domain containing 5  ‐2.5 
100316
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  Mir1940  microRNA 1940  ‐2.5 
12873  1359  Cpa3  carboxypeptidase A3, mast cell  ‐2.5 










13009  8048  Csrp3  cysteine and glycine‐rich protein 3  ‐2.6 
17260  4208  Mef2c  myocyte enhancer factor 2C  ‐2.6 
213081  57728  Wdr19  WD repeat domain 19  ‐2.6 
13396  1750  Dlx6  distal‐less homeobox 6  ‐2.6 
244923  401265  Klhl31  kelch‐like 31 (Drosophila)  ‐2.6 

















67099  151194  Mettl21a  methyltransferase like 21A  ‐2.6 
243277  283383  Gpr133  G protein‐coupled receptor 133  ‐2.6 
170938  729747  Zfp617  zinc finger protein 617  ‐2.6 
73649  79901  Cybrd1  cytochrome b reductase 1  ‐2.6 
245671  11279  Klf8  Kruppel‐like factor 8  ‐2.6 
104759  122618  Pld4  phospholipase D family, member 4  ‐2.7 
78977  64208  Popdc3  popeye domain containing 3  ‐2.7 
68802  84665  Mypn  myopalladin  ‐2.7 
229900  388646  Gbp7  guanylate binding protein 7  ‐2.7 
22157  7287  Tulp1  tubby like protein 1  ‐2.7 





76294  140458  Asb5  ankyrin repeat and SOCs box‐containing 5  ‐2.7 
22142  7846  Tuba1a  tubulin, alpha 1A  ‐2.7 



















668413    Gm9158  predicted gene 9158  ‐2.8 
18424  5015  Otx2  orthodenticle homolog 2 (Drosophila)  ‐2.8 
23960  4938  Oas1g  2'‐5' oligoadenylate synthetase 1G  ‐2.8 














330096  152573  Shisa3  shisa homolog 3 (Xenopus laevis)  ‐2.8 
213742    Xist  inactive X specific transcripts  ‐2.9 




231507  51316  Plac8  placenta‐specific 8  ‐2.9 
103511  254228  Fam26e  family with sequence similarity 26, member E  ‐2.9 
209588  6398  Sectm1a  secreted and transmembrane 1A  ‐2.9 
73804  11004  Kif2c  kinesin family member 2C  ‐2.9 
66847  135114  Hint3  histidine triad nucleotide binding protein 3  ‐2.9 
17329    Cxcl9  chemokine (C‐X‐C motif) ligand 9  ‐2.9 
13482  1803  Dpp4  dipeptidylpeptidase 4  ‐2.9 
69938  9805  Scrn1  secernin 1  ‐2.9 
106393  6345  Srl  sarcalumenin  ‐2.9 
22355  7434  Vipr2  vasoactive intestinal peptide receptor 2  ‐2.9 
246728  4939  Oas2  2'‐5' oligoadenylate synthetase 2  ‐3.0 
69550    Bst2  bone marrow stromal cell antigen 2  ‐3.0 
56338  10628  Txnip  thioredoxin interacting protein  ‐3.0 
17189  4151  Mb  myoglobin  ‐3.0 









60440    Iigp1  interferon inducible GTPase 1  ‐3.1 
17996  4703  Neb  nebulin  ‐3.1 
17896  4635  Myl4  myosin, light polypeptide 4  ‐3.1 
12661  10752  Chl1  cell adhesion molecule with homology to L1CAM  ‐3.2 










11464  70  Actc1  actin, alpha, cardiac muscle 1  ‐3.3 
18175  4892  Nrap  nebulin‐related anchoring protein  ‐3.3 





234311  55601  Ddx60  DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 60  ‐3.3 
20292  6356  Ccl11  chemokine (C‐C motif) ligand 11  ‐3.4 

















21953  7136  Tnni2  troponin I, skeletal, fast 2  ‐3.5 





78321  200539  Ankrd23  ankyrin repeat domain 23  ‐3.5 
11447  1144  Chrnd  cholinergic receptor, nicotinic, delta polypeptide  ‐3.6 
12653  1114  Chgb  chromogranin B  ‐3.6 
66139  389827  Tmem8c  transmembrane protein 8C  ‐3.6 
236573  163351  Gbp9  guanylate‐binding protein 9  ‐3.6 
59006  51778  Myoz2  myozenin 2  ‐3.6 










98660  477  Atp1a2  ATPase, Na+/K+ transporting, alpha 2 polypeptide  ‐3.7 
17930  9172  Myom2  myomesin 2  ‐3.8 
68016  347273  Murc  muscle‐related coiled‐coil protein  ‐3.8 
228003  10324  Kbtbd10  kelch repeat and BTB (POZ) domain containing 10  ‐3.9 
11932  482  Atp1b2  ATPase, Na+/K+ transporting, beta 2 polypeptide  ‐3.9 





108015  1143  Chrnb4  cholinergic receptor, nicotinic, beta polypeptide 4  ‐4.0 











240327    Gm4951  predicted gene 4951  ‐4.3 












20215  6295  Sag  retinal S‐antigen  ‐4.5 
17286  4223  Meox2  mesenchyme homeobox 2  ‐4.6 






11474    Actn3  actinin alpha 3  ‐4.8 
12372  844  Casq1  calsequestrin 1  ‐4.9 
60596  2982  Gucy1a3  guanylate cyclase 1, soluble, alpha 3  ‐5.0 
21957  7140  Tnnt3  troponin T3, skeletal, fast  ‐5.0 









668923    Zfp442  zinc finger protein 442  ‐5.4 
21955  7138  Tnnt1  troponin T1, skeletal, slow  ‐5.4 
107765  27063  Ankrd1  ankyrin repeat domain 1 (cardiac muscle)  ‐5.5 
21925  7125  Tnnc2  troponin C2, fast  ‐5.6 
19661  5949  Rbp3  retinol binding protein 3, interstitial  ‐5.7 
13380  22943  Dkk1  dickkopf homolog 1 (Xenopus laevis)  ‐5.9 
13346  1674  Des  desmin  ‐5.9 
53318    Pdlim3  PDZ and LIM domain 3  ‐6.0 
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11472  88  Actn2  actinin alpha 2  15.8 
16365  730249  Irg1  immunoresponsive gene 1  15.4 
12372  844  Casq1  calsequestrin 1  14.9 





107765  27063  Ankrd1  ankyrin repeat domain 1 (cardiac muscle)  13.5 
78321  200539  Ankrd23  ankyrin repeat domain 23  13.5 





109272  4604  Mybpc1  myosin binding protein C, slow‐type  12.1 
66106  23676  Smpx  small muscle protein, X‐linked  11.9 
269799  440077  Clec4a1  C‐type lectin domain family 4, member a1  11.7 
53318    Pdlim3  PDZ and LIM domain 3  11.1 


















58185  91543  Rsad2  radical S‐adenosyl methionine domain containing 2  9.4 
76757  10345  Trdn  triadin  9.4 









17996  4703  Neb  nebulin  9.0 
17167  8685  Marco  macrophage receptor with collagenous structure  8.8 
230787  9473  Themis2  thymocyte selection associated family member 2  8.6 
100034
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  Wfdc17  WAP four‐disulfide core domain 17  8.5 
170744  51311  Tlr8  toll‐like receptor 8  8.4 





13346  1674  Des  desmin  8.3 





21952  7135  Tnni1  troponin I, skeletal, slow 1  8.1 
80719  10261  Igsf6  immunoglobulin superfamily, member 6  8.1 
17879  4619  Myh1  myosin, heavy polypeptide 1, skeletal muscle, adult  8.0 
12350  761  Car3  carbonic anhydrase 3  7.9 
80891    Fcrls  Fc receptor‐like S, scavenger receptor  7.9 














12504  920  Cd4  CD4 antigen  7.6 





17930  9172  Myom2  myomesin 2  7.3 
11449  1146  Chrng  cholinergic receptor, nicotinic, gamma polypeptide  7.3 
279572    Tlr13  toll‐like receptor 13  7.3 
59006  51778  Myoz2  myozenin 2  7.2 
17896  4635  Myl4  myosin, light polypeptide 4  7.1 








14289  2358  Fpr2  formyl peptide receptor 2  6.9 
233571  5031  P2ry6  pyrimidinergic receptor P2Y, G‐protein coupled, 6  6.9 
432555    Gm5431  predicted gene 5431  6.9 
12045  597  Bcl2a1b  B cell leukemia/lymphoma 2 related protein A1b  6.8 





17533  4360  Mrc1  mannose receptor, C type 1  6.8 
17189  4151  Mb  myoglobin  6.8 
15945  3627  Cxcl10  chemokine (C‐X‐C motif) ligand 10  6.8 





545205  81696  Olfr111  olfactory receptor 111  6.6 
74091  80896  Npl  N‐acetylneuraminate pyruvate lyase  6.6 
19309  5837  Pygm  muscle glycogen phosphorylase  6.4 
76294  140458  Asb5  ankyrin repeat and SOCs box‐containing 5  6.4 
23833    Cd52  CD52 antigen  6.4 
228003  10324  Kbtbd10  kelch repeat and BTB (POZ) domain containing 10  6.3 
21956  7139  Tnnt2  troponin T2, cardiac  6.3 





17079  4064  Cd180  CD180 antigen  6.2 
12362  834  Casp1  caspase 1  6.2 
12517  971  Cd72  CD72 antigen  6.2 
50498  10148  Ebi3  Epstein‐Barr virus induced gene 3  6.1 





21953  7136  Tnni2  troponin I, skeletal, fast 2  6.0 






11464  70  Actc1  actin, alpha, cardiac muscle 1  5.7 









22138  7273  Ttn  titin  5.6 
241431  129446  Xirp2  xin actin‐binding repeat containing 2  5.6 
22139  7276  Ttr  transthyretin  5.6 
56792  26228  Stap1  signal transducing adaptor family member 1  5.6 





15953    Ifi47  interferon gamma inducible protein 47  5.4 
12373  845  Casq2  calsequestrin 2  5.4 
19692  5967  Reg1  regenerating islet‐derived 1  5.3 
21926  7124  Tnf  tumor necrosis factor  5.3 
434246  493829  Trim72  tripartite motif‐containing 72  5.3 










66139  389827  Tmem8c transmembrane protein 8C  5.2 
23880  2533  Fyb  FYN binding protein  5.2 
14293  2357  Fpr1  formyl peptide receptor 1  5.1 
192187  23166  Stab1  stabilin 1  5.1 
13009  8048  Csrp3  cysteine and glycine‐rich protein 3  5.1 
27052  313  Aoah  acyloxyacyl hydrolase  5.1 
13025    Ctla2b  cytotoxic T lymphocyte‐associated protein 2 beta  5.1 
11475  59  Acta2  actin, alpha 2, smooth muscle, aorta  5.0 









231655  8638  Oasl1  2'‐5' oligoadenylate synthetase‐like 1  4.9 





15109  3034  Hal  histidine ammonia lyase  4.8 
19293  5816  Pvalb  parvalbumin  4.7 
17085  4063  Ly9  lymphocyte antigen 9  4.7 








71733  56241  Susd2  sushi domain containing 2  4.7 
547253  54625  Parp14  poly (ADP‐ribose) polymerase family, member 14  4.7 
16197  3575  Il7r  interleukin 7 receptor  4.7 
100040
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11459  58  Acta1  actin, alpha 1, skeletal muscle  4.6 
215632  23550  Psd4  pleckstrin and Sec7 domain containing 4  4.6 
75345  57823  Slamf7  SLAM family member 7  4.6 





21426  22797  Tfec  transcription factor EC  4.5 
60440    Iigp1  interferon inducible GTPase 1  4.5 
20293  6347  Ccl12  chemokine (C‐C motif) ligand 12  4.5 
12267  719  C3ar1  complement component 3a receptor 1  4.5 
13040  1520  Ctss  cathepsin S  4.5 





23960  4938  Oas1g  2'‐5' oligoadenylate synthetase 1G  4.4 





11816  348  Apoe  apolipoprotein E  4.3 
240327    Gm4951  predicted gene 4951  4.3 
12506  962  Cd48  CD48 antigen  4.3 
231805  29992  Pilra  paired immunoglobin‐like type 2 receptor alpha  4.3 
73149    Clec4a3  C‐type lectin domain family 4, member a3  4.3 
12869    Cox8b  cytochrome c oxidase, subunit VIIIb  4.3 
16168  3600  Il15  interleukin 15  4.3 
12523  8832  Cd84  CD84 antigen  4.3 
55985  10563  Cxcl13  chemokine (C‐X‐C motif) ligand 13  4.2 
83490  118788  Pik3ap1  phosphoinositide‐3‐kinase adaptor protein 1  4.2 









21345  6876  Tagln  transgelin  4.2 
236312  3428  Pyhin1  pyrin and HIN domain family, member 1  4.2 





12845  1311  Comp  cartilage oligomeric matrix protein  4.2 
244923  401265  Klhl31  kelch‐like 31 (Drosophila)  4.2 
19264  5788  Ptprc  protein tyrosine phosphatase, receptor type, C  4.1 
20363  6414  Sepp1  selenoprotein P, plasma, 1  4.1 
20292  6356  Ccl11  chemokine (C‐C motif) ligand 11  4.1 
53311  4608  Mybph  myosin binding protein H  4.1 
17929  8736  Myom1  myomesin 1  4.1 
22041  7018  Trf  transferrin  4.0 
17227    Mcpt4  mast cell protease 4  4.0 





14127  2207  Fcer1g  Fc receptor, IgE, high affinity I, gamma polypeptide  4.0 
98660  477  Atp1a2  ATPase, Na+/K+ transporting, alpha 2 polypeptide  4.0 
16411  3687  Itgax  integrin alpha X  4.0 









20305    Ccl6  chemokine (C‐C motif) ligand 6  3.9 
333564    Fndc3c1  fibronectin type III domain containing 3C1  3.9 
380732    Gm885  predicted gene 885  3.9 





12774  1234  Ccr5  chemokine (C‐C motif) receptor 5  3.9 
12797  1264  Cnn1  calponin 1  3.9 





17928  4656  Myog  myogenin  3.9 
20190  6261  Ryr1  ryanodine receptor 1, skeletal muscle  3.8 
219144  115761  Arl11  ADP‐ribosylation factor‐like 11  3.8 




11932  482  Atp1b2  ATPase, Na+/K+ transporting, beta 2 polypeptide  3.8 
20612  6614  Siglec1  sialic acid binding Ig‐like lectin 1, sialoadhesin  3.8 
57329  56914  Otor  otoraplin  3.8 
211228  126364  Lrrc25  leucine rich repeat containing 25  3.8 
17882  4620  Myh2  myosin, heavy polypeptide 2, skeletal muscle, adult  3.8 
81799  114899  C1qtnf3  C1q and tumor necrosis factor related protein 3  3.8 







11689  240  Alox5  arachidonate 5‐lipoxygenase  3.7 
66889  79589  Rnf128  ring finger protein 128  3.7 





23967  130497  Osr1  odd‐skipped related 1 (Drosophila)  3.7 
16409  3684  Itgam  integrin alpha M  3.7 



















22337  7421  Vdr  vitamin D receptor  3.7 
15559  3357  Htr2b  5‐hydroxytryptamine (serotonin) receptor 2B  3.6 
12266  718  C3  complement component 3  3.6 
108101  83706  Fermt3  fermitin family homolog 3 (Drosophila)  3.6 
58916  9499  Myot  myotilin  3.6 
116847  5549  Prelp  proline arginine‐rich end leucine‐rich repeat  3.6 
107769  53346  Tm6sf1  transmembrane 6 superfamily member 1  3.6 
22177  7305  Tyrobp  TYRO protein tyrosine kinase binding protein  3.6 
15163  3059  Hcls1  hematopoietic cell specific Lyn substrate 1  3.6 
16822  3937  Lcp2  lymphocyte cytosolic protein 2  3.6 
20303  6351  Ccl4  chemokine (C‐C motif) ligand 4  3.6 
17916  4542  Myo1f  myosin IF  3.6 
14311  63924  Cidec  cell death‐inducing DFFA‐like effector c  3.6 
98932  10398  Myl9  myosin, light polypeptide 9, regulatory  3.6 




18198  4593  Musk  muscle, skeletal, receptor tyrosine kinase  3.6 
23828  11149  Bves  blood vessel epicardial substance  3.5 
236573  163351  Gbp9  guanylate‐binding protein 9  3.5 
320832  10326  Sirpb1a  signal‐regulatory protein beta 1A  3.5 










54199  9034  Ccrl2  chemokine (C‐C motif) receptor‐like 2  3.5 





17884  4622  Myh4  myosin, heavy polypeptide 4, skeletal muscle  3.5 
98365  89886  Slamf9  SLAM family member 9  3.5 
20128    Trim30a  tripartite motif‐containing 30A  3.5 
54396  345611  Irgm2  immunity‐related GTPase family M member 2  3.5 
105855  3071  Nckap1l  NCK associated protein 1 like  3.5 
19220  5737  Ptgfr  prostaglandin F receptor  3.5 
18826  3936  Lcp1  lymphocyte cytosolic protein 1  3.5 





108015  1143  Chrnb4  cholinergic receptor, nicotinic, beta polypeptide 4  3.4 












15162  3055  Hck  hemopoietic cell kinase  3.4 
20375  6688  Sfpi1  SFFV proviral integration 1  3.4 
245945  54502  Rbm47  RNA binding motif protein 47  3.4 
21393  8557  Tcap  titin‐cap  3.4 
212032  3101  Hk3  hexokinase 3  3.4 












83453  91851  Chrdl1  chordin‐like 1  3.4 






17476  219972  Mpeg1  macrophage expressed gene 1  3.3 
16145    Igtp  interferon gamma induced GTPase  3.3 
20345  6404  Selplg  selectin, platelet (p‐selectin) ligand  3.3 
12495  953  Entpd1  ectonucleoside triphosphate diphosphohydrolase 1  3.3 
20821  6737  Trim21  tripartite motif‐containing 21  3.3 
20210    Saa3  serum amyloid A 3  3.3 





56620  93978  Clec4n  C‐type lectin domain family 4, member n  3.3 
16414  3689  Itgb2  integrin beta 2  3.3 
12524  942  Cd86  CD86 antigen  3.3 





12978  1436  Csf1r  colony stimulating factor 1 receptor  3.2 









12044  597  Bcl2a1a  B cell leukemia/lymphoma 2 related protein A1a  3.2 













403395  10143  Clec3a  C‐type lectin domain family 3, member a  3.2 
234214  8470  Sorbs2  sorbin and SH3 domain containing 2  3.1 
225594    Gm4841  predicted gene 4841  3.1 
12813  1300  Col10a1  collagen, type X, alpha 1  3.1 
12839  1297  Col9a1  collagen, type IX, alpha 1  3.1 
21916  7111  Tmod1  tropomodulin 1  3.1 








12493  951  Cd37  CD37 antigen  3.1 










246728  4939  Oas2  2'‐5' oligoadenylate synthetase 2  3.1 
68279  255231  Mcoln2  mucolipin 2  3.1 
80910  53831  Gpr84  G protein‐coupled receptor 84  3.1 
214854  93082  Neurl3  neuralized homolog 3 homolog (Drosophila)  3.1 
22778  10320  Ikzf1  IKAROS family zinc finger 1  3.1 





12308  794  Calb2  calbindin 2  3.0 
19695  130120  Reg3g  regenerating islet‐derived 3 gamma  3.0 
26434  23627  Prnd  prion protein dublet  3.0 
17060  29760  Blnk  B cell linker  3.0 
15360  3158  Hmgcs2  3‐hydroxy‐3‐methylglutaryl‐Coenzyme A synthase 2  3.0 
57278  4059  Bcam  basal cell adhesion molecule  3.0 
22376  7454  Was  Wiskott‐Aldrich syndrome homolog (human)  3.0 
13178  1633  Dck  deoxycytidine kinase  3.0 
12489    Cd33  CD33 antigen  3.0 





16331  3635  Inpp5d  inositol polyphosphate‐5‐phosphatase D  3.0 





17970  4688  Ncf2  neutrophil cytosolic factor 2  3.0 
77652    Zfp955a  zinc finger protein 955A  3.0 






242702  127294  Myom3  myomesin family, member 3  3.0 









319476  57408  Lrtm1  leucine‐rich repeats and transmembrane domains 1  2.9 
15439  3240  Hp  haptoglobin  2.9 
387163    Mir145  microRNA 145  2.9 
12950  1404  Hapln1  hyaluronan and proteoglycan link protein 1  2.9 





11501  101  Adam8  a disintegrin and metallopeptidase domain 8  2.9 
14129  2209  Fcgr1  Fc receptor, IgG, high affinity I  2.9 





246730  4938  Oas1a  2'‐5' oligoadenylate synthetase 1A  2.9 
55987  119587  Cpxm2  carboxypeptidase X 2 (M14 family)  2.9 
54353  8935  Skap2  src family associated phosphoprotein 2  2.9 
12837  1295  Col8a1  collagen, type VIII, alpha 1  2.9 
20649  6641  Sntb1  syntrophin, basic 1  2.9 
232413  160364  Clec12a  C‐type lectin domain family 12, member a  2.9 
54140  552  Avpr1a  arginine vasopressin receptor 1A  2.9 
494468  64860  Armcx5  armadillo repeat containing, X‐linked 5  2.9 













24110  11274  Usp18  ubiquitin specific peptidase 18  2.9 





67713  131118  Dnajc19  DnaJ (Hsp40) homolog, subfamily C, member 19  2.8 
22437  165904  Xirp1  xin actin‐binding repeat containing 1  2.8 
11522  126  Adh1  alcohol dehydrogenase 1 (class I)  2.8 
26888  50856  Clec4a2  C‐type lectin domain family 4, member a2  2.8 
11629  199  Aif1  allograft inflammatory factor 1  2.8 
















11754  8639  Aoc3  amine oxidase, copper containing 3  2.8 
13618  1910  Ednrb  endothelin receptor type B  2.8 
217944  9771  Rapgef5  Rap guanine nucleotide exchange factor (GEF) 5  2.8 
100042
856 
  Gm4070  predicted gene 4070  2.8 
12715  1158  Ckm  creatine kinase, muscle  2.8 









12496  954  Entpd2  ectonucleoside triphosphate diphosphohydrolase 2  2.8 






226409  84083  Zranb3  zinc finger, RAN‐binding domain containing 3  2.8 
17972  4689  Ncf4  neutrophil cytosolic factor 4  2.8 
56426  11235  Pdcd10  programmed cell death 10  2.8 














11630  202  Aim1  absent in melanoma 1  2.7 
20684    Sp100  nuclear antigen Sp100  2.7 
12140  2173  Fabp7  fatty acid binding protein 7, brain  2.7 
56525  9310  Zfp235  zinc finger protein 235  2.7 





72258  54207  Kcnk10  potassium channel, subfamily K, member 10  2.7 
14199  2273  Fhl1  four and a half LIM domains 1  2.7 




216869  409  Arrb2  arrestin, beta 2  2.7 
11936    Fxyd2  FXYD domain‐containing ion transport regulator 2  2.7 






327978  162394  Slfn5  schlafen 5  2.7 
65221  51296  Slc15a3  solute carrier family 15, member 3  2.7 
71607  124460  Snx20  sorting nexin 20  2.7 





93697  79664  Narg2  NMDA receptor‐regulated gene 2  2.7 





217012  146862  Unc45b  unc‐45 homolog B (C. elegans)  2.7 
93677  442721  Lmod2  leiomodin 2 (cardiac)  2.7 
12587  8190  Mia1  melanoma inhibitory activity 1  2.7 










170741  29990  Pilrb1  paired immunoglobin‐like type 2 receptor beta 1  2.6 










668923    Zfp442  zinc finger protein 442  2.6 
21924  7134  Tnnc1  troponin C, cardiac/slow skeletal  2.6 












  Mir1983  microRNA 1983  2.6 

















52855  3903  Lair1  leukocyte‐associated Ig‐like receptor 1  2.6 
23792  8745  Adam23  a disintegrin and metallopeptidase domain 23  2.6 
78771  79772  Mctp1  multiple C2 domains, transmembrane 1  2.6 
23845  23601  Clec5a  C‐type lectin domain family 5, member a  2.6 
227929  9595  Cytip  cytohesin 1 interacting protein  2.6 
12508  963  Cd53  CD53 antigen  2.6 
20963  6850  Syk  spleen tyrosine kinase  2.6 






67689  221  Aldh3b1  aldehyde dehydrogenase 3 family, member B1  2.6 







381148  389333  Gm1614  predicted gene 1614  2.5 
11829  361  Aqp4  aquaporin 4  2.5 
16956  4023  Lpl  lipoprotein lipase  2.5 
71310  23158  Tbc1d9  TBC1 domain family, member 9  2.5 
20254  7857  Scg2  secretogranin II  2.5 
666794  221662  Rbm24  RNA binding motif protein 24  2.5 
19354  5880  Rac2  RAS‐related C3 botulinum substrate 2  2.5 
19378  8854  Aldh1a2  aldehyde dehydrogenase family 1, subfamily A2  2.5 
100101
484 
  Trac  T cell receptor alpha constant  2.5 
93695  10457  Gpnmb  glycoprotein (transmembrane) nmb  2.5 
240665  54619  Ccnj  cyclin J  2.5 
12033  55973  Bcap29  B cell receptor associated protein 29  2.5 
16988    Lst1  leukocyte specific transcript 1  2.5 





94176  1794  Dock2  dedicator of cyto‐kinesis 2  2.5 




234311  55601  Ddx60  DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 60  2.5 
15442  10855  Hpse  heparanase  2.5 
15464    Hrc  histidine rich calcium binding protein  2.5 
16186  3561  Il2rg  interleukin 2 receptor, gamma chain  2.5 
18761  5588  Prkcq  protein kinase C, theta  2.5 




















  Mir1940  microRNA 1940  2.5 
622976    Gm6377  predicted gene 6377  2.5 
231042  11097  Nupl2  nucleoporin like 2  2.5 
72580  221302  Zufsp  zinc finger with UFM1‐specific peptidase domain  2.5 
14580  2670  Gfap  glial fibrillary acidic protein  2.5 
14990    H2‐M2  histocompatibility 2, M region locus 2  2.4 
66491  5441  Polr2l  polymerase (RNA) II (DNA directed) polypeptide L  2.4 
16181  3557  Il1rn  interleukin 1 receptor antagonist  2.4 

















18830  5360  Pltp  phospholipid transfer protein  2.4 
66793  79645  Efcab1  EF hand calcium binding domain 1  2.4 
211770  10221  Trib1  tribbles homolog 1 (Drosophila)  2.4 
14594    Ggta1  glycoprotein galactosyltransferase alpha 1, 3  2.4 
67532  4236  Mfap1a  microfibrillar‐associated protein 1A  2.4 


















17969  653361  Ncf1  neutrophil cytosolic factor 1  2.4 
67664    Rnf125  ring finger protein 125  2.4 
30878  8862  Apln  apelin  2.4 
12741  7122  Cldn5  claudin 5  2.4 





66847  135114  Hint3  histidine triad nucleotide binding protein 3  2.4 
54711  5326  Plagl2  pleiomorphic adenoma gene‐like 2  2.4 
15944    Irgm1  immunity‐related GTPase family M member 1  2.4 
68526  151556  Gpr155  G protein‐coupled receptor 155  2.4 





56338  10628  Txnip  thioredoxin interacting protein  2.4 
16548  3795  Khk  ketohexokinase  2.4 
74481  116071  Batf2  basic leucine zipper transcription factor, ATF‐like 2  2.4 
723842    Mir329  microRNA 329  2.4 
381484    Gm5150  predicted gene 5150  2.4 













56193  5341  Plek  pleckstrin  2.4 
22294  8409  Uxt  ubiquitously expressed transcript  2.4 
268859  54715  Rbfox1  RNA binding protein, fox‐1 homolog (C. elegans) 1  2.4 
69556  91272  Bod1  biorientation of chromosomes in cell division 1  2.3 
77630  56978  Prdm8  PR domain containing 8  2.3 
98711  157506  Rdh10  retinol dehydrogenase 10 (all‐trans)  2.3 
17095  4066  Lyl1  lymphoblastomic leukemia 1  2.3 




240690  9705  St18  suppression of tumorigenicity 18  2.3 
100526
475 
  Mir3076  microRNA 3076  2.3 










19271  5795  Ptprj  protein tyrosine phosphatase, receptor type, J  2.3 
108755  57226  Lyrm2  LYR motif containing 2  2.3 
13808  2027  Eno3  enolase 3, beta muscle  2.3 
18636  5199  Cfp  complement factor properdin  2.3 
110006  2990  Gusb  glucuronidase, beta  2.3 











209086  219285  Samd9l  sterile alpha motif domain containing 9‐like  2.3 
20307    Ccl8  chemokine (C‐C motif) ligand 8  2.3 
100379
145 
  Snora23  small nucleolar RNA, H/ACA box 23  2.3 
217303  11314  Cd300a  CD300A antigen  2.3 
236451  51131  Gm4902  predicted gene 4902  2.3 
15900  3394  Irf8  interferon regulatory factor 8  2.3 
18557  5129  Cdk18  cyclin‐dependent kinase 18  2.3 
100217
459 









14064  2151  F2rl2  coagulation factor II (thrombin) receptor‐like 2  2.3 
98999  57169  Znfx1  zinc finger, NFX1‐type containing 1  2.3 
16194  3570  Il6ra  interleukin 6 receptor, alpha  2.3 
13527  1837  Dtna  dystrobrevin alpha  2.3 
76820  81553  Fam49a  family with sequence similarity 49, member A  2.3 




16592  2171  Fabp5  fatty acid binding protein 5, epidermal  2.3 










56045  25939  Samhd1  SAM domain and HD domain, 1  2.3 
319713  22885  Ablim3  actin binding LIM protein family, member 3  2.2 
24088  7097  Tlr2  toll‐like receptor 2  2.2 
24131  11155  Ldb3  LIM domain binding 3  2.2 
235956    Zfp825  zinc finger protein 825  2.2 





19204  5724  Ptafr  platelet‐activating factor receptor  2.2 
13654  1959  Egr2  early growth response 2  2.2 
18574  5153  Pde1b  phosphodiesterase 1B, Ca2+‐calmodulin dependent  2.2 
233199  4606  Mybpc2  myosin binding protein C, fast‐type  2.2 
21789  7980  Tfpi2  tissue factor pathway inhibitor 2  2.2 
27047  4958  Omd  osteomodulin  2.2 
65255  51666  Asb4  ankyrin repeat and SOCS box‐containing 4  2.2 
76808  6142  Rpl18a  ribosomal protein L18A  2.2 
117167  79689  Steap4  STEAP family member 4  2.2 
14130  2213  Fcgr2b  Fc receptor, IgG, low affinity IIb  2.2 










12721  11151  Coro1a  coronin, actin binding protein 1A  2.2 





18295  4969  Ogn  osteoglycin  2.2 
16453  3718  Jak3  Janus kinase 3  2.2 
67281  6167  Rpl37  ribosomal protein L37  2.2 
235380  23312  Dmxl2  Dmx‐like 2  2.2 












19229  2185  Ptk2b  PTK2 protein tyrosine kinase 2 beta  2.2 











277203  116211  Tm4sf19 transmembrane 4 L six family member 19  2.2 
19716    Bex1  brain expressed gene 1  2.2 
20911  6813  Stxbp2  syntaxin binding protein 2  2.2 
13051  1524  Cx3cr1  chemokine (C‐X3‐C) receptor 1  2.2 





20167  6253  Rtn2  reticulon 2 (Z‐band associated protein)  2.2 















216892  124976  Spns2  spinster homolog 2  2.2 
209200  151636  Dtx3l  deltex 3‐like (Drosophila)  2.2 





69121  25884  Chrdl2  chordin‐like 2  2.2 
20603  6611  Sms  spermine synthase  2.2 
100217
423 
  Snord19  small nucleolar RNA, C/D box 19  2.2 












21922  7123  Clec3b  C‐type lectin domain family 3, member b  2.2 
20530  1318  Slc31a2  solute carrier family 31, member 2  2.2 
170938  729747  Zfp617  zinc finger protein 617  2.2 
211255  84078  Kbtbd7  kelch repeat and BTB (POZ) domain containing 7  2.2 
18767  5569  Pkia  protein kinase inhibitor, alpha  2.2 










19661  5949  Rbp3  retinol binding protein 3, interstitial  2.2 
237313  53832  Il20ra  interleukin 20 receptor, alpha  2.2 






56503  54851  Ankrd49  ankyrin repeat domain 49  2.2 





67168  10161  Lpar6  lysophosphatidic acid receptor 6  2.2 









18546  5121  Pcp4  Purkinje cell protein 4  2.2 
18987  5452  Pou2f2  POU domain, class 2, transcription factor 2  2.2 
15061  10964  H28  histocompatibility 28  2.2 





57435  729359  Plin4  perilipin 4  2.1 
18359    Olfr59  olfactory receptor 59  2.1 
140483  3176  Hnmt  histamine N‐methyltransferase  2.1 
















71816  285671  Rnf180  ring finger protein 180  2.1 
66493  51258  Mrpl51  mitochondrial ribosomal protein L51  2.1 





20302  414062  Ccl3  chemokine (C‐C motif) ligand 3  2.1 
56744  5196  Pf4  platelet factor 4  2.1 
19075  5557  Prim1  DNA primase, p49 subunit  2.1 















14081  2180  Acsl1  acyl‐CoA synthetase long‐chain family member 1  2.1 





231238  23231  Sel1l3  sel‐1 suppressor of lin‐12‐like 3 (C. elegans)  2.1 






192166  1757  Sardh  sarcosine dehydrogenase  2.1 
20311  6372  Cxcl5  chemokine (C‐X‐C motif) ligand 5  2.1 









71916  11062  Dus4l  dihydrouridine synthase 4‐like (S. cerevisiae)  2.1 















22770  11244  Zhx1  zinc fingers and homeoboxes 1  2.1 





68631  51084  Cryl1  crystallin, lambda 1  2.1 
231724  144715  Rad9b  RAD9 homolog B (S. cerevisiae)  2.1 















11813  344  Apoc2  apolipoprotein C‐II  2.1 
99586  1806  Dpyd  dihydropyrimidine dehydrogenase  2.1 
76574  84879  Mfsd2a  major facilitator superfamily domain containing 2A  2.1 
545428  285025  Ccdc141  coiled‐coil domain containing 141  2.1 
100526
503 
  Mir3096  microRNA 3096  2.1 





16190  3566  Il4ra  interleukin 4 receptor, alpha  2.1 
12859    Cox5b  cytochrome c oxidase, subunit Vb  2.1 
12767  7852  Cxcr4  chemokine (C‐X‐C motif) receptor 4  2.1 










18823  5354  Plp1  proteolipid protein (myelin) 1  2.1 

















208890  115111  Slc26a7  solute carrier family 26, member 7  2.0 
380855    Rsl1  regulator of sex limited protein 1  2.0 



















244198  283298  Olfml1  olfactomedin‐like 1  2.0 





74748  56833  Slamf8  SLAM family member 8  2.0 
66943  80148  Pqlc1  PQ loop repeat containing 1  2.0 
224109  375387  Lrrc33  leucine rich repeat containing 33  2.0 
70839  64805  P2ry12  purinergic receptor P2Y, G‐protein coupled 12  2.0 
60533  29126  Cd274  CD274 antigen  2.0 
320678  25900  Iffo1  intermediate filament family orphan 1  2.0 
16157  3590  Il11ra1  interleukin 11 receptor, alpha chain 1  2.0 
241062  80055  Pgap1  post‐GPI attachment to proteins 1  2.0 





239759  200879  Liph  lipase, member H  2.0 
59011  58529  Myoz1  myozenin 1  2.0 






18197  51617  Nsg2  neuron specific gene family member 2  2.0 






333883  966  Cd59b  CD59b antigen  2.0 
56175  25825  Bace2  beta‐site APP‐cleaving enzyme 2  2.0 
17927  4654  Myod1  myogenic differentiation 1  2.0 













114301  54873  Palmd  palmdelphin  2.0 
13628  1917  Eef1a2  eukaryotic translation elongation factor 1 alpha 2  2.0 
14667  2760  Gm2a  GM2 ganglioside activator protein  2.0 
74760  5866  Rab3il1  RAB3A interacting protein (rabin3)‐like 1  2.0 
69743  54897  Casz1  castor zinc finger 1  2.0 
67255  7570  Zfp422  zinc finger protein 422  2.0 
208777  25992  Sned1  sushi, nidogen and EGF‐like domains 1  2.0 
54156  25975  Egfl6  EGF‐like‐domain, multiple 6  2.0 
100216
532 
  Snord2  small nucleolar RNA, C/D box 2  2.0 





22276  7390  Uros  uroporphyrinogen III synthase  2.0 
17159  4125  Man2b1  mannosidase 2, alpha B1  2.0 
19885  6097  Rorc  RAR‐related orphan receptor gamma  2.0 
71839  29948  Osgin1  oxidative stress induced growth inhibitor 1  2.0 
226610  149297  Fam78b  family with sequence similarity 78, member B  2.0 
108961  79733  E2f8  E2F transcription factor 8  2.0 
53858  10069  Rwdd2b  RWD domain containing 2B  2.0 
70598  27145  Filip1  filamin A interacting protein 1  2.0 
270084  54947  Lpcat2  lysophosphatidylcholine acyltransferase 2  2.0 
68857  285605  Dtwd2  DTW domain containing 2  2.0 
66109  27075  Tspan13  tetraspanin 13  2.0 
240038    Gm4944  predicted gene 4944  2.0 
20112  6196  Rps6ka2  ribosomal protein S6 kinase, polypeptide 2  2.0 
387142    Mir24‐1  microRNA 24‐1  2.0 
72195  9913  Supt7l  suppressor of Ty 7 (S. cerevisiae)‐like  2.0 
545938  284323  Zfp607  zinc finger proten 607  2.0 





240067    Zfp952  zinc finger protein 952  2.0 
434484  11262  Sp140  Sp140 nuclear body protein  2.0 




208426  654502  Iqcj  IQ motif containing J  2.0 
68051  10204  Nutf2  nuclear transport factor 2  2.0 





216984  2124  Evi2b  ecotropic viral integration site 2b  2.0 
56188  5348  Fxyd1  FXYD domain‐containing ion transport regulator 1  2.0 
58522  57159  Trim54  tripartite motif‐containing 54  2.0 









13877  2079  Erh  enhancer of rudimentary homolog (Drosophila)  2.0 
13423  1777  Dnase2a deoxyribonuclease II alpha  2.0 
13405  1756  Dmd  dystrophin, muscular dystrophy  2.0 










21915  1841  Dtymk  deoxythymidylate kinase  2.0 
64378  54112  Gpr88  G‐protein coupled receptor 88  2.0 
100316
932 
  Snora28  small nucleolar RNA, H/ACA box 28  2.0 







16859  284194  Lgals9  lectin, galactose binding, soluble 9  2.0 
18858  5376  Pmp22  peripheral myelin protein 22  2.0 
227522  10557  Rpp38  ribonuclease P/MRP 38 subunit (human)  2.0 





236920  9754  Stard8  START domain containing 8  2.0 
545007    Gm5796  predicted gene 5796  2.0 
12475  929  Cd14  CD14 antigen  2.0 
69668  84317  Ccdc115  coiled‐coil domain containing 115  2.0 
15216  3077  Hfe  hemochromatosis  2.0 




27261  79930  Dok3  docking protein 3  2.0 
71701  87178  Pnpt1  polyribonucleotide nucleotidyltransferase 1  2.0 
27364  63826  Srr  serine racemase  2.0 
13236    Defa25  defensin, alpha, 25  2.0 
23961    Oas1b  2'‐5' oligoadenylate synthetase 1B  2.0 





22761  161882  Zfpm1  zinc finger protein, multitype 1  ‐2.0 
258381  130075  Olfr460  olfactory receptor 460  ‐2.0 
13528  1838  Dtnb  dystrobrevin, beta  ‐2.0 






269060  747  Dagla  diacylglycerol lipase, alpha  ‐2.0 
110761    Igkj3  immunoglobulin kappa joining 3  ‐2.0 





101540  25865  Prkd2  protein kinase D2  ‐2.0 












244550  79883  Podnl1  podocan‐like 1  ‐2.0 
12942  56138  Pcdha11 protocadherin alpha 11  ‐2.0 
14172  8817  Fgf18  fibroblast growth factor 18  ‐2.0 









58172  9792  Sertad2  SERTA domain containing 2  ‐2.0 




















338374  282617  Il28b  interleukin 28B  ‐2.0 
74236    Gsdmcl1 gasdermin C‐like 1  ‐2.0 
66720  317719  Klhl10  kelch‐like 10 (Drosophila)  ‐2.0 
216363  117177  Rab3ip  RAB3A interacting protein  ‐2.0 
380912  55893  Zfp395  zinc finger protein 395  ‐2.0 
258490    Olfr492  olfactory receptor 492  ‐2.0 





14085  2184  Fah  fumarylacetoacetate hydrolase  ‐2.0 
105841  22898  Dennd3  DENN/MADD domain containing 3  ‐2.0 
545055    Cma2  chymase 2, mast cell  ‐2.0 
223669  7553  Zfp7  zinc finger protein 7  ‐2.0 















192285  51317  Phf21a  PHD finger protein 21A  ‐2.0 
24064  10253  Spry2  sprouty homolog 2 (Drosophila)  ‐2.0 
68744    Zfp740  zinc finger protein 740  ‐2.0 
100039
681 







72194  84961  Fbxl20  F‐box and leucine‐rich repeat protein 20  ‐2.0 
217138  79170  Prr15l  proline rich 15‐like  ‐2.0 
12111  633  Bgn  biglycan  ‐2.0 






79456  9401  Recql4  RecQ protein‐like 4  ‐2.0 




80981  379  Arl4d  ADP‐ribosylation factor‐like 4D  ‐2.0 










19376  83871  Rab34  RAB34, member of RAS oncogene family  ‐2.0 
100041
576 
  Gm3414  predicted gene 3414  ‐2.0 










16440  3710  Itpr3  inositol 1,4,5‐triphosphate receptor 3  ‐2.0 
233204  79735  Tbc1d17 TBC1 domain family, member 17  ‐2.0 
625901    Gm6634  predicted gene 6634  ‐2.0 






17532  22808  Mras  muscle and microspikes RAS  ‐2.0 







  Gm3470  predicted gene 3470  ‐2.0 
20226  6301  Sars  seryl‐aminoacyl‐tRNA synthetase  ‐2.0 
16160  3593  Il12b  interleukin 12b  ‐2.0 










12903  1381  Crabp1  cellular retinoic acid binding protein I  ‐2.0 
72469  113026  Plcd3  phospholipase C, delta 3  ‐2.0 





66616  51429  Snx9  sorting nexin 9  ‐2.0 








382066  56980  Prdm10  PR domain containing 10  ‐2.0 











23797  10000  Akt3  thymoma viral proto‐oncogene 3  ‐2.1 
320376  63035  Bcorl1  BCL6 co‐repressor‐like 1  ‐2.1 
76867  84236  Rhbdd1  rhomboid domain containing 1  ‐2.1 
77045  605  Bcl7a  B cell CLL/lymphoma 7A  ‐2.1 
627967    Gm6816  ribosomal protein S4, X‐linked pseudogene  ‐2.1 
22074  5646  Try4  trypsin 4  ‐2.1 
624262    Gm6489  Aly/REF export factor pseudogene  ‐2.1 
71898    Apol9b  apolipoprotein L 9b  ‐2.1 
19734  6004  Rgs16  regulator of G‐protein signaling 16  ‐2.1 











214897  53944  Csnk1g1  casein kinase 1, gamma 1  ‐2.1 





12399  864  Runx3  runt related transcription factor 3  ‐2.1 
231642  121642  Alkbh2  alkB, alkylation repair homolog 2 (E. coli)  ‐2.1 
22710    Zfp52  zinc finger protein 52  ‐2.1 









72938  51668  Hspb11  heat shock protein family B (small), member 11  ‐2.1 
24066  81848  Spry4  sprouty homolog 4 (Drosophila)  ‐2.1 








57265  2535  Fzd2  frizzled homolog 2 (Drosophila)  ‐2.1 





244059  1106  Chd2  chromodomain helicase DNA binding protein 2  ‐2.1 







223672    Apol9a  apolipoprotein L 9a  ‐2.1 
229603  56957  Otud7b  OTU domain containing 7B  ‐2.1 
97423    R74862  expressed sequence R74862  ‐2.1 
51902  11237  Rnf24  ring finger protein 24  ‐2.1 











73244    Prl8a1  prolactin family 8, subfamily a, member 1  ‐2.1 
241846  149986  Lsm14b  LSM14 homolog B (SCD6, S. cerevisiae)  ‐2.1 
16323  3624  Inhba  inhibin beta‐A  ‐2.1 
22715  346171  Zfp57  zinc finger protein 57  ‐2.1 
240776  343450  Kcnt2  potassium channel, subfamily T, member 2  ‐2.1 
229599  148523  Gm129  predicted gene 129  ‐2.1 
60345  83714  Nrip2  nuclear receptor interacting protein 2  ‐2.1 
17686  4437  Msh3  mutS homolog 3 (E. coli)  ‐2.1 
106628  9322  Trip10  thyroid hormone receptor interactor 10  ‐2.1 
16880  3977  Lifr  leukemia inhibitory factor receptor  ‐2.1 
22658  7703  Pcgf2  polycomb group ring finger 2  ‐2.1 
76267  3992  Fads1  fatty acid desaturase 1  ‐2.1 
22026  7182  Nr2c2  nuclear receptor subfamily 2, group C, member 2  ‐2.1 
218772  5915  Rarb  retinoic acid receptor, beta  ‐2.1 










243743  91584  Plxna4  plexin A4  ‐2.1 





















64292  9536  Ptges  prostaglandin E synthase  ‐2.2 
101809  399473  Spred3  sprouty‐related, EVH1 domain containing 3  ‐2.2 
171463  54756  Il17rd  interleukin 17 receptor D  ‐2.2 
320913    Trdv2‐2  T cell receptor delta variable 2‐2  ‐2.2 
214305  84439  Hhipl1  hedgehog interacting protein‐like 1  ‐2.2 
75605  10765  Kdm5b  lysine (K)‐specific demethylase 5B  ‐2.2 











20016  9533  Polr1c  polymerase (RNA) I polypeptide C  ‐2.2 
14009  2115  Etv1  ets variant gene 1  ‐2.2 





278097  54470  Armcx6  armadillo repeat containing, X‐linked 6  ‐2.2 
19817    Rn7sk  RNA, 7SK, nuclear  ‐2.2 
234839  9780  Fam38a  family with sequence similarity 38, member A  ‐2.2 
360213  80128  Trim46  tripartite motif‐containing 46  ‐2.2 
17082  9173  Il1rl1  interleukin 1 receptor‐like 1  ‐2.2 
224111  26043  Ubxn7  UBX domain protein 7  ‐2.2 
333670  150248  Gm867  predicted gene 867  ‐2.2 
76809  140707  Bri3bp  Bri3 binding protein  ‐2.2 
17131  4092  Smad7  SMAD family member 7  ‐2.2 
433968  654364  Gm5566  predicted pseudogene 5566  ‐2.2 
319615    Zfp944  zinc finger protein 944  ‐2.2 








23964  57451  Odz2  odd Oz/ten‐m homolog 2 (Drosophila)  ‐2.2 
12803  1270  Cntf  ciliary neurotrophic factor  ‐2.2 





107449  219699  Unc5b  unc‐5 homolog B (C. elegans)  ‐2.2 
94227  51050  Pi15  peptidase inhibitor 15  ‐2.2 
353237  56134  Pcdhac2  protocadherin alpha subfamily C, 2  ‐2.2 





16560  547  Kif1a  kinesin family member 1A  ‐2.2 



















22724  51043  Zbtb7b  zinc finger and BTB domain containing 7B  ‐2.2 
19224  5742  Ptgs1  prostaglandin‐endoperoxide synthase 1  ‐2.3 
408062    Zfp873  zinc finger protein 873  ‐2.3 
16416  3690  Itgb3  integrin beta 3  ‐2.3 






78248  51309  Armcx1  armadillo repeat containing, X‐linked 1  ‐2.3 
13875  2077  Erf  Ets2 repressor factor  ‐2.3 






21827  7059  Thbs3  thrombospondin 3  ‐2.3 
73490  145282  Mipol1  mirror‐image polydactyly gene 1 homolog (human)  ‐2.3 
100041
651 
  Gm3453  predicted gene 3453  ‐2.3 






















    ‐2.3 
634104  121275  Olfr287  olfactory receptor 287  ‐2.3 
























15361  3159  Hmga1  high mobility group AT‐hook 1  ‐2.3 
16987  4047  Lss  lanosterol synthase  ‐2.3 









74205  2181  Acsl3  acyl‐CoA synthetase long‐chain family member 3  ‐2.4 
19989  6129  Rpl7  ribosomal protein L7  ‐2.4 


















70574  1368  Cpm  carboxypeptidase M  ‐2.4 
19411  5916  Rarg  retinoic acid receptor, gamma  ‐2.4 
26372  1185  Clcn6  chloride channel 6  ‐2.4 
26970  30814  Pla2g2e  phospholipase A2, group IIE  ‐2.4 
22350  7430  Ezr  ezrin  ‐2.4 
20744  55342  Strbp  spermatid perinuclear RNA binding protein  ‐2.4 
230936  148479  Phf13  PHD finger protein 13  ‐2.4 
67338  117584  Rffl  ring finger and FYVE like domain containing protein  ‐2.4 
18712  5292  Pim1  proviral integration site 1  ‐2.4 









17231    Mcpt8  mast cell protease 8  ‐2.4 
11433    Acp5  acid phosphatase 5, tartrate resistant  ‐2.4 
207596  79875  Thsd4  thrombospondin, type I, domain containing 4  ‐2.5 





75785  54800  Klhl24  kelch‐like 24 (Drosophila)  ‐2.5 
22032  9618  Traf4  TNF receptor associated factor 4  ‐2.5 
432985    Gm5476  type II keratin Kb17P pseudogene  ‐2.5 
217166  9572  Nr1d1  nuclear receptor subfamily 1, group D, member 1  ‐2.5 
380629  51696  Heca  headcase homolog (Drosophila)  ‐2.5 
51793  23564  Ddah2  dimethylarginine dimethylaminohydrolase 2  ‐2.5 
71130  284948  Sh2d6  SH2 domain containing 6  ‐2.5 
15203  9843  Heph  hephaestin  ‐2.5 
223775  415116  Pim3  proviral integration site 3  ‐2.5 
11898  445  Ass1  argininosuccinate synthetase 1  ‐2.5 
13807  2026  Eno2  enolase 2, gamma neuronal  ‐2.5 
100217
442 
  Snora30  small nucleolar RNA, H/ACA box 30  ‐2.5 
11854  29984  Rhod  ras homolog gene family, member D  ‐2.5 
13809  2028  Enpep  glutamyl aminopeptidase  ‐2.5 
16398  3673  Itga2  integrin alpha 2  ‐2.5 








223920  8435  Soat2  sterol O‐acyltransferase 2  ‐2.6 












16797  27040  Lat  linker for activation of T cells  ‐2.6 
436479    Trav9‐2  T cell receptor alpha variable 9‐2  ‐2.6 
258168    Olfr566  olfactory receptor 566  ‐2.6 





114716  200734  Spred2  sprouty‐related, EVH1 domain containing 2  ‐2.6 





12096  632  Bglap  bone gamma carboxyglutamate protein  ‐2.6 
210544  93594  Wdr67  WD repeat domain 67  ‐2.6 
100217
418 
  Snora44  small nucleolar RNA, H/ACA box 44  ‐2.6 























77583  147111  Notum  notum pectinacetylesterase homolog (Drosophila)  ‐2.7 










233651  8642  Dchs1  dachsous 1 (Drosophila)  ‐2.7 
23966  26011  Odz4  odd Oz/ten‐m homolog 4 (Drosophila)  ‐2.7 
17392  4314  Mmp3  matrix metallopeptidase 3  ‐2.7 
19222  5739  Ptgir  prostaglandin I receptor (IP)  ‐2.7 
56742  84722  Psrc1  proline/serine‐rich coiled‐coil 1  ‐2.7 
15937  8870  Ier3  immediate early response 3  ‐2.7 
14573  2668  Gdnf  glial cell line derived neurotrophic factor  ‐2.7 
21677  8463  Tead2  TEA domain family member 2  ‐2.7 









105349  8644  Akr1c18  aldo‐keto reductase family 1, member C18  ‐2.8 
22762  23414  Zfpm2  zinc finger protein, multitype 2  ‐2.8 
12531  994  Cdc25b  cell division cycle 25B  ‐2.8 
353326  388015  Rtl1  retrotransposon‐like 1  ‐2.8 
16971  4035  Lrp1  low density lipoprotein receptor‐related protein 1  ‐2.8 
70892  79739  Ttll7  tubulin tyrosine ligase‐like family, member 7  ‐2.8 





15370  3164  Nr4a1  nuclear receptor subfamily 4, group A, member 1  ‐2.8 
319146    Ifnz  interferon zeta  ‐2.8 





67169    Nradd  neurotrophin receptor associated death domain  ‐2.8 
223752  23151  Gramd4  GRAM domain containing 4  ‐2.8 
19883  6095  Rora  RAR‐related orphan receptor alpha  ‐2.8 
12297  784  Cacnb3  calcium channel, voltage‐dependent, beta 3 subunit ‐2.8 
97086  133308  Nhedc2  Na+/H+ exchanger domain containing 2  ‐2.8 
19225  5743  Ptgs2  prostaglandin‐endoperoxide synthase 2  ‐2.9 
16878  3976  Lif  leukemia inhibitory factor  ‐2.9 





381269  55686  Mreg  melanoregulin  ‐2.9 




14942  2999  Gzme  granzyme E  ‐2.9 





13599  9427  Ecel1  endothelin converting enzyme‐like 1  ‐3.0 









15364    Hmga2  high mobility group AT‐hook 2  ‐3.0 






























228775  57761  Trib3  tribbles homolog 3 (Drosophila)  ‐3.2 
11839  374  Areg  amphiregulin  ‐3.2 
15331    Hmgn2  high mobility group nucleosomal binding domain 2  ‐3.2 
26399  5608  Map2k6  mitogen‐activated protein kinase kinase 6  ‐3.3 
66192    Lage3  L antigen family, member 3  ‐3.3 
74747  54541  Ddit4  DNA‐damage‐inducible transcript 4  ‐3.3 
232790  126014  Oscar  osteoclast associated receptor  ‐3.4 
70377  91319  Derl3  Der1‐like domain family, member 3  ‐3.4 















  Tcp10c  t‐complex protein 10c  ‐3.5 
100126
434 
  Trgj4  T cell receptor gamma joining 4  ‐3.7 







71847    Gmcl1l  germ cell‐less homolog 1 (Drosophila)‐like  ‐3.8 
18415  22824  Hspa4l  heat shock protein 4 like  ‐4.0 
13052  1525  Cxadr  coxsackie virus and adenovirus receptor  ‐4.0 
17395  4318  Mmp9  matrix metallopeptidase 9  ‐4.0 
11567  10677  Avil  advillin  ‐4.1 
12452  901  Ccng2  cyclin G2  ‐4.2 
16156  3589  Il11  interleukin 11  ‐4.2 
20379  6424  Sfrp4  secreted frizzled‐related protein 4  ‐4.3 
23886  9518  Gdf15  growth differentiation factor 15  ‐4.5 







23892  26585  Grem1  gremlin 1  ‐4.7 
71973  348093  Rbpms2  RNA binding protein with multiple splicing 2  ‐4.7 
93710  56113  Pcdhga2  protocadherin gamma subfamily A, 2  ‐4.7 















13406  1758  Dmp1  dentin matrix protein 1  ‐6.0 
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15511    Hspa1b  heat shock protein 1B  12.1 
13874  2069  Ereg  epiregulin  6.0 
11839  374  Areg  amphiregulin  5.7 





16156  3589  Il11  interleukin 11  4.7 
14621  127534  Gjb4  gap junction protein, beta 4  4.7 
18049  4803  Ngf  nerve growth factor  4.5 
100303
740 
  Snora75  small nucleolar RNA, H/ACA box 75  4.5 
240672  1847  Dusp5  dual specificity phosphatase 5  4.2 
20753  6698  Sprr1a  small proline‐rich protein 1A  4.2 
18164  4884  Nptx1  neuronal pentraxin 1  4.1 
16323  3624  Inhba  inhibin beta‐A  4.0 
14282  2354  Fosb  FBJ osteosarcoma oncogene B  4.0 
22138  7273  Ttn  titin  3.6 
18124  8013  Nr4a3  nuclear receptor subfamily 4, group A, member 3  3.5 
21930  7130  Tnfaip6  tumor necrosis factor alpha induced protein 6  3.5 
76294  140458  Asb5  ankyrin repeat and SOCs box‐containing 5  3.5 
107765  27063  Ankrd1  ankyrin repeat domain 1 (cardiac muscle)  3.4 
17996  4703  Neb  nebulin  3.4 
15200  1839  Hbegf  heparin‐binding EGF‐like growth factor  3.3 










16878  3976  Lif  leukemia inhibitory factor  3.2 




13406  1758  Dmp1  dentin matrix protein 1  3.2 
12869    Cox8b  cytochrome c oxidase, subunit VIIIb  3.2 
76650  140809  Srxn1  sulfiredoxin 1 homolog (S. cerevisiae)  3.1 
55948  2810  Sfn  stratifin  3.1 
68802  84665  Mypn  myopalladin  3.1 
19225  5743  Ptgs2  prostaglandin‐endoperoxide synthase 2  3.1 
















15331    Hmgn2  high mobility group nucleosomal binding domain 2  2.9 
78321  200539  Ankrd23  ankyrin repeat domain 23  2.9 
16398  3673  Itga2  integrin alpha 2  2.9 
14584  9945  Gfpt2  glutamine fructose‐6‐phosphate transaminase 2  2.9 
74155  54206  Errfi1  ERBB receptor feedback inhibitor 1  2.8 





74249  79442  Lrrc2  leucine rich repeat containing 2  2.8 









12372  844  Casq1  calsequestrin 1  2.7 
13653  1958  Egr1  early growth response 1  2.6 
387221    Mir27b  microRNA 27b  2.6 
12715  1158  Ckm  creatine kinase, muscle  2.6 
93701  8641  Pcdhgb4 protocadherin gamma subfamily B, 4  2.6 
68794  2318  Flnc  filamin C, gamma  2.6 
241431  129446  Xirp2  xin actin‐binding repeat containing 2  2.6 
17930  9172  Myom2  myomesin 2  2.6 
18175  4892  Nrap  nebulin‐related anchoring protein  2.6 




17312  10462  Clec10a  C‐type lectin domain family 10, member A  2.5 


















118452  79870  Baalc  brain and acute leukemia, cytoplasmic  2.5 
22437  165904  Xirp1  xin actin‐binding repeat containing 1  2.5 
13345  117581  Twist2  twist homolog 2 (Drosophila)  2.5 
20855  6781  Stc1  stanniocalcin 1  2.5 
19734  6004  Rgs16  regulator of G‐protein signaling 16  2.5 
13346  1674  Des  desmin  2.5 
15558  3356  Htr2a  5‐hydroxytryptamine (serotonin) receptor 2A  2.4 
226695  3428  Ifi205  interferon activated gene 205  2.4 
19124  10544  Procr  protein C receptor, endothelial  2.4 
109272  4604  Mybpc1  myosin binding protein C, slow‐type  2.4 
100217
420 
  Snora81  small nucleolar RNA, H/ACA box 81  2.4 























110308  3852  Krt5  keratin 5  2.4 
12224  688  Klf5  Kruppel‐like factor 5  2.4 












13009  8048  Csrp3  cysteine and glycine‐rich protein 3  2.3 
66175  389125  Mustn1  musculoskeletal, embryonic nuclear protein 1  2.3 
21955  7138  Tnnt1  troponin T1, skeletal, slow  2.3 















  Snora44  small nucleolar RNA, H/ACA box 44  2.3 
14281  2353  Fos  FBJ osteosarcoma oncogene  2.3 
68016  347273  Murc  muscle‐related coiled‐coil protein  2.3 





78977  64208  Popdc3  popeye domain containing 3  2.3 
93677  442721  Lmod2  leiomodin 2 (cardiac)  2.3 
228785  85366  Mylk2  myosin, light polypeptide kinase 2, skeletal muscle  2.3 
381058  54346  Unc93a  unc‐93 homolog A (C. elegans)  2.2 









66402    Sln  sarcolipin  2.2 
21925  7125  Tnnc2  troponin C2, fast  2.2 
228003  10324  Kbtbd10  kelch repeat and BTB (POZ) domain containing 10  2.2 





241452  10170  Dhrs9  dehydrogenase/reductase (SDR family) member 9  2.2 
19735  5997  Rgs2  regulator of G‐protein signaling 2  2.2 
11472  88  Actn2  actinin alpha 2  2.2 
16193  3569  Il6  interleukin 6  2.2 
244668  57568  Sipa1l2  signal‐induced proliferation‐associated 1 like 2  2.2 
100861
491 
  Rn5s20  5S RNA 20  2.2 




545938  284323  Zfp607  zinc finger proten 607  2.2 





































13628  1917  Eef1a2  eukaryotic translation elongation factor 1 alpha 2  2.1 
71920  255324  Epgn  epithelial mitogen  2.1 
76722  1160  Ckmt2  creatine kinase, mitochondrial 2  2.1 
243905    Zfp568  zinc finger protein 568  2.1 
59006  51778  Myoz2  myozenin 2  2.1 
100316
681 
  Mir1900  microRNA 1900  2.1 
233315  54893  Mtmr10  myotubularin related protein 10  2.1 










216961  84940  Coro6  coronin 6  2.1 
58916  9499  Myot  myotilin  2.1 
53318    Pdlim3  PDZ and LIM domain 3  2.1 
14825  2920  Cxcl1  chemokine (C‐X‐C motif) ligand 1  2.1 


















57742    Abhd1  abhydrolase domain containing 1  2.1 







  Mir467c  microRNA 467c  2.1 
15117  3037  Has2  hyaluronan synthase 2  2.1 
68680  161247  Fitm1  fat storage‐inducing transmembrane protein 1  2.1 





217304  124599  Cd300lb  CD300 antigen like family member B  2.1 
17082  9173  Il1rl1  interleukin 1 receptor‐like 1  2.1 
67426  56997  Adck3  aarF domain containing kinase 3  2.0 
100124
391 















21953  7136  Tnni2  troponin I, skeletal, fast 2  2.0 
16978  9208  Lrrfip1  leucine rich repeat (in FLII) interacting protein 1  2.0 
12702  9021  Socs3  suppressor of cytokine signaling 3  2.0 
14283  8061  Fosl1  fos‐like antigen 1  2.0 
116904  57538  Alpk3  alpha‐kinase 3  2.0 
22074  5646  Try4  trypsin 4  2.0 
11447  1144  Chrnd  cholinergic receptor, nicotinic, delta polypeptide  2.0 
16402  3678  Itga5  integrin alpha 5 (fibronectin receptor alpha)  2.0 
100041
585 
262  Amd2  S‐adenosylmethionine decarboxylase 2  2.0 
639396    Gm7265  predicted gene 7265  2.0 
15936  9592  Ier2  immediate early response 2  2.0 
20339  6401  Sele  selectin, endothelial cell  2.0 









27273  5166  Pdk4  pyruvate dehydrogenase kinase, isoenzyme 4  2.0 
















98660  477  Atp1a2  ATPase, Na+/K+ transporting, alpha 2 polypeptide  2.0 





17869  4609  Myc  myelocytomatosis oncogene  2.0 
245282    Apol10a  apolipoprotein L 10A  2.0 
433766  84676  Trim63  tripartite motif‐containing 63  2.0 
77889  81606  Lbh  limb‐bud and heart  2.0 
18054    Ngp  neutrophilic granule protein  ‐2.0 














15018  3105  H2‐Q7  histocompatibility 2, Q region locus 7  ‐2.0 
268697  891  Ccnb1  cyclin B1  ‐2.0 
223780  79924  Adm2  adrenomedullin 2  ‐2.0 
230099  768  Car9  carbonic anhydrase 9  ‐2.0 
408065    Zfp456  zinc finger protein 456  ‐2.0 







































668349    Gm9119  predicted pseudogene 9119  ‐2.1 





18197  51617  Nsg2  neuron specific gene family member 2  ‐2.1 
18189  9378  Nrxn1  neurexin I  ‐2.1 
14293  2357  Fpr1  formyl peptide receptor 1  ‐2.2 




















22139  7276  Ttr  transthyretin  ‐2.3 





319236  85363  Trim12c  tripartite motif‐containing 12C  ‐2.3 





17286  4223  Meox2  mesenchyme homeobox 2  ‐2.4 










15007  3105  H2‐Q10  histocompatibility 2, Q region locus 10  ‐2.4 














77630  56978  Prdm8  PR domain containing 8  ‐2.5 
13004  1463  Ncan  neurocan  ‐2.5 
100316
832 
  Mir1895  microRNA 1895  ‐2.6 
112407  112399  Egln3  EGL nine homolog 3 (C. elegans)  ‐2.6 
12140  2173  Fabp7  fatty acid binding protein 7, brain  ‐2.6 
18126  4843  Nos2  nitric oxide synthase 2, inducible  ‐2.6 
104001  6252  Rtn1  reticulon 1  ‐2.6 













547420    Trav7‐3  T cell receptor alpha variable 7‐3  ‐2.9 
56471  81551  Stmn4  stathmin‐like 4  ‐2.9 
11829  361  Aqp4  aquaporin 4  ‐2.9 
11535  133  Adm  adrenomedullin  ‐3.1 
54678    Zfp108  zinc finger protein 108  ‐3.2 
100217
415 
  Scarna6  small Cajal body‐specific RNA 6  ‐3.3 
668413    Gm9158  predicted gene 9158  ‐3.3 
13193  1641  Dcx  doublecortin  ‐3.4 
15039    H2‐T22  histocompatibility 2, T region locus 22  ‐3.8 
14580  2670  Gfap  glial fibrillary acidic protein  ‐4.1 
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  Snora75  small nucleolar RNA, H/ACA box 75  13.9 
14282  2354  Fosb  FBJ osteosarcoma oncogene B  9.2 
15116  3036  Has1  hyaluronan synthase1  8.9 
11839  374  Areg  amphiregulin  8.4 





240672  1847  Dusp5  dual specificity phosphatase 5  7.6 
381651  152816  Gm1045  predicted gene 1045  7.3 
16156  3589  Il11  interleukin 11  7.1 
16878  3976  Lif  leukemia inhibitory factor  6.4 
18124  8013  Nr4a3  nuclear receptor subfamily 4, group A, member 3  5.5 
18049  4803  Ngf  nerve growth factor  5.5 
16323  3624  Inhba  inhibin beta‐A  5.2 
14621  127534  Gjb4  gap junction protein, beta 4  4.9 
21930  7130  Tnfaip6  tumor necrosis factor alpha induced protein 6  4.8 
76650  140809  Srxn1  sulfiredoxin 1 homolog (S. cerevisiae)  4.8 
15200  1839  Hbegf  heparin‐binding EGF‐like growth factor  4.7 
100217
420 
  Snora81  small nucleolar RNA, H/ACA box 81  4.5 
20310  2921  Cxcl2  chemokine (C‐X‐C motif) ligand 2  4.4 
19215  5730  Ptgds  prostaglandin D2 synthase (brain)  4.4 
19225  5743  Ptgs2  prostaglandin‐endoperoxide synthase 2  4.3 











  Mir1900  microRNA 1900  4.0 








14584  9945  Gfpt2  glutamine fructose‐6‐phosphate transaminase 2  3.7 















387221    Mir27b  microRNA 27b  3.5 
15370  3164  Nr4a1  nuclear receptor subfamily 4, group A, member 1  3.5 
100216
474 
83887  Ttll2  tubulin tyrosine ligase‐like family, member 2  3.4 
16193  3569  Il6  interleukin 6  3.4 
387216    Mir23a  microRNA 23a  3.4 
74155  54206  Errfi1  ERBB receptor feedback inhibitor 1  3.3 
12985  1440  Csf3  colony stimulating factor 3 (granulocyte)  3.2 
19124  10544  Procr  protein C receptor, endothelial  3.2 
13406  1758  Dmp1  dentin matrix protein 1  3.2 









751520    Mir680‐3  microRNA 680‐3  3.1 
55948  2810  Sfn  stratifin  3.0 
56708  23529  Clcf1  cardiotrophin‐like cytokine factor 1  3.0 
246791    Obox3  oocyte specific homeobox 3  3.0 









14825  2920  Cxcl1  chemokine (C‐X‐C motif) ligand 1  2.9 
12014  60468  Bach2  BTB and CNC homology 2  2.9 





226695  3428  Ifi205  interferon activated gene 205  2.9 




381823  81575  Apold1  apolipoprotein L domain containing 1  2.9 
15117  3037  Has2  hyaluronan synthase 2  2.9 
19734  6004  Rgs16  regulator of G‐protein signaling 16  2.8 
100217
459 





20393  6446  Sgk1  serum/glucocorticoid regulated kinase 1  2.8 
100217
418 
  Snora44  small nucleolar RNA, H/ACA box 44  2.8 





13537  1844  Dusp2  dual specificity phosphatase 2  2.7 
100313
519 
  Snord17  small nucleolar RNA, C/D box 17  2.7 
19735  5997  Rgs2  regulator of G‐protein signaling 2  2.7 









723842    Mir329  microRNA 329  2.6 
14283  8061  Fosl1  fos‐like antigen 1  2.6 
14281  2353  Fos  FBJ osteosarcoma oncogene  2.6 






20698  8877  Sphk1  sphingosine kinase 1  2.6 
20855  6781  Stc1  stanniocalcin 1  2.5 





654309    Nrp  neural regeneration protein  2.5 
107652  6675  Uap1  UDP‐N‐acetylglucosamine pyrophosphorylase 1  2.5 
17869  4609  Myc  myelocytomatosis oncogene  2.5 
57742    Abhd1  abhydrolase domain containing 1  2.5 
24064  10253  Spry2  sprouty homolog 2 (Drosophila)  2.5 
71920  255324  Epgn  epithelial mitogen  2.5 









18793  5329  Plaur  plasminogen activator, urokinase receptor  2.5 
215418  64651  Csrnp1  cysteine‐serine‐rich nuclear protein 1  2.4 
70574  1368  Cpm  carboxypeptidase M  2.4 











21333  6863  Tac1  tachykinin 1  2.4 
68794  2318  Flnc  filamin C, gamma  2.4 
54720  1827  Rcan1  regulator of calcineurin 1  2.4 
20515  6574  Slc20a1  solute carrier family 20, member 1  2.4 
118452  79870  Baalc  brain and acute leukemia, cytoplasmic  2.4 
14620  2707  Gjb3  gap junction protein, beta 3  2.3 
15937  8870  Ier3  immediate early response 3  2.3 
235086  22997  Igsf9b  immunoglobulin superfamily, member 9B  2.3 


















56437  6236  Rrad  Ras‐related associated with diabetes  2.3 
12869    Cox8b  cytochrome c oxidase, subunit VIIIb  2.3 
100217
434 
  Snord88c  small nucleolar RNA, C/D box 88C  2.3 
434795    Gm5639  predicted pseudogene 5639  2.3 
545848    Igkv4‐80  immunoglobulin kappa variable 4‐80  2.3 
11898  445  Ass1  argininosuccinate synthetase 1  2.3 















76294  140458  Asb5  ankyrin repeat and SOCs box‐containing 5  2.3 
15558  3356  Htr2a  5‐hydroxytryptamine (serotonin) receptor 2A  2.3 
78321  200539  Ankrd23  ankyrin repeat domain 23  2.3 
100217
423 
  Snord19  small nucleolar RNA, C/D box 19  2.3 
387135    Mir18  microRNA 18  2.3 
258956    Olfr535  olfactory receptor 535  2.3 
21824  7056  Thbd  thrombomodulin  2.3 
21953  7136  Tnni2  troponin I, skeletal, fast 2  2.2 
22437  165904  Xirp1  xin actin‐binding repeat containing 1  2.2 
27273  5166  Pdk4  pyruvate dehydrogenase kinase, isoenzyme 4  2.2 
14619  2706  Gjb2  gap junction protein, beta 2  2.2 
436522  5644  Try10  trypsin 10  2.2 
67534  9654  Ttll4  tubulin tyrosine ligase‐like family, member 4  2.2 
71436  23767  Flrt3  fibronectin leucine rich transmembrane protein 3  2.2 
12372  844  Casq1  calsequestrin 1  2.2 
100861
491 





244668  57568  Sipa1l2  signal‐induced proliferation‐associated 1 like 2  2.2 
258420  390445  Olfr221  olfactory receptor 221  2.2 
100316
700 
  Mir1949  microRNA 1949  2.2 
14190  10875  Fgl2  fibrinogen‐like protein 2  2.2 
21925  7125  Tnnc2  troponin C2, fast  2.2 





19692  5967  Reg1  regenerating islet‐derived 1  2.2 












19252  1843  Dusp1  dual specificity phosphatase 1  2.1 
63953  11221  Dusp10  dual specificity phosphatase 10  2.1 




24066  81848  Spry4  sprouty homolog 4 (Drosophila)  2.1 
100526
503 
  Mir3096  microRNA 3096  2.1 














67603  1848  Dusp6  dual specificity phosphatase 6  2.1 
20655  6647  Sod1  superoxide dismutase 1, soluble  2.1 
13346  1674  Des  desmin  2.1 







  Traj12  T cell receptor alpha joining 12  2.1 
100217
456 
  Snord53  small nucleolar RNA, C/D box 53  2.1 
13654  1959  Egr2  early growth response 2  2.1 







  Snora30  small nucleolar RNA, H/ACA box 30  2.1 
100526
546 
  Mir3068  microRNA 3068  2.1 
109272  4604  Mybpc1  myosin binding protein C, slow‐type  2.1 






14313  10468  Fst  follistatin  2.1 









66589  7335  Ube2v1  ubiquitin‐conjugating enzyme E2 variant 1  2.1 
100124
487 




21955  7138  Tnnt1  troponin T1, skeletal, slow  2.1 





381650    Thap6  THAP domain containing 6  2.1 
20190  6261  Ryr1  ryanodine receptor 1, skeletal muscle  2.1 
14173  2247  Fgf2  fibroblast growth factor 2  2.1 
268449    Rpl23a  ribosomal protein L23A  2.0 





13653  1958  Egr1  early growth response 1  2.0 
116904  57538  Alpk3  alpha‐kinase 3  2.0 
382277    Gm5169  predicted gene 5169  2.0 





381485  84675  Trim55  tripartite motif‐containing 55  2.0 
15936  9592  Ier2  immediate early response 2  2.0 
100216
540 
  Snord95  small nucleolar RNA, C/D box 95  2.0 
12937  56142  Pcdha6  protocadherin alpha 6  2.0 
17067    Ly6c1  lymphocyte antigen 6 complex, locus C1  2.0 
545007    Gm5796  predicted gene 5796  2.0 
















































  Mir1963  microRNA 1963  2.0 










12061  623  Bdkrb1  bradykinin receptor, beta 1  2.0 
12955  1410  Cryab  crystallin, alpha B  2.0 
21983  7162  Tpbg  trophoblast glycoprotein  2.0 









666253    Gm8005  predicted gene 8005  2.0 
100526
475 
  Mir3076  microRNA 3076  2.0 
268878  344905  Atp13a5  ATPase type 13A5  2.0 
19331  401409  Rab19  RAB19, member RAS oncogene family  2.0 
723839    Mir323  microRNA 323  2.0 
258319  79295  Olfr187  olfactory receptor 187  2.0 
13730  2012  Emp1  epithelial membrane protein 1  2.0 
50790  2182  Acsl4  acyl‐CoA synthetase long‐chain family member 4  2.0 





77578  607  Bcl9  B cell CLL/lymphoma 9  ‐2.0 
20419  79801  Shcbp1  Shc SH2‐domain binding protein 1  ‐2.0 
235106  50863  Ntm  neurotrimin  ‐2.0 
223267  87769  A2ld1  AIG2‐like domain 1  ‐2.0 









243371  65999  Lrrc61  leucine rich repeat containing 61  ‐2.0 
216505  113791  Pik3ip1  phosphoinositide‐3‐kinase interacting protein 1  ‐2.0 
194744  203427  Slc25a43  solute carrier family 25, member 43  ‐2.0 









68385  116238  Tlcd1  TLC domain containing 1  ‐2.0 
243529  8971  H1fx  H1 histone family, member X  ‐2.0 





20460  6491  Stil  Scl/Tal1 interrupting locus  ‐2.0 
20585  6596  Hltf  helicase‐like transcription factor  ‐2.0 
545812  29990  Pilrb2  paired immunoglobin‐like type 2 receptor beta 2  ‐2.0 
100306
943 
  Scarna13  small Cajal body‐specific RNA 1  ‐2.0 
277154  57523  Nynrin  NYN domain and retroviral integrase containing  ‐2.0 
20878  6790  Aurka  aurora kinase A  ‐2.0 
76816  10806  Sdccag8  serologically defined colon cancer antigen 8  ‐2.0 
50915  2888  Grb14  growth factor receptor bound protein 14  ‐2.0 
22137  7272  Ttk  Ttk protein kinase  ‐2.1 
270906  55771  Prr11  proline rich 11  ‐2.1 





11829  361  Aqp4  aquaporin 4  ‐2.1 





666561    Gm8165  predicted gene 8165  ‐2.1 
270192  51560  Rab6b  RAB6B, member RAS oncogene family  ‐2.1 
13380  22943  Dkk1  dickkopf homolog 1 (Xenopus laevis)  ‐2.1 
229905  56267  Ccbl2  cysteine conjugate‐beta lyase 2  ‐2.1 
67824  57407  Nmral1  NmrA‐like family domain containing 1  ‐2.1 




20091    Rps3a  ribosomal protein S3A  ‐2.1 
104383  283248  Rcor2  REST corepressor 2  ‐2.1 
15229  2297  Foxd1  forkhead box D1  ‐2.1 





93714  56109  Pcdhga6  protocadherin gamma subfamily A, 6  ‐2.2 
228019  79828  Mettl8  methyltransferase like 8  ‐2.2 
17286  4223  Meox2  mesenchyme homeobox 2  ‐2.2 
93709  56114  Pcdhga1  protocadherin gamma subfamily A, 1  ‐2.2 










229841  1062  Cenpe  centromere protein E  ‐2.2 
93712  56111  Pcdhga4  protocadherin gamma subfamily A, 4  ‐2.2 
12140  2173  Fabp7  fatty acid binding protein 7, brain  ‐2.2 
15444  3208  Hpca  hippocalcin  ‐2.2 
20299  6367  Ccl22  chemokine (C‐C motif) ligand 22  ‐2.2 
71904  164091  Paqr7  progestin and adipoQ receptor family member VII  ‐2.2 
20128    Trim30a  tripartite motif‐containing 30A  ‐2.3 





73804  11004  Kif2c  kinesin family member 2C  ‐2.3 
668923    Zfp442  zinc finger protein 442  ‐2.3 
19395  10235  Rasgrp2  RAS, guanyl releasing protein 2  ‐2.3 
100217
422 
  Snord13  small nucleolar RNA, C/D box 13  ‐2.3 
668413    Gm9158  predicted gene 9158  ‐2.3 


















  Trgj4  T cell receptor gamma joining 4  ‐2.4 


























408065    Zfp456  zinc finger protein 456  ‐2.5 
74438  157807  Clvs1  clavesin 1  ‐2.5 





13193  1641  Dcx  doublecortin  ‐2.6 










112407  112399  Egln3  EGL nine homolog 3 (C. elegans)  ‐2.9 



















APPENDIX 6: ALL GENES UP-REGULATED OR DOWN-REGULATED BY 





















434869    Gm15097  predicted gene 15097  3.1 





545655    Gm13287  predicted gene 13287  2.9 
16687  3854  Krt6a  keratin 6A  2.8 
67242  79833  Gemin6  gem (nuclear organelle) associated protein 6  2.7 
100503555    Gm19767  predicted gene, 19767  2.7 
258265    Olfr1333  olfactory receptor 1333  2.7 
16580  3833  Kifc5b  kinesin family member C5B  2.7 
19395  10235  Rasgrp2  RAS, guanyl releasing protein 2  2.7 
100041787    Gm15292  predicted gene 15292  2.6 
15444  3208  Hpca  hippocalcin  2.5 
93701  8641  Pcdhgb4  protocadherin gamma subfamily B, 4  2.5 
171203    Vmn1r9  vomeronasal 1 receptor 9  2.4 
414758    Zfp826  zinc finger protein 826  2.3 














107815    Scml2  sex comb on midleg‐like 2 (Drosophila)  2.1 








13681  1973  Eif4a1  eukaryotic translation initiation factor 4A1  2.1 
668139    Gm8995  predicted gene 8995  2.1 
13056  1534  Cyb561  cytochrome b‐561  2.1 
17996  4703  Neb  nebulin  2.0 





723841    Mir328  microRNA 328  2.0 
233001    Nlrp9a  NLR family, pyrin domain containing 9A  2.0 
100306945    Snora73b  small nucleolar RNA, H/ACA box 73b  2.0 






19661  5949  Rbp3  retinol binding protein 3, interstitial  2.0 
233199  4606  Mybpc2  myosin binding protein C, fast‐type  2.0 
93713  56110  Pcdhga5  protocadherin gamma subfamily A, 5  2.0 
619973    Gm12538  predicted gene 12538  2.0 
68215  283742  Fam98b  family with sequence similarity 98, member B  2.0 
216881  23302  Wscd1  WSC domain containing 1  2.0 
20272  6332  Scn7a  sodium channel, voltage‐gated, type VII, alpha  2.0 
258782    Olfr914  olfactory receptor 914  ‐2.0 
19870    Snord73a  small nucleolar RNA, C/D box U73A  ‐2.0 
56471  81551  Stmn4  stathmin‐like 4  ‐2.0 
381823  81575  Apold1  apolipoprotein L domain containing 1  ‐2.0 
100217465    Snord111  small nucleolar RNA, C/D box 111  ‐2.0 
52712  7566  Zkscan6  zinc finger with KRAB and SCAN domains 6  ‐2.0 
100526546    Mir3068  microRNA 3068  ‐2.0 
83702  1109  Akr1c6  aldo‐keto reductase family 1, member C6  ‐2.0 
14853  23708  Gspt2  G1 to S phase transition 2  ‐2.0 
16878  3976  Lif  leukemia inhibitory factor  ‐2.0 
628573    Gm6897  predicted pseudogene 6897  ‐2.0 
258420  390445  Olfr221  olfactory receptor 221  ‐2.0 





103142  8608  Rdh9  retinol dehydrogenase 9  ‐2.0 
77630  56978  Prdm8  PR domain containing 8  ‐2.0 




258956    Olfr535  olfactory receptor 535  ‐2.0 
19783    Rprl1  ribonuclease P RNA‐like 1  ‐2.1 
13371  1734  Dio2  deiodinase, iodothyronine, type II  ‐2.1 
18508  5080  Pax6  paired box gene 6  ‐2.1 
258095    Olfr119  olfactory receptor 119  ‐2.1 
13796  2016  Emx1  empty spiracles homeobox 1  ‐2.1 
100503066    Gm14966  predicted gene 14966  ‐2.1 





268449    Rpl23a  ribosomal protein L23A  ‐2.1 
665211  79973  Gm14326  predicted gene 14326  ‐2.1 
407831  79652  Tmem204  transmembrane protein 204  ‐2.1 





319236  85363  Trim12c  tripartite motif‐containing 12C  ‐2.2 
100217453    Snord16a  small nucleolar RNA, C/D box 16A  ‐2.2 
100529076    Snord42a  small nucleolar RNA, C/D box 42A  ‐2.2 
85029    Rpph1  ribonuclease P RNA component H1  ‐2.2 
15039    H2‐T22  histocompatibility 2, T region locus 22  ‐2.2 
381651  152816  Gm1045  predicted gene 1045  ‐2.2 
666532  90317  Gm13139  predicted gene 13139  ‐2.2 
100217443    Snord12  small nucleolar RNA, C/D box 12  ‐2.2 
665205    Gm14327  predicted gene 14327  ‐2.2 
100302601    Snord83b  small nucleolar RNA, C/D box 83B  ‐2.2 
15018  3105  H2‐Q7  histocompatibility 2, Q region locus 7  ‐2.2 
100302565    Snord68  small nucleolar RNA, C/D box 68  ‐2.2 
57349    Ppbp  pro‐platelet basic protein  ‐2.2 
27211    Snord35a  small nucleolar RNA, C/D box 35A  ‐2.3 
791090    Ighv2‐6‐8  immunoglobulin heavy variable 2‐6‐8  ‐2.3 
436522  5644  Try10  trypsin 10  ‐2.3 
100217464    Snora41  small nucleolar RNA, H/ACA box 41  ‐2.3 
20284  11341  Scrg1  scrapie responsive gene 1  ‐2.3 





104433    Snora62  small nucleolar RNA, H/ACA box 62  ‐2.4 




20655  6647  Sod1  superoxide dismutase 1, soluble  ‐2.4 
17067    Ly6c1  lymphocyte antigen 6 complex, locus C1  ‐2.4 
100313519    Snord17  small nucleolar RNA, C/D box 17  ‐2.5 
246791    Obox3  oocyte specific homeobox 3  ‐2.5 
100217442    Snora30  small nucleolar RNA, H/ACA box 30  ‐2.5 
19872    Rny1  RNA, Y1 small cytoplasmic, Ro‐associated  ‐2.5 
751520    Mir680‐3  microRNA 680‐3  ‐2.5 
54678    Zfp108  zinc finger protein 108  ‐2.5 
100302529    Snord72  small nucleolar RNA, C/D box 72  ‐2.6 
545848    Igkv4‐80  immunoglobulin kappa variable 4‐80  ‐2.6 





100216531    Snord1b  small nucleolar RNA, C/D box 1B  ‐2.8 
545007    Gm5796  predicted gene 5796  ‐2.9 
100039794    Gm2427  predicted gene 2427  ‐2.9 
545645    Gm13283  predicted gene 13283  ‐3.0 
19215  5730  Ptgds  prostaglandin D2 synthase (brain)  ‐3.1 





100217428    Snord57  small nucleolar RNA, C/D box 57  ‐3.4 
100316832    Mir1895  microRNA 1895  ‐3.9 
666348    Apol7e  apolipoprotein L 7e  ‐3.9 
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